Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
Patent Information
- Application Number
- PCT/US2024/027315
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-27
- Filing Date
- 2024-05-01
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for myotonic dystrophy type 1 (DM1) lack specificity and effectiveness, particularly for severe forms like congenital and childhood DM1, which result in significant morbidity and mortality, with existing therapies mainly focused on symptom management rather than addressing the underlying mutated dystrophia myotonica protein kinase (DMPK) mRNA expression.
Development of adeno-associated virus (AAV) compositions and methods utilizing AAV capsid variants and modulatory polynucleotides, such as RNAi agents, to specifically target and reduce or eliminate mutated DMPK mRNA expression in muscle and cardiac tissues, aiming to slow or halt disease progression.
The AAV-based approach potentially offers a targeted mechanism to reduce DMPK mRNA expression, thereby ameliorating symptoms and potentially halting or reversing muscular and other symptoms of DM1, improving quality of life and lifespan for affected individuals.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERSRELATED TO DYSTROPHIA MYOTONICA PROTEIN KINASERELATED APPLICATIONS
[0001] Tills application claims the benefit of and priority to US Provisional / Application SerialNo. 63 / 499,923, filed May 3, 2023, and US Provisional Application Serial No. 63 / 593,824, filedOctober 27, 2023, the contents of each of which are incorporated herein by reference in their entirety.SEQUENCE LISTING
[0002] The present application is being filed along with a Sequence Listing in electronic format.The Sequence Listing file, entitled 14640.0084-00304 SL.xml, was created on March 22, 2024, and is5,498,524 bytes in size. The information in electronic format of the Sequence Listing is incorporated herein by reference in its entirety.FIELD
[0003] Described herein are compositions and methods relating to adeno -associated virus (AAV) viral particles for the delivery of polynucleotides, e.g., modulatory polynucleotides, for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA and their use in the treatment of myotonic dystrophy type 1 (DM1) and other disorders associated with or caused by mutated DMPK mRNA. In some embodiments, compositions described herein may be used to treat a subject in need thereof, such as a human subject diagnosed with DM1 or another condition resulting from mutatedDMPK mRNA or aberrant DMPK mRNA expression.BACKGROUND
[0004] Dystrophia myotonica protein kinase (DMPK) (also referred to as myotoni c dystrophy protein kinase) is an enzy me encoded by the DMPK gene (Ensembl Gene ID No.ENSG00000104936), which is found on chromosome 19. The DMPK gene is also known as DM15, DM1PK, DMK, MDPK, and MT-PK.
[0005] The DMPK protein is thought to be involved in cell communication and appears to play important roles in at least heart, muscle, and brain cells.
[0006] Mutation(s) in DMPK cause myotonic dystrophy type 1 (DM1 ). DM1 is characterized by progressive muscle wasting and weakness. Muscle weakness is most often observed in distal muscles, and myotonia, cataracts, hypogonadism, frontal balding and electrocardiogram changes are also observed. There are an estimated 500,000 cases of DM1 worldwide.
[0007] DM1 is typically caused by trinucleotide repeat expansions in the DMPK gene. Trinucleotide repeat expansions occur to a repeated CTG segment in DMPK. Non-diseased humanstypically have 5-37 CTG repeats (SEQ ID NO: 6430). The number of CTG repeats determines the form of DM1 and the severity of disease. CTG repeats of the trinucleotide repeat expansion may be uninterrupted or may be interrupted with one or more other nucleotides.
[0008] Patients with 38-49 CTG repeats (SEQ ID NO: 6431) are typically asymptomatic.
[0009] Patients with 50-150 CTG repeats (SEQ ID NO: 6432) may manifest with mild DM1. Mild DM1 symptoms typically begin between the ages of 20 and 70 years. Mild DM1 is characterized by cataracts, myotonia, and mild muscle weakness, and patients have a normal life span.
[0010] Patients with 50 to 1000 CTG repeats (SEQ ID NO: 6433) may manifest with classic DM1. Classic DM1 symptoms typically begin in adulthood. Classic DM1 is characterized by muscle weakness and wasting, myotonia, cataracts, cardiac conduction abnormalities, and a myopathic face. Adults may be physically disabled and have a shortened lifespan.
[0011] Patients with CTG repeat lengths greater than 800 may manifest with childhood DM1. Symptoms of childhood DM1 typically begin around age 10. Childhood DM1 is characterized by learning difficulties and psychosocial problems (e.g., family problems, depression, anxiety), slurred speech, hand muscle myotonia, and heart conduction abnormalities.
[0012] Patients with CTG repeat lengths greater than 1000 may manifest with congenital DM1 . Patients with congenital DM1 show symptoms before birth. Symptoms of congenital DM1 visible before birth include decreased fetal movement in the uterus, polyhydramnios, clubfoot, and ventriculomegaiy. Congenital DM1 is characterized by hypotonia, and severe weakness at birth. Further symptoms of congenital DM1 include a tented appearance of the upper lip, dysarthria, intellectual disability, hypotonia, respiratory insufficiency, and early death.
[0013] In DM1 patients, the mutated DMPK gene produces an altered (mutated) mRNA. The altered mRNA is thought to trap proteins and forms foci within cells. Said foci interfere with protein production, which prevents proper cell function. Without being limited by theory, the foci may trap proteins that have a function in mRNA splicing, thereby disrupting proper (normal) mRNA splicing patterns. In muscle cells, this results in muscle weakness. DM1 particularly affects cardiac, smooth, and skeletal muscle.
[0014] There are no specific treatments for DM1, and some forms of DM! such as congenital DM1 and childhood DM1 result in decreased lifespan. Existing treatments are directed to managing symptoms and maximizing patients’ quality of life and independence. Treatments directed to managing symptoms include anti-diabetic drugs, anti-myotonic drugs (e.g., mexiletine), and nonsteroidal anti-inflamroatoiy drugs.
[0015] The present disclosure provides improved pharmaceutical compositions and methods. In some embodiments, the disclosure provides methods of treatment using AA V capsid variants that are capable of delivering modulatory polynucleotides to a target cell or tissue, e.g., a cell or tissue of the muscle, heart, and / or CNS.SUMMARY
[0016] The present disclosure addresses these challenges by providing AAV-based compositions comprising AAV capsid variants and methods for treating DMPK-related disorders in subjects, and methods for treating DMPK-related disorders in subjects. In some embodiments, the DMPK-related disorder is DM1. In various embodiments, disclosed herein are compositions and methods directed to AAV-based gene delivery of modulatory polynucleotides for reducing or eliminating expression of DMPK (e.g, mutated DMPK mRNA) to treat DM1 . The compositions and methods are useful to reduce the effects of mutated DMPK mRNA expression, and to slow, halt or reverse muscular and other symptoms of DM1. In some embodiments, mutated DMPK mRNA expression refers to expression of DMPK mRNA comprising 50 or more CTG trinucleotide repeats (SEQ ID NO: 6434). Unless otherwise specified, DMPK, DM15, DM1 PK, DMK, MDPK, and MT-PK are synonymous terms and are used interchangeably to refer to the DMPK gene. DMPK is used to refer to the transcript encoding the DMPK protein, DMPK protein refers to the protein encoded by the DMPK gene and mRNA. DM1 is used to refer to myotonic dystrophy type 1.
[0017] In some embodiments, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleotide sequence encoding a modulatory polynucleotide for reducing or eliminating expression of a dystrophia myotonica protein kinase (DMPK) mRNA. In some embodiments, the modulatory polynucleotide reduces or eliminates mRNA encoding mutant DMPK (e.g., comprising aberrant CTG repeats). In some embodiments, the AAV capsid is an AAV capsid variant. In some embodiments, the AAV capsid variant is an AAV9 capsid variant.
[0018] In some embodiments, the present disclosure provides an adeno-associated virus (AAV) particle comprising: a) an AAV capsid variant comprising an amino acid sequence having the following formula: [N1]-[N2]-[N3], wherein: (i) optionally [N1] comprises XL X2, and X3, wherein at least one of XI, X2, or X3 is G; (ii) [N2] comprises the amino acid sequence of SPH; and (iii) [N3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino acid; and b) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA. In some embodiments, the amino acid sequence [N1]-[N2]-[N3] is in hypervariable loop IV of the AAV capsid variant. In some embodiments, 3 the AAV capsid variant is an AAV9 capsid variant. In some embodiments, [N 1] comprises XI, X2, and X3, wherein at least one of XI, X2, or X3 is G. In some embodiments, [N2]-[N3j comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941).
[0019] In some embodiments, the present disclosure provides an adeno-associated vims (AAV7) particle comprising a viral genome comprising (a) a nucleic acid sequence encoding a modulatory' polynucleotide for reducing or eliminating expression of mutated dystrophia my otonica protein kinase (DMPK) mRNA, optionally wherein the modulatory' polynucleotide comprises an RNAi agenttargeting DMPK mRNA, and (b) and an AAV9 capsid variant comprising the amino acid sequence of SPHSKA (SEQ ID NO: 941). In some embodiments, the amino acid sequence of SPHSKA (SEQ ID NO: 941 ) is in hypervariable loop IV of the AAV9 capsid variant. In some embodiments, the amino acid sequence of SPHSKA (SEQ ID NO: 941) is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 4 or SEQ ID NO: 36.
[0020] In some embodiments, the AAV9 capsid variant comprises one, two, or all of: an N at an amino acid position corresponding to position 452, an E at an amino acid position corresponding to position 451 , and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 4. In some embodiments, the AAV9 capsid variant comprises the amino acid sequence of KTENVSGSPIISKAQNQQT (SEQ ID NO: 3272).
[0021] In some embodiments, the AA V9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 90% identity' to SEQ ID NO: 4; (ii) a VP2 protein comprising an amino acid sequence having at least 90% identity' to positions 138-742 of SEQ ID NO: 4; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 90% identity to positions 203- 742 of SEQ ID NO: 4.
[0022] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 95% identity' to SEQ ID NO: 4; (ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 4; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 4.
[0023] In some embodiments, the AAV9 capsid variant comprises: (i) a VP 1 protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 4; (ii) a VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 4; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 99% identity' to positions 203- 742 of SEQ ID NO: 4.
[0024] In some embodiments, the AAV 9 capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4: (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4; and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4.
[0025] In some embodiments, the AAV9 capsid variant comprises: (i) the amino acid sequence of SPHSKA (SEQ ID NO: 941). wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 4; (ii) an E at an amino acid position corresponding to position 451 and a V at an amino acid position corresponding to position 453 of SEQ ID NO: 4: and (iii) no oth er modifications relative to wild type AAV9.
[0026] In some embodiments, the AAV9 capsid variant comprises one, two, or all of: an E at an amino acid position corresponding to position 451, an R at an amino acid position corresponding to position 452, and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 36.In some embodiments, the AAV 9 capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589).
[0027] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 36; (ii) a VP2 protein comprising an amino acid sequence having at least 90% identity’ to positions 138-742 SEQ ID NO: 36; and / or (iii) a VP3 protein comprising art amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 36.
[0028] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 36; (ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 36; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 36.
[0029] In some embodiments, the AA V9 capsid variant comprises: (i) a VP1 protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 36; (ii) a VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 36; and / or (iii) a VP3 protein comprising an amino acid sequence having at least 99% identity’ to positions 203- 742 of SEQ ID NO: 36.
[0030] In some embodiments, the AAV9 capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 36; and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36.
[0031] In some embodiments, the AAV9 capsid vanant comprises: (i) the amino acid sequence SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 36; (ii) an E at an amino acid position corresponding to position 451, an R at an amino acid position corresponding to position 452, and a V at an amino acid position corresponding to position 453 of SEQ ID NO: 36; and (iii) no other modifications relative to wild type AAV9.
[0032] In some embodiments, the present disclosure provides an AAV particle comprising an AAV capsid variant comprising an amino acid sequence having the following formula: [N 1 ]~[N2] - [N3], wherein the [N1]-[N2]-[N3] is present immediately subsequent to a position corresponding to the amino acid position 452 of SEQ ID NO: 982; and wherein the AAV capsid variant comprises an amino acid sequence at least 90% identical, e.g., at least 91%, at least 92%, at least 93%, at least 94%. at least 95%, at least 96%, at least 97%. at least 98%, at least 99%, or 100% identical, to the amino acid sequence of SEQ ID NO: 982, e.g., to positions 203-742 of SEQ ID NO: 982.
[0033] In some embodiments, [N1] comprises GHD. In some embodiments, [N1] comprises the amino acid G at a position corresponding to position 453, tire amino acid H at position 454, and theamino acid D at position 455 of SEQ ID NO: 138 or SEQ ID NO: 982. In some embodiments, [N3] comprises KSG.
[0034] In some embodiments, the AAV capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to SEQ ID NO: 982; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 203-742. of SEQ ID NO: 982.
[0035] In some embodiments, the AAV capsid vanant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to SEQ ID NO: 982; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 982.
[0036] In some embodiments, the AAV capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982. or an amino acid sequence liaving at least 99% identity to SEQ ID NO: 982; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence liaving at least 99% identity to positions 203-742 of SEQ ID NO: 982.
[0037] In some embodiments, the AAV capsid variant comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982.
[0038] In some embodiments, the modulatory polynucleotide comprises a molecular scaffold, wherein the molecular scaffold comprises: (a) a 5 flanking region, optionally comprising any one of SEQ ID NOs: 6413-6416; (b) a loop region, optionally comprising any one of SEQ ID NOs: 6417- 6421; and (c) a 3 flanking region, optionally comprising any one of SEQ ID NOs: 6422.-6427.
[0039] In some embodiments, (a) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414 or SEQ ID NO: 6415; (b) the loop region of the molecular scaffold comprises SEQ ID NO: 6417, SEQ ID NO: 6418, or SEQ ID NO: 6421; and (c) the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6423, SEQ ID NO: 6424, or SEQ ID NO: 6425.
[0040] In some embodiments, the 5 flanking region of the molecular scaffold comprises SEQ IDNO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3 flankingregion of the molecular scaffold comprises SEQ ID NO: 6423. In some embodiments, the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6415. the loop region of the molecular scaffold comprises SEQ ID NO: 6421, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6425. In some embodiments, the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 64 i 7, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 642.4. In some embodiments, the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6418, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6423.
[0041] In some embodiments, the modulatory polynucleotide further comprises siRNA.
[0042] In some embodiments, the modulatory polynucleotide further comprises shRNA.
[0043] In some embodiments, the modulatory' polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more DMPK mRNA transcripts (e.g., one or more mutated DMPK mRNA transcripts), and wherein the passenger strand and the guide strand are located, respectively, on a 5 arm and a 3 arm of a stem loop structure, wherein the passenger strand is located between the 5" flanking region and the loop region and the guide strand is located between the loop region and the 3 flanking region.
[0844] In some embodiments, the modulatory polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more DMPK mRNA transcripts (e.g., one or more mutated DMPK mRNA transcripts), and wherein the guide strand and the passenger strand are located, respectively, on a 5 arm and a 3 arm of a stem loop structure, wherein the guide strand is located between the 5 flanking region and the loop region and tire passenger strand is located between the loop region and the 3 flanking region.
[0045] In some embodiments, the passenger strand is 15-30 nucleotides in length. In some embodiments, the passenger strand is 21-25 nucleotides in length. In some embodiments, the guide strand is 15-30 nucleotides in length. In some embodiments, the guide strand is 21-25 nucleotides in length. In some embodiments, the passenger strand is a t least 70% complementary to the guide strand.
[0046] In some embodiments, the one or more DMPK mRNA transcripts comprises SEQ ID NO: 6428 or SEQ ID NO: 6429, or a trinucleotide repeat expansion thereof.
[0047] In some embodiments, the viral genome comprises a promoter operably linked to the nucleic acid sequence encoding the modulatory polynucleotide.
[0048] In some embodiments, the viral genome further comprises an inverted terminal repeat (ITR) sequence.
[0049] In some embodiments, the viral genome comprises an ITR sequence positioned 5 relative to the nucleic acid sequence encoding tire modulatory' polynucleotide. In some embodiments, the viral genome comprises an ITR sequence positioned 3 relative to the nucleic acid sequence encoding the modulatory polynucleotide. In some embodiments, the viral genome comprises an ITR sequencepositioned 5 relative to the nucleic acid sequence encoding the modulatory polynucleotide, and an ITR sequence positioned 3 relative to the nucleic acid sequence encoding the modulatory polynucleotide.
[0050] In some embodiments, the present disclosure provides an AAV particle comprising (a) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises anRNAi agent targeting DMPK mRNA, and (b) an AAV capsid variant comprising: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4: and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4.
[0051] In some embodiments, the present disclosure provides an AAV particle comprising (a) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and (b) an AAV capsid variant comprising: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 36; and / or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36.
[0852] In some embodiments, the present disclosure provides a cell comprising the AAV particle of any one of tire preceding embodiments. In some embodiments, the cell is a mammalian cell (e.g., an HEK293 cell), an insect cell (e.g., an Sf9 cell), or a bacterial cell.
[0853] In some embodiments, tire present disclosure provides a method of making an AAV particle disclosed herein, the method comprising: (i) providing a cell comprising the viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA; and (ii) incubating the cell under conditions suitable to encapsulate the viral genome in the AAV capsid variant; thereby making the AAV particle.
[0054] In some embodiments, the AAV capsid variant of the AAV particle comprises: (i) a VP 1 protein comprising the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%. at least 98%, or at least 99% identity) to SEQ ID NO: 4; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98?% or at least 99% identity) to positions 138-742 SEQ ID NO: 4; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 4.
[0055] In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of positions 138-742 of SEQ ID NO: 4, and / or the amino acid sequence of positions 203-742 of SEQ ID NO: 4.
[0056] In some embodiments, the AAV capsid variant of the AAV particle comprises (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 36; (ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 36; or (hi) a VP3 protein comprising the amino acid sequence of positions 203- 742 of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 36.
[0057] In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 36, the amino acid sequence of positions 138-742 of SEQ ID NO: 36, and / or the amino acid sequence of positions 203-742 of SEQ ID NO: 36,
[0858] In some embodiments, the A AV capsid variant of the AAV particle comprises: (i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g.. at least 90%, at least 91%, at least 92%, at least 93%. at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity ) to SEQ ID NO: 982; (ii) a VP2 protein comprising the amin acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 982; or (iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 982.
[0059] In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982, the amino acid sequence of positions 138-742 of SEQ ID NO: 982, and / or the amino acid sequence of positions 203-742 of SEQ ID NO: 982.
[0060] In some embodiments, the method further comprises, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the ceil.
[0061] In some embodiments, the cell comprises a second nucleic acid molecule encoding the AAV capsid variant. In some embodiments, the method further comprises, prior to step (i), introducing the second nucleic acid molecule into the cell.
[0062] In some embodiments, the cell comprises a mammalian cell (e.g., an HEK293 cell), an insect cell (e.g., an Sf9 cell), or a bacterial cell.
[0063] In some embodiments, the present disclosure provides a pharmaceutical composition comprising an AAV particle disclosed herein and a pharmaceutically acceptable excipient.
[0064] In some embodiments, the present disclosure provides a method of delivering an A AV particle encoding a modulatory polynucleotide for reducing or eliminating expression of mutated DMPK mRNA to a subject, comprising administering to the subject an effective amount of a pharmaceutical composition or AAV particle disclosed herein.
[0065] In some embodiments, the present disclosure provides a method of treating a subject having or diagnosed with having a DMPK-related disorder, comprising administering to the subject an effective amount of a pharmaceutical composition or AAV particle disclosed herein. In some embodiments, the DMPK-related disorder is a DMPK-related neurodegenerative or neuromuscular disorder. In some embodiments, the DMPK-related neurodegenerative or neuromuscular disorder is myotonic dystrophy 1 (DM1). In some embodiments, the DM1 is congenital DM1 .
[0866] In some embodiments, the present disclosure provides a method of treating a subject having myotonic dystrophy 1 (DM1) or diagnosed with having myotonic dystrophy 1 (DM1), comprising administering to the subject an effective amount of a pharmaceutical composition or AAV particle disclosed herein. In some embodiments, the DM1 is congenital DM1.
[0067] In some embodiments, the subject has one or more mutations in the DMPK gene.
[0068] In some embodiments, the at least one mutation in the DMPK gene comprises a trinucleotide repeat expansion. In some embodiments, the trinucleotide repeat expansion in the DMPK gene is 50 or more CTG repeats (SEQ ID NO: 6434).
[0069] In some embodiments, the treating results in prevention of progression of the disorder in the subject. In some embodiments, the treating results in amelioration of the disorder. In some embodiments, the treating results in a change in one or more biomarkers of the disorder.
[0070] In some embodiments, the treating results in amelioration of at least one symptom of the disorder. In some embodiments, the at least one symptom comprises cataracts, myotonia, muscle weakness and wasting, cardiac conduction abnormalities, a myopathic face, learning difficulties, psychosocial problems including depression and / or anxiety, slurred speech, decreased fetal movement in the uterus, polyhydramnios, clubfoot, ventriculomegaly, hypotonia, a tented appearance of the upper lip, dysarthria, intellectual disability, hypotonia, respiratory insufficiency, or a combination thereof
[0071] In some embodiments, the subject is a human.
[0072] In some embodiments, the pharmaceutical composition or AAV particle is delivered to a cell, tissue, or region of muscle, optionally wherein the pharmaceutical composition or AAV particle is delivered via intravenous administration. In some embodiments, the muscle is one or more of cardiac, smooth, and / or skeletal muscle (e.g., quadriceps, vastus lateralis, and / or gastrocnemius), optionally wherein the pharmaceutical composition or AAV particle is delivered via intravenous administration.
[0073] In some embodiments, the pharmaceutical composition or AAV particle is delivered to a cell, tissue, or region of the CNS, e.g., a region of the brain or spinal cord, e.g,, the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brain stem caudate-putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof, and / or to neurons, e.g. GABAergic neurons, glutamatergic neurons, or a combination thereof.
[0074] In some embodiments, the method of delivering or treating further comprises evaluating, e.g., measuring, modulatory polynucleotide expression., the level of mutated DMPK mRNA expression, and / or the level of normal DMPK splicing in the subject, optionally DMPK mRNA splicing, in the subject, e.g., in a cell, tissue, or fluid of the subject.
[0075] In some embodiments, evaluating the level of modulatory polynucleotide expression is performed prior to and subsequent to administration of the pharmaceutical composition or AAV particle. In some embodiments, the level of modulatory polynucleotide expression prior to treatment is compared to the level of modulatory polynucleotide expression subsequent to administration.
[0876] In some embodiments, the level of modulatory polynucleotide expression is evaluated in a muscle cell or tissue. In some embodiments, the level of modulatory polynucleotide expression is evaluated in a cell or tissue of the central nervous system (e.g., parenchyma) from the subject. In some embodiments, the subject’s level of mutated DMPK mRNA expression subsequent to administration is decreased relative to the subject’s level of mutated DMPK mRNA expression prior to administration.
[0077] In some embodiments, the administration of a pharmaceutical composition or AAV particle described herein results in an increase in: (i) an increase in the number and / or level of viral genomes (VG) per cell in a muscle cell or tissue of the subject relative to the number and / or level of VG per cell in a non-muscle cell or tissue of the subject; (ii) a decrease in mutated DMPK mRNA expression in a muscle cell or tissue of the subject relative to baseline and / or relative to mutated DMPK mRNA expression in a muscle cell or tissue of an individual with a DMPK-related disorder who has not been administered the pharmaceutical composition or AAV particle; and / or (iii) an increase in normal mRNA splicing, optionally DMPK mRNA splicing, in a muscle cell or tissue of the subject relative to baseline and / or relative to normal mRNA splicing, optionally DMPK mRNA splicing, in a muscle cell or tissue of an individual with a DMPK-related disorder who has not been administered the pharmaceutical composition or AAV particle.
[0078] In some embodiments, the administration of a pharmaceutical composition or AAV particle described herein results in: (i) an increase in the number and / or level of viral genomes (VG) per cell in a CNS tissue (e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof of the subject relative to the number and / or level of VG per cell in a peripheral tissue of the subject; (ii) a decrease in mutated DMPK mRNA expression in a cell or a tissue of the CNS (e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof) of the subject relative to baseline and / or relative to mutated DMPK mRNA expression in a CNS cell or tissue of an individual with a DMPK-related disorder who has not been administered the pharmaceutical composition or AAV particle: and / or (iii) an increase in normal mRNA splicing, optionally DMPK mRNA splicing, in a cell or tissue of the CN S (e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof) of the subject relative to baseline and / or relative to normal mRNA splicing, optionally DMPK mRNA splicing, in a CNS cell or tissue of an individual with a DMPK-related disorder who has not been administered the pharmaceutical composition or AAV particle.
[0879] In some embodiments, the method of treating farther comprises administering to the subject at least one additional therapeutic agent and / or therapy. In some embodiments, the at least one additional therapeutic agent and / or therapy comprises an agent and / or therapy for treating the DMPK- related disorder. In some embodiments, the at least one additional therapeutic agent and / or therapy comprises an anti-diabetic drug, an anti-myotonic drug (e.g., mexiletine), a non-steroidal antiinflammatory drug, or a combination thereof.
[0080] In some embodiments, the method of treating further comprises administering an immunosuppressant to the subject. In some embodiments, the immunosuppressant comprises a corticosteroid (for example, and without limitation, prednisone, prednisolone, methylprednisolone, and / or dexamethasone), adrenocorticotropic hormone, rapamycin, mycophenolate mofetil, tacrolimus, rituximab, eculizumab hydroxychloroquine, alemtuzumab, hydroxyurea, fludarabine, and / or busulfan.
[0081] In some embodiments, the present disclosure provides a pharmaceutical composition or AAV particle described herein for use in the treatment of a DMPK-related disorder. In some embodiments, the DMPK -related disorder is my otonic dystrophy type 1 (DM1). In some embodiments, the DMPK -related disorder is congenital DM1.
[0082] In some embodiments, the present disclosure provides a use of a pharmaceutical composition or AAV particle described herein in the manufacture of a medicament for the treatment of a DMPK-related disorder. In some embodiments, the DMPK-related disorder is myotonic dystrophy type 1 (DM1). In some embodiments. DMPK-related disorder is congenital DM1.
[0083] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following enumerated embodiments.Enumerated Embodiments1. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome, wherein the viral genome comprises a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3], wherein:(i) optionally [N1] comprises XI, X2, and X3, wherein at least one of XI, X2, or X3 is G;(ii) [N2] comprises the amino acid sequence of SPH; and(iii) [N 3] comprises X4, X5, and X6, wherein at least one of X4, X5, or X6 is a basic amino add, e.g., aK orR.2. The AAV particle of embodiment 1, wherein X4, X5, or both of [N3] is a K.3. The AAV particle of embodiment 1 or 2, wherein X4, X5, or X6 of [N3] is an R.4. The AAV particle of any one of embodiments 1-3, wherein:(a) X4 of [N3] is: K, S, A, V, T, G, F, W. V, N, or R;(b) X5 of [ N 3 ] is: S, K, T. F, I, L, Y, H, M, or R; and / or(c) X6 of [N3] is: G, A, R, M, I, N. T, Y, D, P, V, L, E, W, N, Q, K, or S; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c).5. The AAV particle of any one of embodiments 1-4, wherein [N3] comprises SK, KA, KS, AR, RM, VK, AS, SR, VK, KR, KK, KN, VR, RS, RK, KT, TS, KF, FG, KI, IG, KL, LG, TT, TY, KY, YG, KD, KP, TR, RG, VR, GA, SL, SS, FL, WK, SA, RA, LR, KW, RR, GK, TK, NK, AK, KV, KG, KH, KM, TG, SE, SV, SW, SN, HG, SQ, LW, MG, MA, or SG.6. The AAV particle of any one of embodiments 1-5, wherein [N3] is or comprises SKA. KSG, ARM,VKS, ASR, VKI, KKN. VRM, RKA, KTS, KFG, KIG, KLG, KTT. KTY, KYG, SKD, SKP, TRG,VRG, KRG, GAR, KSA, KSR, SKL, SRA, SKR, SLR, SRG, SSR, FLR, SKW, SKS, WKA, VRR, SKV, SKT. SKG, GKA, TKA, NKA, SKL, SKN. AKA, KTG, KSL, KSE, KSV, KSW, KSN, KHG, KSQ, KSK, KLW, WKG, KMG, KMA, orRSG.7. The AAV particle of any one of embodiments 1-6, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 4701), SPHKS (SEQ ID NO: 4704). SPHAR (SEQ ID NO: 4705), SPHVK (SEQ ID NO: 4706), SPHAS (SEQ ID NO: 4707), SPHKK (SEQ ID NO: 4708), SPHVR (SEQ ID NO: 4709), SPHRK (SEQ ID NO: 4710), SPHKT (SEQ ID NO: 4711), SPHKF (SEQ ID NO: 4712), SPHKI (SEQ ID NO: 4713), SPHKL (SEQ ID NO: 4714), SPHKY (SEQ ID NO: 4715). SPHTR (SEQ ID NO: 4716), SPHKR (SEQ ID NO: 4717), SPHGA (SEQ ID NO: 4718). SPHSR (SEQ ID NO: 4719), SI-TISL (SEQ ID NO: 4720), SPHSS (SEQ ID NO: 4721), SPHFL (SEQ ID NO: 4722), SPHWK (SEQ ID NO: 4723), SPHGK (SEQ ID NO: 4724), SPHTK (SEQ ID NO: 4725), SPHNK (SEQ ID NO: 4726), SPHAK (SEQ ID NO: 4727), SPHKH (SEQ ID NO: 4728), SPHKM (SEQ ID NO: 4729), or SPHRS (SEQ ID NO: 4730).8. The AAV particle of any one of embodiments 1-7, wherein [N2]-[N3] is or comprises:(i) SPHSKA (SEQ ID NO: 941), SPHKSG (SEQ ID NO: 946), SPHARM (SEQ ID NO: 947), SPHVKS (SEQ ID NO: 948), SPHASR (SEQ ID NO: 949). SPHVKI (SEQ ID NO: 950), SPIIKKN (SEQ ID NO: 954), SPHVRM (SEQ ID NO: 955), SPHRKA (SEQ ID NO: 956), SPHKFG (SEQ ID NO: 957), SPHKIG (SEQ ID NO: 958), SPHKLG (SEQ ID NO: 959). SPHK.TS (SEQ ID NO: 963), SPHKTT (SEQ ID NO: 964), SPHKTY (SEQ ID NO: 965), SPHKYG (SEQ ID NO: 966), SPHSKD (SEQ ID NO: 967), SPHSKP (SEQ ID NO: 968), SPHTRG (SEQ ID NO: 972), SPIIVRG (SEQ ID NO: 973), SPHKRG (SEQ ID NO: 974), SPIIGAR (SEQ ID NO: 975), SPHKSA (SEQ ID NO: 977), SPHKSR (SEQ ID NO: 951), SPHSKL (SEQ ID NO: 960), SPHSRA (SEQ ID NO: 969), SPHSKR (SEQ ID NO: 978), SPHSLR (SEQ ID NO: 952), SPHSRG (SEQ ID NO: 961), SPHSSR (SEQ ID NO: 970), SPHFLR (SEQ ID NO: 979), SPHSKW (SEQ ID NO: 953), SPHSKS (SEQ ID NO: 962), SPHWKA (SEQ ID NO: 971), SPHVRR (SEQ ID NO: 980), SPHSKT (SEQ ID NO: 4731), SPHSKG (SEQ ID NO: 4732), SPHGKA (SEQ ID NO: 4733). SPHNKA (SEQ ID NO: 4734), SPHSKN (SEQ ID NO: 4735), SPHAKA (SEQ ID NO: 4736). SPHSKV (SEQ ID NO: 4737), SPHKTG (SEQ ID NO: 4738). SPHTKA (SEQ ID NO: 4739), SPHKSL (SEQ ID NO: 4740), SPHKSE (SEQ ID NO: 4741), SPHKSV (SEQ ID NO: 4742), SPHKS W (SEQ ID NO: 4743), SPHKSN (SEQ ID NO: 4744), SPHKHG (SEQ ID NO: 4745). SPHKSQ (SEQ ID NO: 4746), SPHKSK (SEQ ID NO: 4747), SPHKLW (SEQ ID NO: 4748), SPHWKG (SEQ ID NO: 4749), SPHKMG (SEQ ID NO: 4750), SPHKMA (SEQ ID NO: 4751), or SPHRSG (SEQ ID NO: 976):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one. two. or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).9. The AAV particle of any one of embodiments 1-8, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., V. R, D, E, M, T, I, S, A, N, L. K, H, P, W. or C), an amino acid other than S at position 454 (e.g., V, L. N, D, H, R, P, G, T, I, A, E, Y, M, or Q), and / or an amino acid other than G at position 455 (e.g., C, L, D, E, Y, H, V, A, N. P, or S), numbered according to any one of SEQ ID NOs: 36-59, 138. 981, or 982.10. The AAV particle of any one of embodiments 1-8, wherein the AAV capsid variant comprises the amino acid G at position 453, the amino acid S at position 454, and the amino acid G at position 455, numbered according to SEQ ID NO: 138 or 981.1 1. The AAV particle of any one of embodiments 1-9, wherein the AAV capsid variant comprises the amino acid G at position 453, the amino acid H at position 454, and the amino acid D at position 455, numbered according to SEQ ID NO: 138 or 982.12. The AAV particle of any one of embodiments 1-11, wherein [N1] comprises X1, X2, and X3, wherein at least one of XI, X2, or X3 is G.13. The AAV particle of any one of embodiments 1-12, wherein:(a) X1 of [N 1] is: G, V, R, D, E, M, T, I, S, A, N, L, K, H, P, W, or C;(b) X2 of [N1] is: S, V, L, N, D, H, R, P, G, T, I, A, E, Y, M, or Q; and / or(c) X3 of [N 1] is: G, C, L, D, E, Y, H, V, A, N, P, or S; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c).14. The AAV particle of any one of embodiments 1 -13, wherein [N1] comprises GS, SG, GH, HD, GQ, QD, VS. CS. GR, RG, QS, SH, MS, RN, TS, IS, GP, ES, SS. GN, AS, NS, LS, GG, KS. GT, PS, RS, GI, WS, DS, ID, GL, DA, DG, ME, EN, KN, KE, Al, NG, PG, TG, SV, IG. LG, AG, EG, SA, YD. HE, HG, RD, ND, PD, MG, QV, DD. HN, HP, GY, GM, GD. or HS.15. The AAV particle of any one of embodiments 1-14, wherein [N1] is or comprises GSG, GHD,GQD, VSG, CSG, GRG, CSH, GQS, GSH, RVG, CSC, GLL, GDD, GHE, GNY, MSG, RNG, TSG, ISG, GPG, ESC. SSG, GNG, ASG, NSG, LSG, GGG, KSG. HSG, GTG, PSG, GS V, RSG, GIG,WSG, DSG, IDG, GLG, DAG, DGG, MEG, ENG, GSA, KNG, KEG, AIG, GYD, GHG, GRD, GND, GPD, GMG, GQV, GHN, GHP, or GHS.16. The AAV particle of any one of embodiments 1-15, wherein [N1]-[N2] comprises:(i) SGSPH (SEQ ID NO: 4752), HDSPH (SEQ ID NO: 4703), QDSPH (SEQ ID NO: 4753), RGSPH (SEQ ID NO: 4754), SHSPH (SEQ ID NO: 4755), QSSPH (SEQ ID NO: 4756), DDSPH (SEQ ID NO: 4757), HESPH (SEQ ID NO: 4758), NYSPH (SEQ ID NO: 4759), VGSPH (SEQ ID NO: 4760), SCSPH (SEQ ID NO: 4761), LLSPH (SEQ ID NO: 4762). NGSPH (SEQ ID NO: 4763), PGSPH (SEQ ID NO: 4764). GGSPH (SEQ ID NO: 4765), TGSPH (SEQ ID NO: 4766), SVSPH (SEQ ID NO: 4767), IGSPH (SEQ ID NO: 4768), DGSPH (SEQ ID NO: 4769), LGSPH (SEQ ID NO: 4770), AGSPH (SEQ ID NO: 4771), EGSPH (SEQ ID NO: 4772), SASPH (SEQ ID NO: 4773), YDSPH (SEQ ID NO: 4774), HGSPH (SEQ ID NO: 4775), RDSPH (SEQ ID NO: 4776), NDSPH (SEQ ID NO: 4777), PDSPH (SEQ ID NO: 4778), MGSPH (SEQ ID NO: 4779), QVSPH (SEQ ID NO: 4780), HNSPH (SEQ ID NO: 4781), HPSPH (SEQ ID NO: 4782), orHSSPH (SEQ ID NO: 4783);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof;(iii an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).17. The AAV particle of any one of embodiments 1-16, wherein [N1]-[N2] is or comprises:(i) GSGSPH (SEQ ID NO: 4695), GHDSPH (SEQ ID NO: 4784), GQDSPH (SEQ ID NO: 4785), VSGSPH (SEQ ID NO: 4786), CSGSPH (SEQ ID NO: 4787), GRGSPH (SEQ ID NO: 4788), CSHSPH (SEQ ID NO: 4789), GQSSPH (SEQ ID NO: 4790), GSHSPH (SEQ ID NO: 4791), GDDSPH (SEQ ID NO: 4792), GHESPH (SEQ ID NO: 4793), GNYSPH (SEQ ID NO: 4794), R VGSPH (SEQ ID NO: 4795), GSCSPH (SEQ ID NO: 4796), GLLSPH (SEQ ID NO: 4797), MSGSPH (SEQ ID NO: 4798), RNGSPH (SEQ ID NO: 4799), TSGSPH (SEQ ID NO: 4800), ISGSPH (SEQ ID NO: 4801), GPGSPH (SEQ ID NO: 4802), ESGSPH (SEQ ID NO: 4803), SSGSPH (SEQ ID NO: 4804), GNGSPH (SEQ ID NO: 4805). ASGSPH (SEQ ID NO: 4806), NSGSPH (SEQ ID NO: 4807), LSGSPH (SEQ ID NO: 4808), GGGSPH (SEQ ID NO: 4809), KSGSPH (SEQ ID NO: 4810), HSGSPH (SEQ ID NO: 4811), GTGSPH (SEQ ID NO: 4812), PSGSPH (SEQ ID NO: 4813). GSVSPH (SEQ ID NO: 4814), RSGSPH (SEQ ID NO: 4815), GIGSPH (SEQ ID NO: 4816), WSGSPH (SEQ ID NO: 4817), DSGSPH (SEQ ID NO: 4818), IDGSPH (SEQ ID NO: 4819), GLGSPH (SEQ ID NO: 4820), DAGSPH (SEQ ID NO: 482.1), DGGSPH (SEQ ID NO: 4822), MEGSPH (SEQ ID NO: 4823), ENGSPH (SEQ ID NO: 4824),GSASPH (SEQ ID NO: 4825), KNGSPH (SEQ ID NO: 4826), KEGSPH (SEQ ID NO: 4827), AIGSPH (SEQ ID NO: 4828), GYDSPH (SEQ ID NO: 4829), GHGSPH (SEQ ID NO: 4830). GRDSPH (SEQ ID NO: 4831), GNDSPH (SEQ ID NO: 4832), GPDSPH (SEQ ID NO: 4833), GMGSPH (SEQ ID NO: 4834), GQVSPH (SEQ ID NO: 4835), GHNSPH (SEQ ID NO: 4836). GHPSPH (SEQ ID NO: 4837), or GHSSPH (SEQ ID NO: 4838);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4. or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).18. The AAV particle of any one of embodiments 1-17, wherein [N1]-[N2]-[N3] comprises:(i) SGSPHSK (SEQ ID NO: 4839), HDSPHKS (SEQ ID NO: 4840), SGSPHAR (SEQ ID NO: 4841), SGSPHVK (SEQ ID NO: 4842), QDSPHKS (SEQ ID NO: 4843), SGSPHKK (SEQ ID NO: 4844), SGSPHVR (SEQ ID NO: 4845). SGSPHAS (SEQ ID NO: 4846), SGSPHRK (SEQ ID NO: 4847), SGSPHKT (SEQ ID NO: 4848), SHSPHKS (SEQ ID NO: 4849). QSSPHRS (SEQ ID NO: 4850). RGSPHAS (SEQ ID NO: 4851), RGSPHSK (SEQ ID NO: 4852), SGSPHKF (SEQ ID NO: 4853). SGSPHKI (SEQ ID NO: 4854), SGSPHKL (SEQ ID NO: 4855), SGSPHKY (SEQ ID NO: 4856). SGSPHTR (SEQ ID NO: 4857), SHSPHKR (SEQ ID NO: 4858), SGSPHGA (SEQ ID NO: 4859), HDSPHKR (SEQ ID NO: 4860), DDSPHKS (SEQ ID NO: 4861), HESPIIKS (SEQ ID NO: 4862), NYSPHKI (SEQ ID NO: 4863). SGSPHSR (SEQ ID NO: 4864), SGSPIISL (SEQ ID NO: 4865), SGSPIISS (SEQ ID NO: 4866), VGSPHSK (SEQ ID NO: 4867), SCSPHRK (SEQ ID NO: 4868), SGSPHFL (SEQ ID NO: 4869), LLSPHWK (SEQ ID NO: 4870), NGSPHSK (SEQ ID NO: 4871), PGSPHSK (SEQ ID NO: 4872), GGSPHSK (SEQ ID NO: 4873), TGSPHSK (SEQ ID NO: 4874), SVSPHGK (SEQ ID NO: 4875), SGSPHTK (SEQ ID NO: 4876), IGSPHSK (SEQ ID NO: 4877), DGSPHSK (SEQ ID NO: 4878), SGSPHNK (SEQ ID NO: 4879), LGSPHSK (SEQ ID NO: 4880), AGSPHSK (SEQ ID NO: 4881), EGSPHSK (SEQ ID NO: 4882), SASPHSK (SEQ ID NO: 4883), SGSPHAK (SEQ ID NO: 4884), HDSPHKI (SEQ ID NO: 4885), YDSPHKS (SEQ ID NO: 4886), HDSPHKT (SEQ ID NO: 4887). RGSPHKR (SEQ ID NO: 4888), HGSPHSK (SEQ ID NO: 4889), RDSPHKS (SEQ ID NO: 4890), NDSPHK.S (SEQ ID NO: 4891), QDSPHKI (SEQ ID NO: 4892), PDSPHK I (SEQ ID NO: 4893 ), PDSPHKS (SEQ ID NO: 4894), MGSPHSK (SEQ ID NO: 4895), HDSPHKH (SEQ ID NO: 4896), QVSPHKS (SEQ ID NO: 4897), HNSPHKS (SEQ ID NO: 4898), NGSPHKR (SEQ ID NO: 4899), HDSPIIKY (SEQ ID NO: 4900), NDSPIIKI (SEQ ID NO: 4901), IIDSPHKL (SEQ ID NO: 4902). HPSPHWK (SEQ ID NO: 4903), HDSPIIKM (SEQ ID NO: 4904), orHSSPHRS (SEQ ID NO: 4905);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, or 6 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).19. The AAV particle of any one of embodiments 1-18, wherein [N1]-[N2]-[N3] is or comprises:(i) GSGSPHSKA (SEQ ID NO: 4697), GHDSPHKSG (SEQ ID NO: 4698), GSGSPI I ARM (SEQ ID NO: 4906), GSGSPHVKS (SEQ ID NO: 4907), GQDSPHKSG (SEQ ID NO: 4908), GSGSPHASR (SEQ ID NO: 4909), GSGSPHVK1 (SEQ ID NO: 4910), GSGSPHKKN (SEQ ID NO: 4911), GSGSPHVRM (SEQ ID NO: 4912), VSGSPHSKA (SEQ ID NO: 4913), CSGSPHSKA (SEQ ID NO: 4914), GSGSPHRKA (SEQ ID NO: 4915), CSGSPHKTS (SEQ ID NO: 4916), CSHSPHKSG (SEQ ID NO: 4917), GQSSPHRSG (SEQ ID NO: 4918), GRGSPHASR (SEQ ID NO: 4919), GRGSPHSKA (SEQ ID NO: 4920), GSGSPHKFG (SEQ ID NO: 4921), GSGSPHKIG (SEQ ID NO: 4922), GSGSPHKLG (SEQ ID NO: 4923), GSGSPHKTS (SEQ ID NO: 4924), GSGSPHKTT (SEQ ID NO: 4925), GSGSPHKTY (SEQ ID NO: 4926), GSGSPHKYG (SEQ ID NO: 4927). GSGSPHSKD (SEQ ID NO: 4928), GSGSPHSKP (SEQ ID NO: 4929), GSGSPHTRG (SEQ ID NO: 4930), GSGSPHVRG (SEQ ID NO: 4931), GSHSPHKRG (SEQ ID NO: 4932), GSHSPHKSG (SEQ ID NO: 4933), VSGSPHASR (SEQ ID NO: 4934), VSGSPHGAR (SEQ ID NO: 4935), VSGSPHKFG (SEQ ID NO: 4936), GHDSPHKRG (SEQ ID NO: 4937), GDDSPHKSG (SEQ ID NO: 4938), GHESPHKSA (SEQ ID NO: 4939). GHDSPHKSA (SEQ ID NO: 4940), GN YSPHKIG (SEQ ID NO: 4941), GHDSPHKSR (SEQ ID NO: 4942), GSGSPHSKL (SEQ ID NO: 4943), GSGSPHSRA (SEQ ID NO: 4944), GSGSPHSKR (SEQ ID NO: 4945), GSGSPHSLR (SEQ ID NO: 4946), GSGSPHSRG (SEQ ID NO: 4947), GSGSPHSSR (SEQ ID NO: 4948), RVGSPHSKA (SEQ ID NO: 4949), GSCSPHRKA (SEQ ID NO: 4950), GSGSPHFLR (SEQ ID NO: 4951), GSGSPHSKW (SEQ ID NO: 4952), GSGSPHSKS (SEQ ID NO: 4953), GLLSPHWKA (SEQ ID NO: 4954), GSGSPHVRR (SEQ ID NO: 4955), GSGSPHSKV (SEQ ID NO: 4956), MSGSPHSKA (SEQ ID NO: 4957), RNGSPHSKA (SEQ ID NO: 4958), TSGSPHSKA (SEQ ID NO: 4959), ISGSPHSKA (SEQ ID NO: 4960), GPGSPHSKA (SEQ ID NO: 4961), GSGSPHSKT (SEQ ID NO: 4962), ESGSPHSKA (SEQ ID NO: 4963), SSGSPHSKA (SEQ ID NO: 4964), GNGSPHSKA (SEQ ID NO: 4965). ASGSPHSKA (SEQ ID NO: 4966), NSGSPHSKA (SEQ ID NO: 4967), ESGSPHSKA (SEQ ID NO: 4968), GGGSPHSKA (SEQ ID NO: 4969), KSGSPHSKA (SEQ ID NO: 4970), GGGSPHSKS (SEQ ID NO: 4971), GSGSPHSKG (SEQ ID NO: 4972). ESGSPHSKA (SEQ ID NO: 4973), GTGSPHSKA (SEQ ID NO: 4974), PSGSPHSKA (SEQ ID NO: 4975), GSVSPHGKA (SEQ ID NO: 4976). RSGSPHSKA (SEQ ID NO: 4977), GSGSPHTKA (SEQ ID NO: 4978), GIGSPHSKA (SEQ ID NO: 4979), WSGSPI ISKA (SEQ ID NO: 4980),DSGSPHSKA (SEQ ID NO: 4981), IDGSPHSKA (SEQ ID NO: 4982), GSGSPHNKA (SEQ ID NO: 4983), GLGSPHSKS (SEQ ID NO: 4984), DAGSPHSKA (SEQ ID NO: 4985), DGGSPHSKA (SEQ ID NO: 4986), MEGSPHSKA (SEQ ID NO: 4987), ENGSPHSKA (SEQ ID NO: 4988), GSASPHSKA (SEQ ID NO: 4989), GNGSPHSKS (SEQ ID NO: 4990), KNGSPHSKA (SEQ ID NO: 4991), KEGSPHSKA (SEQ ID NO: 4992), ATGSPHSKA (SEQ ID NO: 4993), GSGSPHSKN (SEQ ID NO: 4994), GSGSPHAKA (SEQ ID NO: 4995). GHDSPHKIG (SEQ ID NO: 4996), GYDSPHKSG (SEQ ID NO: 4997). GHESPHKSG (SEQ ID NO: 4998), GHDSPHKTG (SEQ ID NO: 4999), GRGSPHKRG (SEQ ID NO: 5000), GQDSPHKSG (SEQ ID NO: 4908), GHDSPHKSL (SEQ ID NO: 5001), GHGSPI ISKA (SEQ ID NO: 5002), GHDSPHKSE (SEQ ID NO: 5003), VSGSPHSKA (SEQ ID NO: 4913), GRDSPHKSG (SEQ ID NO: 5004), GNDSPHKSV (SEQ ID NO: 5005), GQDSPHKIG (SEQ ID NO: 5006), GHDSPHKSV (SEQ ID NO: 5007), GPDSPHKIG (SEQ ID NO: 5008), GPDSPHKSG (SEQ ID NO: 5009), GHDSPHKSW (SEQ ID NO: 5010), GHDSPHKSN (SEQ ID NO: 5011), GMGSPHSKT (SEQ ID NO: 5012), GHDSPHKHG (SEQ ID NO: 5013), GQVSPHKSG (SEQ ID NO: 5014), GDDSPHKSV (SEQ ID NO: 5015), GHNSPHKSG (SEQ ID NO: 5016), GNGSPHKRG (SEQ ID NO: 5017), GHDSPHKYG (SEQ ID NO: 5018), GHDSPHKSQ (SEQ ID NO: 5019), GNDSPHKIG (SEQ ID NO: 5020), GHDSPHK.SK (SEQ ID NO: 5021), GHDSPHKLW (SEQ ID NO: 5022), GHPSPHWKG (SEQ ID NO: 5023), GHDSPHKMG (SEQ ID NO: 5024), GHDSPHKMA (SEQ ID NO: 5025), or GHSSPHRSG (SEQ ID NO: 5026);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, or 8 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more titan four different amino acids, rela tive to any one of the amino acid sequences in (i).20. The AAV particle of any one of embodiments 1-19, wherein [N3] comprises SK, KA, KS, or SG.21. The AAV particle of any one of embodiments 1-20, wherein [N3] is or comprises SKA, KSG, or KYG.22. The AA V particle of any one of embodiments 1 -21 , wherein [N2.]-[N3] comprises SPHSK (SEQID NO: 4701), SPHKS (SEQ ID NO: 4704), or SPHKY (SEQ ID NO: 4715).23. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHSKA (SEQ ID NO: 941).24. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHKSG(SEQ ID NO: 946).25. The AAV particle of any one of embodiments 1-22, wherein [N2]-[N3] is or comprises SPHKYG (SEQ ID NO: 966).26. The AAV particle of any one of embodiments 1 -25, wherein [N1] comprises GS, SG, GH, or HD.27. The AAV particle of any one of embodiments 1-26, wherein [N1] is or comprises GSG.28. The AAV particle of any one of embodiments 1-26, wherein [N1] is or comprises GHD.29. The AAV particle of any one of embodiments 1-23 or 26-27, wherein [N1]-[N2]-[N3] comprisesSGSPHSK (SEQ ID NO: 4839).30. The AAV particle of any one of embodiments 1-22, 24, 26, or 28, wherein [N1]-[N2j-[N3] comprises HDSPHKS (SEQ ID NO: 4840).31. The AAV particle of any one of embodiments 1-2.2 or 25-2.7, wherein [N1]-[N2]-[N3] comprisesSGSPHKYG (SEQ ID NO: 5027).32. The AAV particle of any one of embodiments 1-8, 10, 12-23, 26-2.7, or 29, wherein [N1]-[N2]- [ N 3] is or comprises GSGSPHSKA (SEQ ID NO: 4697).33. The AAV particle of any one of embodiments 1-9, 11-22, 24, 26, 28, or 30, wherein [N1]-[N2 j- [N3 ] is or comprises GHDSPHKSG (SEQ ID NO: 4698).34. The AAV particle of any one of embodiments 1-8, 10, 12-22, 25-27, or 31, wherein [N1]-[N2]- [N3] is or comprises GSGSPHKYG (SEQ TD NO: 4927).35. The AAV particle of any one of embodiments 1-34, wherein [N1]-[N2]-[N3] replaces positions453-455, numbered according to SEQ ID NO: 138,36. The AAV particle of any one of embodiments 1-35, wherein the AAV capsid vanant comprises an amino acid other than Q at position 456 (e.g., W, K, R, G, L, V, S, P, II. K, I, M, A, E, or F), an amino acid other than N at position 457 (e.g., Y, C, K, T, H, R. D, V, S, P, G, W, E, F, A, I. M, Q, or L). an amino acid other than Q at position 458 (e.g., G. K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S. E,N, or Y), and / or an amino acid other than Q at position 459 (e.g, H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D. or V), numbered according to SEQ ID NO: 138.37. The AAV particle of any one of embodiments 1 -36, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., W, K, R, G, L, V, S, P, H, K, I, M, A, E, or F), an amino acid other than N at position 463 (e.g., Y. C, K, T, H, R, D, V, S, P, G, W, E, F, A, I, M, Q, or L), an amino acid other than Q at position 464 (e.g., G, K, H, R, T, L, D, A, P, I, F, V, M, W, Y, S, E, N, or Y), and / or an amino acid other than Q at position 465 (e.g., H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D. or V), numbered according to SEQ ID NO: 981, 982, 36, 37, 39, 40, 42-46. 48, 49, 50, 52, 53. 56, or 57.38. The AAV particle of any one of embodiments 1-37, wherein the AAV capsid variant comprises:(a) the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, and / or the amino acid Q at position 459, numbered according to SEQ ID NO: 138; or(b) the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, and / or the amino acid Q at position 465, numbered according to SEQ ID NO: 981, 982, 36, 37, 39, 40, 42-46, 48, 49, 50, 52, 53, 56, or 57.39. The AAV particle of any one of embodiments 1-38, wherein the AAV capsid variant further comprises [N4], wherein [N4] comprises X7 X8 X9 X10, and wherein:(a) X7 is: Q, W, K, R, G, L, V, S, P, II, K, I, M, A, E. or F;(b) X8 is: N, Y, C, K, T, II. R, D, V. S, P. G, W, E, F, A, I. M, Q, or L;(c) X9 is: Q, G. K, H, R, T, L, D, A, P, I, F, V, M, W. Y, S. E, N, or Y; and(d) X10 is: Q, H, L, R, W, K, A, P, E, M, I, S, G, N, Y, C, V, T, D, or V; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g, a conservative substitution, of any of the aforesaid amino acids in (a)-(d).40. The AAV particle of embodiment 39, wherein:(a) X7 of [N4] is Q orR;(b) X8 of [N4] is N or R;(c) X9 of [N4] is Q or R; and(d) X10 of [N4] is Q, L, orR.41. The AAV particle of embodiment 39 or 40, wherein [N4] is or comprises:(i) QNQQ (SEQ ID NO: 5028), WNQQ (SEQ ID NO: 5029), QYYV (SEQ ID NO: 5030), RRQQ (SEQ ID NO: 5031), GCGQ (SEQ ID NO: 5032), LRQQ (SEQ ID NO: 5033), RNQQ (SEQ ID NO: 5034), VNQQ (SEQ ID NO: 5035), FRLQ (SEQ ID NO: 5036), FNQQ (SEQ ID NO: 5037).LLQQ (SEQ ID NO: 5038), SNQQ (SEQ ID NO: 5039), RLQQ (SEQ ID NO: 5040), LNQQ (SEQ ID NO: 5041), QRKL (SEQ ID NO: 5042). LRRQ (SEQ ID NO: 5043), QRLR (SEQ ID NO: 5044), QRRL (SEQ ID NO: 5045), RRLQ (SEQ ID NO: 5046), RLRQ (SEQ ID NO: 5047), SKRQ (SEQ ID NO: 5048), QLYR (SEQ ID NO: 5049), QLTV (SEQ ID NO: 5050), QNKQ (SEQ ID NO: 5051), KNQQ (SEQ ID NO: 5052), QKQQ (SEQ ID NO: 5053), QTQQ (SEQ ID NO: 5054), QNHQ (SEQ ID NO: 5055), QHQQ (SEQ ID NO: 5056), QNQH (SEQ ID NO: 5057), QHR.Q (SEQ ID NO: 5058), LTQQ (SEQ ID NO: 5059), QNQW (SEQ ID NO: 5060), QNTH (SEQ ID NO: 5061). RRRQ (SEQ ID NO: 5062), QYQQ (SEQ ID NO: 5063), QNDQ (SEQ ID NO: 5064), QNRH (SEQ ID NO: 5065), RDQQ (SEQ ID NO: 5066), PNLQ (SEQ ID NO: 5067), HVRQ (SEQ ID NO: 5068), PNQH (SEQ ID NO: 5069), HNQQ (SEQ ID NO: 5070), QSQQ (SEQ ID NO: 5071), QPAK (SEQ ID NO: 5072), QNL A (SEQ ID NO: 5073), QNQL (SEQ ID NO: 5074), QGQQ (SEQ ID NO: 5075), LNRQ (SEQ ID NO: 5076), QNPP (SEQ ID NO: 5077), QNLQ (SEQ ID NO: 5078), QDQE (SEQ ID NO: 5079), QDQQ (SEQ ID NO: 5080), HWQQ (SEQ ID NO: 5081), PNQQ (SEQ ID NO: 5082), PEQQ (SEQ ID NO: 5083), QRTM (SEQ ID NO: 5084), LHQH (SEQ ID NO: 5085), QHRI (SEQ ID NO: 5086), QYIH (SEQ ID NO: 5087), QKFE (SEQ ID NO: 5088), QFPS (SEQ ID NO: 5089). QNPL (SEQ ID NO: 5090), QAI.K (SEQ ID NO: 5091), QNRQ (SEQ ID NO: 5092), QYQH (SEQ ID NO: 5093). QNPQ (SEQ ID NO: 5094), QHQL (SEQ ID NO: 5095), QSPP (SEQ ID NO: 5096), QAKL (SEQ ID NO: 5097). KSQQ (SEQ ID NO: 5098), QDRP (SEQ ID NO: 5099), QNLG (SEQ ID NO: 5100), QAFH (SEQ ID NO: 5101), QNAQ (SEQ ID NO: 5102), HNQL (SEQ ID NO: 5103), QKLN (SEQ ID NO: 5104), QNVQ (SEQ ID NO: 5105), QAQQ (SEQ ID NO: 5106), QTPP (SEQ ID NO: 5107), QPPA (SEQ ID NO: 5108), QERP (SEQ ID NO: 5109), QDLQ (SEQ ID NO: 5110). QAMH (SEQ ID NO: 5111), QHPS (SEQ ID NO: 5112), PGLQ (SEQ ID NO: 5113), QGIR (SEQ ID NO: 5114), QAPA (SEQ ID NO: 5115), QIPP (SEQ ID NO: 5116), QTQL (SEQ ID NO: 5117), QAPS (SEQ ID NO: 5118), QNTY (SEQ ID NO: 5119), QDKQ (SEQ ID NO: 5120), QNHL (SEQ ID NO: 5121), QIGM (SEQ ID NO: 5122), LNKQ (SEQ ID NO: 5123), PNQL (SEQ ID NO: 5124), QLQQ (SEQ ID NO: 5125), QRMS (SEQ ID NO: 5126), QG1L (SEQ ID NO: 5127), QDRQ (SEQ ID NO: 5128), RDWQ (SEQ ID NO: 5129), QERS (SEQ ID NO: 5130), QNYQ (SEQ ID NO: 5131), QRTC (SEQ ID NO: 5132), QIGH (SEQ ID NO: 5133), QGAI (SEQ ID NO: 5134), QVPP (SEQ ID NO: 5135), QVQQ (SEQ ID NO: 5136), LMRQ (SEQ ID NO: 5137), QYSV (SEQ ID NO: 5138), QAIT (SEQ ID NO: 5139), QKTL (SEQ ID NO: 5140), QLHH (SEQ ID NO: 5141), QNII (SEQ ID NO: 5142), QGHH (SEQ ID NO: 5143), QSKV (SEQ ID NO: 5144), QLPS (SEQ ID NO: 5145), IGKQ (SEQ ID NO: 5146), QAIH (SEQ ID NO: 5147), QHGL (SEQ ID NO: 5148), QFMC (SEQ ID NO: 5149), QNQM (SEQ ID NO: 5150), QHLQ (SEQ ID NO: 5151), QPAR (SEQ ID NO: 5152), QSLQ (SEQ ID NO: 5153), QSQL (SEQ ID NO: 5154), HSQQ (SEQ ID NO: 5155), QMPS (SEQ ID NO: 5156), QGSL (SEQ ID NO: 5157), QVPA (SEQ ID NO: 5158). HYQQ (SEQ ID NO: 5159), QVPS (SEQ ID NO: 5160), RGEQ (SEQ ID NO: 5161). PGQQ (SEQ ID NO: 5162), LEQQ (SEQ ID NO: 5163), QNQS (SEQ ID NO: 5164), QKVI (SEQ ID NO: 5165), QNND (SEQ ID NO: 5166), QSVH (SEQID NO: 5167), QPLG (SEQ ID NO: 5168), HNQE (SEQ ID NO: 5169), Q1QQ (SEQ ID NO: 5170), QVRN (SEQ ID NO: 5171), PSNQ (SEQ ID NO: 5172), QVGH (SEQ ID NO: 5173), QRDI (SEQ ID NO: 5174), QMPN (SEQ ID NO: 5175), RGLQ (SEQ ID NO: 5176), PSLQ (SEQ ID NO: 5177), QRDQ (SEQ ID NO: 5178), QAKG (SEQ ID NO: 5179), QSAH (SEQ ID NO: 5180), QSTM (SEQ ID NO: 5181), QREM (SEQ ID NO: 5182), QYRA (SEQ ID NO: 5183), QRQQ (SEQ ID NO: 5184), QWQQ (SEQ ID NO: 5185), QRMN (SEQ ID NO: 5186), GDSQ (SEQ ID NO: 5187), QKIS (SEQ ID NO: 5188), PSMQ (SEQ ID NO: 5189), SPRQ (SEQ ID NO: 5190), MEQQ (SEQ ID NO: 5191), QYQN (SEQ ID NO: 5192), QIRQ (SEQ ID NO: 5193), QSVQ (SEQ ID NO: 5194), RSQQ (SEQ ID NO: 5195), QNKL (SEQ ID NO: 5196), QIQH (SEQ ID NO: 5197), PRQQ (SEQ ID NO: 5198). HTQQ (SEQ ID NO: 5199), QRQH (SEQ ID NO: 5200), RNQE (SEQ ID NO: 5201). QSKQ (SEQ ID NO: 5202), QNQP (SEQ ID NO: 5203), QSPQ (SEQ ID NO: 5204), QTRQ (SEQ ID NO: 5205), QNLH (SEQ ID NO: 5206), QNQE (SEQ ID NO: 5207), LNQP (SEQ ID NO: 5208), QNQD (SEQ ID NO: 5209), QNLL (SEQ ID NO: 5210), QLVI (SEQ ID NO: 5211), RTQE (SEQ ID NO: 5212), QTHQ (SEQ ID NO: 5213), QDQH (SEQ ID NO: 5214), QSQH (SEQ ID NO: 5215), VRQQ (SEQ ID NO: 5216), AWQQ (SEQ ID NO: 5217), QSVP (SEQ ID NO: 5218), QNIQ (SEQ ID NO: 5219), LDQQ (SEQ ID NO: 5220), PDQQ (SEQ ID NO: 5221), ESQQ (SEQ ID NO: 5222), QRQL (SEQ ID NO: 5223), QIIV (SEQ ID NO: 5224), QKQS (SEQ ID NO: 5225), QSHQ (SEQ ID NO: 5226), QFW (SEQ ID NO: 5227), QSQP (SEQ ID NO: 5228). QNEQ (SEQ ID NO: 5229), INQQ (SEQ ID NO: 5230). RNRQ (SEQ ID NO: 5231), RDQK (SEQ ID NO: 5232), QWKR (SEQ ID NO: 5233), ENR.Q (SEQ ID NO: 5234), QTQP (SEQ ID NO: 5235), QKQL (SEQ ID NO: 52.36), RNQL (SEQ ID NO: 5237), ISIQ (SEQ ID NO: 5238), QI 'VC (SEQ ID NO: 5239), QQIM (SEQ ID NO: 5240), LNHQ (SEQ ID NO: 5241), QNQA (SEQ ID NO: 5242), QMIH (SEQ ID NO: 5243), RNHQ (SEQ ID NO: 5244), or QKMN (SEQ ID NO: 5245):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).42. The AA V particle of any one of embodiments 39-41, wherein [N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any of SEQ ID NOs: 1800-2241;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11. or 12 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).43. The AAV particle of any one of embodiments 39-42, wherein [N1]-[N2j-[N3]-[N4] is or comprises GSGSPHSKAQNQQ (SEQ ID NO: 1801).44. The AA V particle of any one of embodiments 39-42, wherein [N1]-[N2]-[N3]-[N4] is or comprises GHDSPHKSGQNQQ (SEQ ID NO: 1800).45. The AAV particle of any one of embodiments 39-42. wherein [N1]-[N2]-[N3]-[N4] is or comprises GSGSPHKYGQNQQT (SEQ ID NO: 910).46. The AAV particle of any one of embodiments 1-45, wherein the AAV capsid variant comprises an amino acid other than T at position 450 (e.g., S, Y, M, A, C, I, R, L, D, F, V, Q, N, H, E, or G), an amino acid other than I at position 451 (e.g., M, P, E, N, D, S, A, T, G, Q, F, V, L, C, H, R, W, or L), and / or an amino acid other than N at position 452 (e.g., M, E, G, Y, W, T, I, Q, F, V, A, L, I, P, K, R, H, S, D, or S), numbered according to any one of SEQ ID NOs: 36-59, 138, 981, or 982.47. The AAV particle of any one of embodiments 1-46, wherein the AAV capsid variant comprises the amino acid T at position 450, the amino acid I at position 451, and / or the amino acid N at position 452, numbered according to any one of SEQ ID NOs: 138, 981, or 982.48. The AAV particle of any one of embodiments 1-47, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XAXBand Xc, and wherein:(a) XAis: T, S, Y, M, A, C, 1, R, L, D, F, V, Q, N, H, E, or G;(b) XBis: I, M, P, E, N, D, S, A, T, G, Q, F, V, L, C, H, R, W, or L; and(c) Xcis: N, M, E, G, Y, W, T, 1, Q, F, V, A, L, I, P, K, R, H, S, D, or S; and optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(c).49. The AA V particle of embodiment 48, wherein [N0] is or comprises TIN, SMN, TIM, YLS, GLS, MPE, MEG, MEY, AEW, CEW. ANN, IPE, ADM, IEY, ADY, IET, MEW, CEY, RIN, MEI, LEY, ADW, IET, DIM, FEQ. MEF, CDQ, LPE, IEN, MES, AEI, VEY, UN, TSN, IEV, MEM, AEV, MDA, VEW, AEQ, LEW, MEL. MET, MEA, IES, MEV, CEI, ATN, MDG, QEV, ADQ, NMN, IEM, ISN, TGN, QQQ, HDW, IEG, TH, TFP, TEK, EIN, TVN, TFN, SIN, TER, TSY, ELH, AIN. SVN, T DN, TF H , TVH, TEN. TSS, TID, TCN, NIN. TEH, AEM, AIK. TDK, TFK. SDQ. TEI, NTN, IET, SIK, TEL, TEA, TAN, TIY, TFS, TES, TTN, TED, TNN, EVIL TIS, TVR, TDR, TIK, NHI. TIP, ESD.TDL, TVP, TVI, AEH, NCL, TVK, NAD, TIT, NCV, TIR, NAL, VIN, TIQ, TEF, TRE, QGE, SEK, NVN, GGE, EFV, SDK, TEQ, EVQ, TEY, NCW, TDV, SDI, NSI, NSL, EVV, TEP, SEE, TWQ. TEV, AVN, GVL, TLN, TEG, TRD, NAI, AEN, AET, ETA, NNL, or any dipeptide thereof.50. The AAV particle of embodiment 48 or 49, wherein [N0]-[N1 ]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 2242-2886;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4. 5, 6, 7, 8. 9, 10. 11, 12, 13, 14, or 15 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids relative to any one of the amino acid sequences in (i).51. The AAV particle of any one of embodiments 48-50, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGSGSPHSKAQNQQ (SEQ ID NO: 2242).52. The AAV particle of any one of embodiments 48-50, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGHDSPHKSGQNQQ (SEQ ID NO: 2.243).53. The AAV particle of any one of embodiments 48-52, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises TINGSGSPHKYGQNQQT (SEQ ID NO: 5246).54. The AAV particle of any one of embodiments 1-53, wherein [N1]-[N2]-[N3] is present in loop IV.55. The AAV particle of any one of embodiments 48-54, wherein [N0] and [N4] are present in loop IV.56. The AAV particle of any one of embodiments 48-55, wherein [N0] is present immediately subsequent to position 449. numbered according to SEQ ID NO: 138.57. The AA V particle of any one of embodiments 48-56, wherein [N0] is present immediately subsequent to position 449, numbered according to any one of SEQ ID NOs: 36-59, 981, or 982,58. The AAV particle of any one of embodiments 48-57. wherein [N0] replaces positions 450, 451. and 452 (e.g., T450, 1451, and N452), numbered according to SEQ ID NO: 138.59. The AAV particle of any one of embodiments 48-58, wherein [N0] replaces positions 450-452 (e.g., T450, 1451 , and N452), numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.60. The AAV particle of any one of embodiments 48-59, wherein [N0] corresponds to positions 450- 452 of any one of SEQ ID NOs: 36-59, 138, 981 or 982.61. The AA V particle of any one of embodiments 48-60, wherein [N0] is present immediately subsequent to position 449 and wherein [N0] replaces positions 450-452 (e.g., T450. 1451, and N452), numbered according to SEQ ID NO: 138.62. The AAV particle of any one of embodiments 48-61, wherein [N0] is present immediately subsequent to position 449 and wherein [N0] replaces positions 450-452 (e.g., T450, 1451, and N452), numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.63. The AAV particle of any one of embodiments 1-62, wherein [N1] is present immediately subsequent to position 452, numbered according to the amino acid sequence of SEQ ID NO: 138.64. The AAV particle of any one of embodiments 1-63, wherein [N1] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 981 or 982.65. The AAV particle of any one of embodiments 1-61, wherein [N1] replaces positions 453-455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO: 138.66. The AAV particle of any one of embodiments 1-64, wherein [N1] replaces positions 453 (e.g., G453), numbered according to SEQ ID NO: 138.67. The AAV particle of any one of embodiments 1-65, wherein [N1] replaces positions 453-455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO: 981 .68. The AAV particle of any one of embodiments 1-65 or 67, wherein [N1] replaces positions 453- 455, numbered according to SEQ ID NO: 982.69. The AA V particle of any one of embodiments 1 -65, 67, or 68, wherein [N 1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453-455 (e.g.. G453,S454, and G455), numbered according to SEQ ID NO: 138.70. The AAV particle of any one of embodiments 1-64 or 66, wherein [N 1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453 (e.g., G453), numbered according to SEQ ID NO: 138.71. The AAV particle of any one of embodiments 1-64, 66 or 70, wherein [N1] is present immediately subsequent to position 452 and wherein [N1] replaces positions 453-455, numbered according to SEQ ID NO: 4, 36, 981 or 982.72. The AAV particle of any one of embodiments 1-71, wherein [N 1] corresponds to positions 453- 455, numbered according to any one of SEQ ID NOs: 4, 36-59, 981, or 982.73. The AAV particle of any one of embodiments 1-72, wherein the AAV capsid variant comprises an amino acid other than S at position 454 and / or an amino acid other than G at position 455, numbered according to SEQ ID NO: 138, 981, or 982.74. The AAV particle of any one of embodiments 1-73, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, numbered according to SEQ ID NO: 138 or 982.75. The AAV particle of any one of embodiments 1-74, wherein the AAV capsid variant comprises a substitution at position 454 (e.g.. S454H) and / or a substitution at position 455 (e.g., G455D). numbered according to SEQ ID NO: 138.76. The AAV particle of any one of embodiments 1-75, wherein the AAV capsid variant comprises the amin acid H at position 454 and the amino acid D at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 138.77. The AAV particle of any one of embodiments 1 -76, wherein the AAV capsid variant comprises the amino acid H at position 454 and the amino acid D at position 455, numbered according to SEQ ID NO: 982.78. The AA V particle of any one of embodiments 1 -77, wherein the AAV capsid variant comprises the amino acid II at position 454 and the amino acid D at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455. numbered according to SEQ ID NO: 982.79. The AAV particle of any one of embodiments 1-72, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, numbered according to SEQ ID NO: 138.80. The AAV particle of any one of embodiments 1 -72 or 79, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 138.81. The AAV particle of any one of embodiments 1-72, 79, or 80, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, numbered according to SEQ ID NO: 981.82. The AAV particle of any one of embodiments 1-72 or 79-81, wherein the AAV capsid variant comprises the amino acid S at position 454 and the amino acid G at position 455, and further comprises the amino acid sequence SPHSKA (SEQ ID NO: 941) immediately subsequent to position 455, numbered according to SEQ ID NO: 981.83. The AAV particle of any one of embodiments 1-82, wherein [N2] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138,84. The AAV particle of any one of embodiments 1-83, wherein [N2] corresponds to positions 456- 458 (e.g.. S456, P457, H458) of SEQ ID NO: 981 or 982.85. The AAV particle of any one of embodiments 1-83, wherein [N2] corresponds to positions 456- 458 (e.g., S456, P457, H458) of any one of SEQ ID NOs: 4 or 36-59.86. The AAV particle of any one of embodiments 1-85, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.87. The AA V particle of any one of embodiments 1-86, wherein [N2] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 4, 36, 981, or 982.88. The / AAV particle of any one of embodiments 1-87, wherein [N2]-[N3] is present immediately subsequent to position 455. numbered according to SEQ ID NO: 4, 36, 981, or 982.89. The AAV particle of any one of embodiments 1-88, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, S4.59, K460, A461) of SEQ ID NO: 981.90. The AAV particle of any one of embodiments 1-88, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.91 . The AA V particle of any one of embodiments 1-90, wherein [N2] is present immediately subsequent to [N 1],92. The AAV particle of any one of embodiments 1-64, 66, 70, or 71, wherein [N3] is present immediately subsequent to [N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.93. The AAV particle of any one of embodiments 1-1-64, 66, 70, 71, or 92, wherein [N3] is present immediately subsequent to [N1]-[N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.94. The AAV particle of any one of embodiments 39-93, wherein [N4] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138,95. The AAV particle of any one of embodiments 39-94, wherein [N4] replaces positions 456-459(e.g., Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.96. The AAV particle of any one of embodiments 39-95, wherein [N4] corresponds to positions 462- 465 (e.g., Q462, N463, Q464, Q465) of SEQ ID NO: 4, 36, 981, or 982.97. The AAV particle of any one of embodiments 39-96, wherein [N2]-[N3]-[N4] replaces positions456-459 (e.g., Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.98. The AAV particle of any one of embodiments 39-97, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 456-459(e.g,, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.99. The AAV particle of any one of embodiments 39-98. wherein [N2]-[N3]-[N4] corresponds to positions 456-465 (e.g., S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981.100. The AAV particle of any one of embodiments 39-98, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 (e.g., S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982.101. The AAV particle of any one of embodiments 39-98, wherein [N2]-[N3]-[N4] corresponds to positions 456-465 of any one of SEQ ID NOs: 4 or 36-59.102. The AAV particle of any one of embodiments 39-101, wherein [N1]-[N2]-[N3]-[N4] replaces positions 453-459 (e.g., G453, S454. G455, Q456, N457, Q458. and Q459), numbered according to SEQ ID NO: 138.103. The AAV particle of any one of embodiments 39-102, wherein [N1]-[N2]-[N3]-[N4] is present immediately subsequent to position 452, and wherein [N 1]-[N2]-[N3]-[N4] replaces positions 453- 459 (e.g., G453, S454, G455, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.104. The AAV particle of any one of embodiments 39-99, 102, or 103, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-465 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981.105. The AAV particle of any one of embodiments 39-98, 100, 102. or 103, wherein [N1]-[N2]-[N3]- [N4] corresponds to positions 453-465 (e.g.. G453, H454, D455, S456, P457, H 458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982.106. The AAV particle of any one of embodiments 39-98, 102, or 103, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-465 of any one of SEQ ID NOs: 4 or 36-59.107. The AAV particle of any one of embodiments 1-99 or 102-104, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, S454, G455, S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981.108. The AAV particle of any one of embodiments 1-98, 100, 102, 103, or 105, wherein [N1]-[N2]- [N3] corresponds to positions 453-461 (e.g., G453, H454, D455, S456, P457, H458, K459, S460,G461) of SEQ ID NO: 982.109. The AAV particle of any one of embodiments 39-98, 102. 103, or 106, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 of any one of SEQ ID NOs: 36-59.110. The AAV particle of any one of embodiments 48-109, wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 450-459 (e.g., T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, and Q459), numbered according to SEQ ID NO: 138.111. The AAV particle of any one of embodiments 48-110. wherein [N0]-[N1]-[N2]-[N3]-[N4] is present immediately subsequent to position 449, and wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 450-459 (e.g,, T450, 1451 , N452, G453, S454. G455, Q456, N457, Q458, and Q459). numbered according io SEQ ID NO: 138.112. The AAV particle of any one of embodiments 48-99, 102-104, or 106, wherein [N0]-[N1]-[N2J-[N3]-[N4] corresponds to positions 450-465 (e.g., T450, 1451, N452, G453, S454, G455, S456, P457,H458, S459, K460, A461, Q462, N463, Q464, Q465) of SEQ ID NO: 981. i 13. The AAV particle of any one of embodiments 48-98, 100, 102, 103, 105, or 108, wherein [N0]- [N1]-[N2]-[N3]-[N4] corresponds to positions 450-465 (e.g., T450, 1451, N452, G453, H454, D455, S456, P457, H458, K459, S460, G461, Q462, N463, Q464, Q465) of SEQ ID NO: 982.114. The AAV particle of any one of embodiments 48-98. 102, 103, 106, or 109, wherein [N0]-[N1]- [N2]-[N3]-[N4] corresponds to positions 450-465 of any one of SEQ ID NOs: 36-59.115. The AAV particle of any one of embodiments 39-114, wherein [N4] replaces positions 462-465 (e.g., Q462, N463, Q464, and Q465), numbered according to SEQ ID NO: 4, 36, 981, or 982.116. The AAV particle of any one of embodiments 39-115, wherein [N2]-[N3]-[N4] replaces positions 462-465 (e.g., Q462, N463, Q464, and Q465), numbered according to SEQ ID NO: 4, 36, 981, or 982.117. The AAV particle of any one of embodiments 39-116, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 462-465(e.g,, Q462, N463, Q464, and Q465), numbered according to SEQ ID NO: 4, 36, 981, or 982.118. The AAV particle of any one of embodiments 1-1 17, wherein [N3] is present immediately subsequent to [N2],119. The AAV particle of any one of embodiments 1-118, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N2]-[N3].120. The AAV particle of any one of embodiments 1-119, wherein the AAV capsid variant comprises, from N-terminus to C -terminus, [N1]-[N2]-[N3],121. The AAV particle of any one of embodiments 48-120, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3].12.2. The AAV particle of any one of embodiments 39-121 , wherein the AAV capsid variant comprises, from N-terminus to C-terrmnus, [N1]-[N2]-[N3]-[N4].123. The AAV particle of any one of embodiments 48-122, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N0]-[N1]-[N2]-[N3]-[N4j.124. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other T at position 460 (e.g., N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S), numbered according to SEQ ID NO: 138.125. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S at position 460, numbered according to SEQ ID NO: 138.126. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid vanant comprises an amino acid other T at position 466 (e.g., N, I, C. H, R, L, D, Y, A, M, Q, I, E, K, P, G or S), numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.127. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid N, I, C, H, R, L, D, Y, A, M, Q, I, E, K, P, G or S at position 466, numbered according to any one of SEQ ID NOs: 36-59, 981 or 982.128. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid other K at position 449 (e.g,, an E, an N, or a T), numbered according to any one of SEQ ID NOs: 36-59, 138, 981 , or 982.129. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino E. N, or T at position 449, numbered according to any one of SEQ ID NOs: 36- 59, 138, 981 or 982.130. An adeno-associated vims (AAV) particle comprising an AAV capsid variant (e.g., an AAV capsid variant) and viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises [A][B] (SEQ ID NO: 4694), wherein:(i) [A] comprises the amino acid sequence of GSGSPH (SEQ ID NO: 4695); and(ii) [B] comprises X1 X2 X 3 X4 X5 X6 X7, wherein:(a) X1 is: S, C, F, or V;(b) X2 is: K, L, R, I, E, Y, V, or S;(c) X3 is: A, R, L, G, I, Y, S, F, or W;(d) X4 is: W, Q, R, G, L, V, S, orF;(e) X5 is: N, Y, R, C, K, or L;(f) X6 is: Q, G, K, R, T, L, or Y; and(g) X7 is: Q. L, R. or V; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(g).131. The AAV particle of embodiment 130, wherein(a) X1 is S;(b) X2 is K orL;(c) X3 is: A, R, orL;(d) X4 is: Q or R;(e) X5 is: N or R;(f) X6 is: Q or R; and(g) X7 is: Q, L, or R.132. The AAV particle of embodiment 130 or 131, wherein [B] comprises:(i) SLLWNQQ (SEQ ID NO: 5247), SKAQYYV (SEQ ID NO: 5248), SKLRRQQ (SEQ ID NO: 5249), SIWQNQQ (SEQ ID NO: 5250), SKAGCGQ (SEQ ID NO: 5251), SRAQNQQ (SEQ ID NO: 5252), SKRLRQQ (SEQ ID NO: 5253), SLRRNQQ (SEQ ID NO: 5254). SRGRNQQ (SEQ ID NO: 5255), SEIVNQQ (SEQ ID NO: 5256), SSRRNQQ (SEQ ID NO: 5257), CLLQNQQ (SEQ ID NO: 5258), SKAFRLQ (SEQ ID NO: 5259), CLAQNQQ (SEQ ID NO: 5260), FLRQNQQ (SEQ ID NO: 5261), SLRFNQQ (SEQ ID NO: 5262), SYLRNQQ (SEQ ID NO: 5263), CSLQNQQ (SEQ ID NO: 5264), VLWQNQQ (SEQ ID NO: 5265), SKWLLQQ (SEQ ID NO: 5266), SLWSNQQ (SEQID NO: 5267), SKRRLQQ (SEQ ID NO: 5268), SVYLNQQ (SEQ ID NO: 5269), SLWLNQQ (SEQID NO: 5270), SKAQRKL (SEQ ID NO: 5271), SKALRRQ (SEQ ID NO: 5272), SKAQRLR (SEQID NO: 5273), SKAQNQQ (SEQ ID NO: 5274), SKAQRRL (SEQ ID NO: 5275), SKARRQQ (SEQ ID NO: 5276), SKARRLQ (SEQ ID NO: 5277), SKSRRQQ (SEQ ID NO: 5278), SKARLRQ (SEQ ID NO: 5279), SKASKRQ (SEQ ID NO: 5280), VRRQNQQ (SEQ ID NO: 5281), SKAQLYR (SEQ ID NO: 5282), SLFRNQQ (SEQ ID NO: 5283), SKAQLTV (SEQ ID NO: 5284);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4. 5, or 6 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).133. The AAV particle of any one of embodiments 130-132, wherein [A][B] comprises:(i) GSGSPHSLLWNQQ (SEQ ID NO: 5285), GSGSPHSKAQYYV (SEQ ID NO: 2060), GSGSPHSKLRRQQ (SEQ ID NO: 2061), GSGSPHSIWQNQQ (SEQ ID NO: 5286), GSGSPHSKAGCGQ (SEQ ID NO: 2062), GSGSPHSRAQNQQ (SEQ ID NO: 2063), GSGSPHSKRLRQQ (SEQ ID NO: 2064), GSGSPHSLRRNQQ (SEQ ID NO: 2065), GSGSPHSRGRNQQ (SEQ ID NO: 2066), GSGSPHSEIVNQQ (SEQ ID NO: 5287), GSGSPHSSRRNQQ (SEQ ID NO: 2067), GSGSPHCLLQNQQ (SEQ ID NO: 5288), GSGSPHSKAFRLQ (SEQ ID NO: 2068). GSGSPHCLAQNQQ (SEQ ID NO: 5289). GSGSPHFLRQNQQ (SEQ ID NO: 2070), GSGSPHSLRFNQQ (SEQ ID NO: 2071), GSGSI-TISYLRNQQ (SEQ ID NO: 5290). GSGSPHCSLQNQQ (SEQ ID NO: 5291), GSGSPHVLWQNQQ (SEQ ID NO: 5292), GSGSPIISKWLLQQ (SEQ ID NO: 2072), GSGSPHSLWSNQQ (SEQ ID NO: 5293), GSGSPHSKRRLQQ (SEQ ID NO: 2073), GSGSPHSVYLNQQ (SEQ ID NO: 5294), GSGSPHSLWLNQQ (SEQ ID NO: 5295), GSGSPHSKAQRKL (SEQ ID NO: 2074), GSGSPHSKAERRQ (SEQ ID NO: 2075), GSGSPHSKAQRLR (SEQ ID NO: 2076), GSGSPHSKAQNQQ (SEQ ID NO: 1801), GSGSPHSKAQRRL (SEQ ID NO: 2077), GSGSPHSKARRQQ (SEQ ID NO: 2078), GSGSPHSKARRLQ (SEQ ID NO: 2079), GSGSPHSKSRRQQ (SEQ ID NO: 2080), GSGSPHSKARLRQ (SEQ ID NO: 2082), GSGSPHSKASKRQ (SEQ ID NO: 2083), GSGSPHVRRQNQQ (SEQ ID NO: 2084), GSGSPHSKAQLYR (SEQ ID NO: 2085), GSGSPI I SLFRNQQ (SEQ ID NO: 5296), GSGSPHSKAQLTV (SEQ ID NO: 2086);.(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).134. The AAV particle of any one of embodiments 130-133, wherein the AAV capsid variant further comprises one, two, or all of an amino acid other than T at position 450 (e.g., S, Y, or G), an amino acid other than I at position 451 (e.g., M or L), and / or an amino acid other than N at position 452 (e.g., S), numbered according to SEQ ID NO: 138.135. The AAV particle of any one of embodiments 130-134, wherein the AA V capsid variant further comprises an S at position 450 and an M at position 451, numbered according to SEQ ID NO: 138.136. The AAV particle of any one of embodiments 130-134, wherein the AAV capsid variant further comprises a Y at position 450, an L at position 451, and an S at position 452, numbered according to SEQ ID NO: 138.137. The AAV particle of any one of embodiments 130-134, wherein the AAV capsid variant further comprises a G at position 450, an L at position 451, and an S at position 452, numbered according to SEQ ID NO: 138.138. The AAV particle of any one of embodiments 130-137, wherein [A] [B] is present in loop IV.139. The AAV particle of any one of embodiments 130-138, wherein [A] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 138.140. The AAV particle of any one of embodiments 130-139, wherein [A] replaces positions 453-455(e.g., G453, S454, G455), numbered according to SEQ ID NO: 138.141. The AAV particle of any one of embodiments 130-140, wherein [A] is present immediately subsequent to position 452, and wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138.142. The AAV particle of any one of embodiments 130-141, wherein [B] is present immediately subsequent to [A],143. The AAV particle of any one of embodiments 130-142, wherein [B] replaces positions 456-459 (e.g., Q456, N457, Q458, Q459), numbered according to SEQ ID NO: 138.144. The AAV particle of any one of embodiments 130-143, wherein [A] [B] replaces positions 453' 459 (e.g., G453, S454, G455, Q456, N457. Q458, Q459), numbered according to SEQ ID NO: 138.145. The AAV particle of any one of embodiments 130-144, wherein [A][B] is present immediately subsequent to position 452, and w'herein [A] [B] replaces positions 453-459 (e.g., G453, S454, G455, Q456, N457, Q458, Q459), numbered according to SEQ ID NO: 138.146. The AAV particle of any one of embodiments 130-145, wherein the AA V capsid variant comprises, from N-terminus to C-terminus, [A][B]_147. An adeno-associated virus (AAV) particle comprising an AAV capsid variant and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises anRNAi agent targeting DMPK mRNA; and wherein the AAV capsid comprises [A][B] (SEQ ID NO: 4699), wherein:(i) [A] comprises XI X2 X3 X4 X5 X6, wherein(a) X1 is T, M. A, C, I, R. L, D, F, V, Q, N, or H;(b) X2 is I, P, E, N, D, S, A, T, M, or Q;(c) X3 is N, E. G, ¥, W, M, T, I, K, Q, F, S, V, A, or L;(d) X4 is G, D, R, or E;(e) X5 is H, Q, N, or D;(f) X6 is D or R; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(f); and(ii) [B] comprises SPHKSG (SEQ ID NO: 946).148. The AAV particle of embodiment 147, wherein(a) XI is: T, M, A, or I;(b) X2 is: E, l orD;(c) X3 is: N, Q, Y, I, M, or V ;(d) X4 is G;(e) X5 is H; and(f) X6 is D,149. The AAV particle of embodiment 147 or 148, wherein [A] comprises:(i) TINGHD (SEQ ID NO: 5297), MPEGHD (SEQ ID NO: 5298), MEGGHD (SEQ ID NO: 5299), MEYGHD (SEQ ID NO: 5300), AE W GHD (SEQ ID NO: 5301), CEWGHD (SEQ ID NO: 5302), ANNGQD (SEQ ID NO: 5303), IPEGHD (SEQ ID NO: 5304), ADMGHD (SEQ ID NO: 5305), IEYGHD (SEQ ID NO: 5306), ADYGHD (SEQ ID NO: 5307), IETGHD (SEQ ID NO: 5308),MEWGHD (SEQ ID NO: 5309), CEYGHD (SEQ ID NO: 5310), RINGED (SEQ ID NO: 5311), MEIGHD (SEQ ID NO: 5312), LEYGHD (SEQ ID NO: 5313), ADWGHD (SEQ ID NO: 5314). IEIGHD (SEQ ID NG: 5315), TIKDND (SEQ ID NO: 5316), DIMGHD (SEQ ID NO: 5317), FEQGHD (SEQ ID NO: 5318), MEFGHD (SEQ ID NO: 5319), CDQGHD (SEQ ID NO: 5320). LPEGHD (SEQ ID NO: 5321), TENGHD (SEQ ID NO: 5322), MESGHD (SEQ ID NO: 5323), A EIGHD ) (SEQ ID NO: 5324), VEY GHD (SEQ ID NO: 5325). TSNGDD (SEQ ID NO: 532.6), IEVGI-ID (SEQ ID NO: 5327), MEMGHD (SEQ ID NO: 5328), AEVGHD (SEQ ID NO: 5329), MDAGHD (SEQ ID NO: 5330), VEWGHD (SEQ ID NO: 5331), AEQGHD (SEQ ID NO: 5332), LEWGHD (SEQ ID NO: 5333), MELGHD (SEQ ID NO: 5334). METGHD (SEQ ID NO: 5335), ME AGH D (SEQ ID NO: 5336), TINRQR (SEQ ID NO: 5337), IESGHD (SEQ ID NO: 5338), TAKDHD (SEQ ID NO: 5339), MEVGHD (SEQ ID NO: 5340), CEIGHD (SEQ ID NO: 5341), ATNGHD (SEQ ID NO: 5342), MDGGHD (SEQ ID NO: 5343), QEVGHD (SEQ ID NO: 5344), ADQGHD (SEQ ID NO: 5345), NMNGHD (SEQ ID NO: 5346), TPWEHD (SEQ ID NO: 5347), IEMGHD (SEQ ID NO: 5348), TANEHD (SEQ ID NO: 5349), QQQGHD (SEQ ID NO: 5350), TPQDHD (SEQ ID NO: 5351), HDWGHD (SEQ ID NO: 5352), IEGGHD (SEQ ID NO: 5353)(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).150. The AA V particle of any one of embodiments 147-149, wherein [A][B] comprises:(i) TINGHDSPHKR (SEQ ID NO: 5354), MPEGHDSPHKS (SEQ ID NO: 5355), MEGGHDSPHKS (SEQ ID NO: 5356), MEYGHDSPHKS (SEQ ID NO: 5357), AEWGHDSPHKS (SEQ ID NO: 5358), CEWGHDSPHKS (SEQ ID NO: 5359), ANNGQDSPHKS (SEQ ID NO: 5360), IPEGHDSPHKS (SEQ ID NO: 5361), ADMGHDSPHKS (SEQ ID NO: 5362), IEYGHDSPHKS (SEQ ID NO: 5363), ADYGHDSPHKS (SEQ ID NO: 5364), IETGHDSPHKS (SEQ ID NO: 5365), MEWGHDSPHKS (SEQ ID NO: 5366), CEYGHDSPHKS (SEQ ID NO: 5367), R1NGHDSPHKS (SEQ ID NO: 5368), MEIGHDSPHKS (SEQ ID NO: 5369), LEYGHDSPHKS (SEQ ID NO: 5370). ADWGHDSPHKS (SEQ ID NO: 5371), IETGHDSPHKS (SEQ ID NO: 5372), TIKDNDSPHKS (SEQ ID NO: 5373), DIMGHDSPHKS (SEQ ID NO: 5374), FEQGHDSPHKS (SEQ ID NO: 5375), MEFGHDSPHKS (SEQ ID NO: 5376). CDQGHDSPHKS (SEQ ID NO: 5377). LPEGHDSPHKS (SEQ ID NO: 5378), IENGHDSPHKS (SEQ ID NO: 5379). MESGHDSPHKS (SEQ ID NO: 5380), AEIGHDSPHKS (SEQ ID NO: 5381), VEYGHDSPHKS (SEQ ID NO: 5382), TSNGDDSPHKS (SEQ ID NO: 5383), IEVGHDSPHKS (SEQ ID NO: 5384). MEMGHDSPHKS (SEQ ID NO: 5385), AEVGHDSPHKS (SEQ ID NO: 5386), MDAGHDSPHKS (SEQ ID NO: 5387), VEWGHDSPHKS(SEQ ID NO: 5388), AEQGHDSPHKS (SEQ ID NO: 5389), LEWGHDSPHKS (SEQ ID NO: 5390), MELGHDSPHKS (SEQ ID NO: 5391), METGHDSPHKS (SEQ ID NO: 5392), MEAGHDSPHKS (SEQ ID NO: 5393), TINRQRSPHKS (SEQ ID NO: 5394), TESGHDSPHKS (SEQ ID NO: 5395), TAKDHDSPHKS (SEQ ID NO: 5396), MEVGHDSPHKS (SEQ ID NO: 5397), CEIGHDSPHKS (SEQ ID NO: 5398), ATNGHDSPHKS (SEQ ID NO: 5399), MDGGHDSPHKS (SEQ ID NO: 5400), QEVGHDSPHKS (SEQ ID NO: 5401). ADQGHDSPHKS (SEQ ID NO: 5402), NMNGHDSPHKS (SEQ ID NO: 5403), TPWEHDSPHKS (SEQ ID NO: 5404), IEMGHDSPI IKS (SEQ ID NO: 5405), TANEHDSPHKS (SEQ ID NO: 5406), TINGHDSPHKS (SEQ ID NO: 5407). QQQGHDSPHKS (SEQ ID NO: 5408), TPQDHDSPHKS (SEQ ID NO: 5409), HDWGHDSPI -IKS (SEQ ID NO: 5410), IEGGHDSPHKS (SEQ ID NO: 5411)(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, e.g., consecutive amino acids, thereof:(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).151. The AAV particle of any one of embodiments 147-150, wherein the A AV capsid variant further comprises one, two, three, four, or all of an amino acid other than Q at position 456 (e.g., R or L), N at position 457 (e.g,, H, K. or R), Q at position 458 (e.g.. R or T), Q at position 459 (H), and / or T at position 460 (N or S), numbered according to SEQ ID NO: 138.152. The AAV particle of any one of embodiments 147-151, wherein the AAV capsid variant further comprises an R at position 456, numbered according to SEQ ID NO: 138.153. The AAV particle of any one of embodiments 147-151, wherein the AAV capsid variant further comprises an L at position 456, numbered according to SEQ ID NO: 138.154. The AAV particle of any one of embodiments 147-153, wherein the AAV capsid variant further comprises an H at position 457 and an R at position 458, numbered according to SEQ ID NO: 138.155. The AAV particle of any one of embodiments 147-153, wherein the AA V capsid variant further comprises a K at position 457 and an N at position 460. numbered according to SEQ ID NO: 138.156. The AAV particle of any one of embodiments 147-153, wherein the AAV capsid variant further comprises a T at position 458. an II at position 459, and an S al position 460, numbered according to SEQ ID NO: 138.157. The AAV particle of any one of embodiments 147-151, wherein the AAV capsid variant further comprises an R at position 456, an R at position 457, and an R at position 458, numbered according to SEQ ID NO: 138.158. The AAV particle of any one of embodiments 147-157, wherein [A] [B] is present in loop IV.159. The AAV particle of any one of embodiments 147-158, wherein [A] is present immediately subsequent to position 449. numbered according to SEQ ID NO: 138.160. The AAV particle of any one of embodiments 147-159, wherein [A] replaces positions 450-453(e.g., T450, 1451, N452, G453), numbered according to SEQ ID NO: 138.161. The AAV particle of any one of embodiments 147-160, wherein [A] is present immediately subsequent to position 449, and wherein [A] replaces positions 450-453 (e.g., T450, 1451, N452, G453), numbered according to SEQ ID NO: 138.162. The AAV particle of any one of embodiments 147-161 , wherein [A][B] replaces positions 450-455 (e.g., T450, 1451, N452. G453, S454, G455), numbered according to SEQ ID NO: 138.163. The AAV particle of any one of embodiments 147-162, wherein [A][B] is present immediately subsequent to position 449, and wherein [A] [B] replaces positions 450-455 (e.g., T450, 1451, N452,G453, S454, G455), numbered according to SEQ ID NO: 138.164. The AAV particle of any one of embodiments 147-163, wherein [B] is present immediately subsequent [A], and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.165. The AAV particle of any one of embodiments 147-164, wherein [B] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 4, 36, 981, or 982.166. The AAV particle of any one of embodiments 147-165, wherein [B] is present immediately subsequent to [A],167. The AAV particle of any one of embodiments 147-166, wherein the AAV capsid variant comprises, from N-terminus to C-temnnus, [A] [B] .168. An adeno-associated vims (AAV) particle comprising an AAV capsid variant (e.g., an AAV capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRN A, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRN A; and wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N 1 ]-[N2]-[ N 3] (SEQ ID NO: 6407), wherein:(i) [N1] comprises X1, X2, and X3, wherein X2 is S and X3 is G;(ii) [N2] comprises the amino acid sequence SPH: and(iii) [N3] comprises X4, X5, and X6, wherein X5 is K.169. The AAV particle of embodiment 168, wherein:(i) X4 of [N3] is S, T, N, or A; and(ii) X5 of [N3 ] is A, V, T, S, G, R, L, or N; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i) or (ii).170. The AAV particle of embodiment 168 or 169, wherein X4 is S and / or X5 is A.171. The AAV particle of any one of embodiments 168-170, wherein [N3] comprises SK, TK, NK, AK , KA, K V, KT. KS, KG, KR, KL . or KN.172. The AAV particle of any one of embodiments 168-171, wherein [N3] is or comprises SKA, SKV, SKT, SKS, SKG, SKR, TKA, NKA, SKL, SKN, or AKA.173. The AAV particle of any one of embodiments 168-172, wherein [N3] is or comprises SKA.174. The AAV particle of any one of embodiments 168-173, wherein [N2]-[N3] comprises SPHSK (SEQ ID NO: 4701), SPHTK (SEQ ID NO: 4725), SPHNK (SEQ ID NO: 4726), or SPHAK (SEQ ID NO: 4727).175. The AAV particle of any one of embodiments 168-174, wherein [N2]-[N3] is or comprises:(i) SPHSK A (SEQ ID NO: 941), SPHSKV (SEQ ID NO: 4737), SPHSKT (SEQ ID NO: 4731), SPHSKS (SEQ ID NO: 962), SPHSKG (SEQ ID NO: 4732), SPHSKR (SEQ ID NO: 978). SPHTKA (SEQ ID NO: 4739). SPHNKA (SEQ ID NO: 4734), SPHSKL (SEQ ID NO: 960), SPHSKN (SEQ ID NO: 4735), or SPHAKA (SEQ ID NO: 4736);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).176. The AAV particle of any one of embodiments 168-175, wherein [N2]-[N3] is or comprises SPHSKA (SEQ ID NO: 941).177. The AAV particle of any one of embodiments 168-176, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., M, T, 1, E, S, A, N, V, L, K, H, P, R, W, or D), numbered according to SEQ ID NO: 138 or 981.178. The AAV particle of any one of embodiments 168-177, wherein the AAV capsid variant comprises the amino acid G at position 453, numbered according to SEQ ID NO: 138 or 981.179. The AAV particle of any one of embodiments 168-178, wherein XI of [N1] is G, M, T, I, E, S, A, N, V, L, K, H, P, R, W, or D; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids.180. The AAV particle of any one of embodiments 168-179, wherein [N1] comprises SG, GS, MS, T S. IS, ES, SS, AS, NS, VS, LS, KS, HS, PS, RS, WS, or DS.181. The AAV particle of any one of embodiments 168-180, wherein [N1] is or comprises: GSG, MSG, TSG, ISG, ESG, SSG, ASG, NSG, VSG, LSG, KSG, HSG, PSG, RSG, WSG, orDSG.182. The AAV particle of any one of embodiments 168-181, wherein [N1] is or comprises GSG.183. The AAV particle of any one of embodiments 168-182, wherein [N1]-[N2] comprises SGSPH (SEQ ID NO: 4752).184. The AAV particle of any one of embodiments 168-183, wherein [N1]-[N2] is or comprises:(i) GSGSPH (SEQ ID NO: 4695), MSGSPH (SEQ ID NO: 4798), TSGSPH (SEQ ID NO: 4800), ISGSPH (SEQ ID NO: 4801), ESGSPH (SEQ ID NO: 4803), SSGSPH (SEQ ID NO: 4804). ASGSPII (SEQ ID NO: 4806), NSGSPH (SEQ ID NO: 4807), VSGSPH (SEQ ID NO: 4786), LSGSPH (SEQ ID NO: 4808), KSGSPH (SEQ ID NO: 4810), IISGSPH (SEQ ID NO: 4811).PSGSPH (SEQ ID NO: 4813), RSGSPH (SEQ ID NO: 4815), WSGSPH (SEQ ID NO: 4817), DSGSPH (SEQ ID NO: 4818);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).185. The AAV particle of any one of embodiments 168-184, wherein [N1]-[N2]-[N3] is or comprises:(i) GSGSPHSKA (SEQ ID NO: 4697), GSGSPHSKV (SEQ ID NO: 4956), MSGSPHSKA (SEQ ID NO: 4957), TSGSPHSKA (SEQ ID NO: 4959), ISGSPHSKA (SEQ ID NO: 4960), GSGSPHSKT (SEQ ID NO: 4962), ESGSPHSKA (SEQ ID NO: 4963), SSGSPHSKA (SEQ ID NO: 4964), GSGSPHSKS (SEQ ID NO: 4953), ASGSPHSKA (SEQ ID NO: 4966), NSGSPHSKA (SEQ ID NO: 4967), VSGSPHSKA (SEQ ID NO: 4913), ESGSPHSKA (SEQ ID NO: 4968), KSGSPHSKA (SEQ ID NO: 4970), GSGSPHSKG (SEQ ID NO: 4972), GSGSPHSKR (SEQ ID NO: 4945), HSGSPHSKA (SEQ ID NO: 4973), PSGSPHSKA (SEQ ID NO: 4975), RSGSPHSKA (SEQ ID NO: 4977), GSGSPHTKA (SEQ ID NO: 4978), WSGSPHSKA (SEQ ID NO: 4980), DSGSPHSKA (SEQ ID NO: 4981), GSGSPHNKA (SEQ ID NO: 4983), GSGSPHSKL (SEQ ID NO: 4943), GSGSPHSKN (SEQ ID NO: 4994), or GSGSPHAKA (SEQ ID NO: 4995);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i): or(iv) an amino acid sequence comprising one, Evo, or three but no more than four different amino acids, rela tive to any one of the amino acid sequences in (i).186. The AAV particle of any one of embodiments 168-185, wherein [N1]-[N2]-[N3] is or comprises GSGSPHSKA (SEQ ID NO: 4697).187. The AAV capsid variant of any one of embodiments 168-186, which comprises an amino acid other than Q at position 456 (e.g,, R, P, H, L, K, I, G, S, M, or E), an amino acid other than N at position 457 (e.g., D, V, S, P, T, G, Y, W, E, R, H, K, F, zA, I, L, or M), an amino acid other than Q at position 458 (e.g., R, L, A. P, H. T, I, F, K. V, M, G, W, Y, S, E, N, or D), an amino acid other than Q at position 459 (e.g., H, K, A. L, P, E, M, I, S, N, R. Y, C, V, T, W, D, G), and / or an amino acid other than T at position 460 (e.g., I. N, S, H, R, L, D, Y, zA, or Q), numbered according to SEQ ID NO: 138.188. The AAV particle of any one of embodiments 168-187, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g., R, P, H, L, K, 1, G, S, M, or E), an amino acid other than N at position 463 (e.g., D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M), an amino acid other than Q at position 464 (e.g., R, L, A, P, H, T, I, F, K, V, M, G, W, Y, S, E, N, or D), an amino acid other than Q at position 465 (e.g., H, K, A, L, P, E, M, I, S, N, R, Y, C, V, T, W, D, G), and / or an amino acid other than T at position 466 (e.g., I, N, S, H, R, L , D, Y, A, or Q), numbered according to SEQ ID NO: 981.189. The AAV particle of any one of embodiments 168-188, wherein the AA V capsid variant comprises the amino acid Q at position 456. the amino acid N at position 457. the amino acid Q at position 458, the amino acid Q at position 459, and / or tire amino acid T at position 460, numbered according to SEQ ID NO: 138.190. The AAV particle of any one of embodiments 168-189, wherein the AAV capsid variant comprises the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, the amino acid Q at position 465, and / or the amino acid T at position 466, numbered according to SEQ ID NO: 981 .191. The AAV particle of any one of embodiments 168-190, wherein the AAV capsid variant further comprises [N4] wherein [N4] comprises X7, X8, X9, X10, and X11, wherein:(a) X7 is Q. R , P, H, L. K, I, G, S, M. or E;(b) X8 is N, D, V, S, P, T, G, Y, W, E, R, H, K, F, A, I, L, or M;(c) X9 is Q, R, L. A, P. H, T, I, F, K, V, M, G, W, Y, S, E, N, D:optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(e).192. The AAV particle of embodiment 191, wherein [N4] is or comprises:(i) QNQQT (SEQ ID NO: 5412), QNRHT (SEQ ID NO: 5413), RDQQT (SEQ ID NO: 5414), PNLQT (SEQ ID NO: 5415), HVRQT (SEQ ID NO: 5416), PNQHT (SEQ ID NO: 5417), QSQQT (SEQ ID NO: 5418). QNQQI (SEQ ID NO: 5419), QPAKT (SEQ ID NO: 5420), QTQQN (SEQ ID NO: 5421), QNLAT (SEQ ID NO: 5422), QNQLT (SEQ ID NO: 5423), QGQQT (SEQ ID NO: 5424), LNRQS (SEQ ID NO: 5425). HNQQT (SEQ ID NO: 5426), QNPPT (SEQ ID NO: 5427), QNLQT (SEQ ID NO: 5428), QYQQT (SEQ ID NO: 5429). QDQET (SEQ ID NO: 5430), QNHQT (SEQ ID NO: 5431), QDQQT (SEQ ID NO: 5432). HWQQT (SEQ ID NO: 5433), PNQQT (SEQ ID NO: 5434), QNQLI (SEQ ID NO: 5435), PEQQT (SEQ ID NO: 5436), QRTMT (SEQ ID NO: 5437),QNQQH (SEQ ID NO: 5438), LHQHT (SEQ ID NO: 5439), QHRIT (SEQ ID NO: 5440), QYIHT (SEQ ID NO: 5441), QKFET (SEQ ID NO: 5442), QFPST (SEQ ID NO: 5443), HNQQR (SEQ ID NO: 5444), QAIKT (SEQ ID NO: 5445), QNRQT (SEQ ID NO: 5446), QYQHT (SEQ ID NO: 5447), QNPQS (SEQ ID NO: 5448), QHQLT (SEQ ID NO: 5449), QSPPT (SEQ ID NO: 5450), QAKLT (SEQ ID NO: 5451), KSQQT (SEQ ID NO: 5452), QDRPT (SEQ ID NO: 5453), QSQQL (SEQ ID NO: 5454), QAFHT (SEQ ID NO: 5455). QKQQD (SEQ ID NO: 5456), QNAQT (SEQ ID NO: 5457), HNQLT (SEQ ID NO: 5458), QNQQY (SEQ ID NO: 5459), QKLNT (SEQ ID NO: 5460), QNVQT (SEQ ID NO: 5461), QAQQT (SEQ ID NO: 5462), QNLQA (SEQ ID NO: 5463), QTPPT (SEQ ID NO: 5464), QYQHA (SEQ ID NO: 5465), QGQQA (SEQ ID NO: 5466), QPPAT (SEQ ID NO: 5467), QERPT (SEQ ID NO: 5468), QDLQT (SEQ ID NO: 5469), QAMHT (SEQ ID NO: 5470), LNQQT (SEQ ID NO: 5471), QHPST (SEQ ID NO: 5472), PGLQT (SEQ ID NO: 5473), QGIRT (SEQ ID NO: 5474), QAPAT (SEQ ID NO: 5475), QSQQI (SEQ ID NO: 5476), QIPPT (SEQ ID NO: 5477), QTQLT (SEQ ID NO: 5478), QAPST (SEQ ID NO: 5479), QNTYA (SEQ ID NO: 5480), QNQHI (SEQ ID NO: 5481), QNHLT (SEQ ID NO: 5482), Q1GMT (SEQ ID NO: 5483), LNKQT (SEQ ID NO: 5484), QLQQT (SEQ ID NO: 5485), QRMST (SEQ ID NO: 5486), QGILT (SEQ ID NO: 5487), QDRQT (SEQ ID NO: 5488), RDWQT (SEQ ID NO: 5489), QNTHD (SEQ ID NO: 5490), PNLQI (SEQ ID NO: 5491), QERST (SEQ ID NO: 5492), QNYQT (SEQ ID NO: 5493), QRTCT (SEQ ID NO: 5494), QIGHT (SEQ ID NO: 5495), QGAIT (SEQ ID NO: 5496), QVPPT (SEQ ID NO: 5497), QVQQI (SEQ ID NO: 5498). LMRQT (SEQ ID NO: 5499), QYSVT (SEQ ID NO: 5500). QAITT (SEQ ID NO: 5501). QKTLT (SEQ ID NO: 5502), QNQWT (SEQ ID NO: 5503), QLHHT (SEQ ID NO: 5504), QNIII (SEQ ID NO: 5505), QGHHT (SEQ ID NO: 5506), QSKVT (SEQ ID NO: 5507), QLPST (SEQ ID NO: 5508). IGKQT (SEQ ID NO: 5509), QAIHT (SEQ ID NO: 5510), QIIGLT (SEQ ID NO: 5511). QFMCT (SEQ ID NO: 5512), QHLQT (SEQ ID NO: 5513), QNHQN (SEQ ID NO: 5514), QPART (SEQ ID NO: 5515), QSLQT (SEQ ID NO: 5516), QSQLT (SEQ ID NO: 5517), QDRQS (SEQ ID NO: 5518), QMPST (SEQ ID NO: 5519), QGSLT (SEQ ID NO: 5520), QVPAT (SEQ ID NO: 5521), QDKQT (SEQ ID NO: 5522), HYQQT (SEQ ID NO: 5523), QVPST (SEQ ID NO: 5524), RGEQT (SEQ ID NO: 5525), PGQQT (SEQ ID NO: 5526), QSLQI (SEQ ID NO: 5527), LEQQT (SEQ ID NO: 5528), QNQST (SEQ ID NO: 5529), QKVIT (SEQ ID NO: 5530). QNNDQ (SEQ ID NO: 5531), QSVHT (SEQ ID NO: 5532). QPLGT (SEQ ID NO: 5533), HNQET (SEQ ID NO: 5534), QNLQI (SEQ ID NO: 5535). QIQQT (SEQ ID NO: 5536), QVRNT (SEQ ID NO: 5537), PSNQT (SEQ ID NO: 5538), QVGHT (SEQ ID NO: 5539), QRDIT (SEQ ID NO: 5540), QMPNT (SEQ ID NO: 5541). RGLQT (SEQ ID NO: 5542), QKQQT (SEQ ID NO: 5543), PSLQT (SEQ ID NO: 5544), QRDQT (SEQ ID NO: 5545), QAKGT (SEQ ID NO: 5546), QSAHT (SEQ ID NO: 5547), QSTMT (SEQ ID NO: 5548), QREMT (SEQ ID NO: 5549), QYRAT (SEQ ID NO: 5550), QWQQT (SEQ ID NO: 5551), QRMNT (SEQ ID NO: 5552), GDSQT (SEQ ID NO: 5553). QKIST (SEQ ID NO: 5554), PSMQT (SEQ ID NO: 5555), SPRQT (SEQ ID NO: 5556). MEQQT (SEQ ID NO: 5557), QYQN'T (SEQ ID NO: 5558), QHQQT(SEQ ID NO: 5559), INQQT (SEQ ID NO: 5560), PNQQH (SEQ ID NO: 5561), ENRQT (SEQ ID NO: 5562), QTQQA (SEQ ID NO: 5563), or QNQAT (SEQ ID NO: 5564);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more titan four different amino acids, relative to any one of the amino acid sequences in (i).193. The AAV particle of embodiment 191 or 192, wherein [N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any of SEQ ID NOs: 200 or 2887-3076;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).194. The AAV particle of any one of embodiments 191-193, wherein [N1]-[N2]-[N3]-[N4] is or comprises GSGSPHSK AQNQQT (SEQ ID NO: 200).195. The AAV particle of any one of embodiments 191-193, wherein [N1]-[N2]-[N3]-[N4] is or comprises VSGSPHSKAQNQQT (SEQ ID NO: 903).196. The AAV particle of any one of embodiments 168-195, wherein the AAV capsid variant comprises an amino acid other than K at position 449 (e.g., T, E, or N), T at position 450 (e.g., S, E,A, N, V, Q, or G), an amino acid other than 1 at position 451 (e.g., F, E, V, L, D, S, C, T, A, N, H, R,G, or W), and / or an amino acid other than N at position 452 (e.g., I, P, K, R, H, S, M, Q, D, T, L, A,Y, V, F, E, W, or G), numbered according to SEQ ID NO: 138 or 981197. The AAV particle of any one of embodiments 168-196, wherein the AA V capsid variant comprises the amino acid K at position 449, the amino acid T at position 450, the amino acid I at position 451, and / or the amino acid N at position 452, numbered according to SEQ ID NO: 138 or 981.198. The AAV particle of any one of embodiments 168-197, wherein the AAV capsid variant further comprises [N0], wherein [N0] comprises XA, XB, Xc, and XD, wherein:(a) XAis K, T, E, or N;(b) XBis T, S, E, A, N, V, Q, or G;(c) Xc is I, F, E, V, L, D, S, C, T, A. N, H, R. G, or W; and(d) XDis N, I, P, K. R, H, S, M, Q, D, T. L, A, Y, V. F, E, W, or G; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d).199. The AAV particle of embodiment 198, wherein [N0] is or comprises:(i) KTII (SEQ ID NO: 5565), KTFP (SEQ ID NO: 5566), KTEK (SEQ ID NO: 5567), KTVN (SEQ ID NO: 5568), KEEN (SEQ ID NO: 5569), KTIN (SEQ ID NO: 5570), TTIN (SEQ ID NO: 5571), KSIN (SEQ ID NO: 5572), KTER (SEQ ID NO: 5573), KELH (SEQ ID NO: 5574), KAIN (SEQ ID NO: 5575), KTDN (SEQ ID NO: 5576), KTFH (SEQ ID NO: 5577), KTSN (SEQ ID NO: 5578), ETIN (SEQ ID NO: 5579), NTIN (SEQ ID NO: 5580), KTEN (SEQ ID NO: 5581), KTSS (SEQ ID NO: 5582), KTCN (SEQ ID NO: 5583), KTEH (SEQ ID NO: 5584), KAEM (SEQ ID NO: 5585), KAIN (SEQ ID NO: 5586), KAIK (SEQ ID NO: 5587), KTDK (SEQ ID NO: 5588), KTFK (SEQ ID NO: 5589), KSDQ (SEQ ID NO: 5590), KTEI (SEQ ID NO: 5591), KTI.D (SEQ ID NO: 5592), KNTN (SEQ ID NO: 5593), KTET (SEQ ID NO: 5594), KTEL (SEQ ID NO: 5595), KNIN (SEQ ID NO: 5596), KTEA (SEQ ID NO: 5597), KTAN (SEQ ID NO: 5598), NTIY (SEQ ID NO: 5599), KTFS (SEQ ID NO: 5600), KTES (SEQ ID NO: 5601). KTTN (SEQ ID NO: 5602), KTED (SEQ ID NO: 5603), KTNN (SEQ ID NO: 5604), KEVH (SEQ ID NO: 5605), KTIS (SEQ ID NO: 5606), KTVR (SEQ ID NO: 5607), KTDR (SEQ ID NO: 5608), ETIK (SEQ ID NO: 5609), KNHI (SEQ ID NO: 5610), KESD (SEQ ID NO: 5611), KTIK (SEQ ID NO: 5612), KTDL (SEQ ID NO: 5613), KTVP (SEQ ID NO: 5614), KTVI (SEQ ID NO: 5615), KAEH (SEQ ID NO: 5616), KNCL (SEQ ID NO: 5617), KTVK (SEQ ID NO: 5618), KNAD (SEQ ID NO: 5619), KTIT (SEQ ID NO: 5620), KNCV (SEQ ID NO: 5621), KN AL (SEQ ID NO: 5622), KVIN (SEQ ID NO: 5623), KTEF (SEQ ID NO: 5624), KTRE (SEQ ID NO: 5625), KQGE (SEQ ID NO: 5626), KSEK (SEQ ID NO: 5627), KNVN (SEQ ID NO: 5628), KGGE (SEQ ID NO: 5629), KEFV (SEQ ID NO: 5630), KSDK (SEQ ID NO: 5631), KTEQ (SEQ ID NO: 5632), KEVQ (SEQ ID NO: 5633), KTEY (SEQ ID NO: 5634), KNCW (SEQ ID NO: 5635), KTDV (SEQ ID NO: 5636), KSDI (SEQ ID NO: 5637), KNSI (SEQ ID NO: 5638), KNSL (SEQ ID NO: 5639), KEVV (SEQ ID NO: 5640), KTEP (SEQ ID NO: 5641), KSEL (SEQ ID NO: 5642), KTWQ (SEQ ID NO: 5643), KTEV (SEQ ID NO: 5644), KAVN (SEQ ID NO: 5645), KGVL (SEQ ID NO: 5646), KTEG (SEQ ID NO: 5647), KTRD (SEQ ID NO: 5648), KTGN (SEQ ID NO: 5649). KNAI (SEQ ID NO: 5650), KAEN (SEQ ID NO: 5651), KAET (SEQ ID NO: 5652), KTVH (SEQ ID NO: 5653), KETA (SEQ ID NO: 5654), KNNL (SEQ ID NO: 5655), EAIN (SEQ ID NO: 5656), KSLN (SEQ ID NO: 5657), KTIP (SEQ ID NO: 5658). orKTIH (SEQ ID NO: 5659);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).200. The AAV particle of embodiment 198 or 199, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 3239-3526 or 3591-3605;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more titan four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).201. The AAV particle of any one of embodiments 198-200, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTINGSGSPHSKAQNQQT (SEQ ID NO: 5660).202. The AAV particle of any one of embodiments 198-200, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589).203. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRN A, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRN A; and wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N 1]-[N2]-[ N 3 ] (SEQ ID NO: 6408), wherein:(i) [N1] comprises X1, X2, and X3, wherein X2 is an amino acid other than S and X3 is an amino acid other than G;(ii) [N2] comprises the amino acid sequence SPH; and(iii) [N3] comprises X4, X5, and X6, wherein X4 is K.204. The AAV particle of embodiment 203, wherein:(i) X5 of [N3] is S, I, T, R, H, Y, L, or M; and(ii) X6 of [N3] is G, A, L, E, V, R, W, N, Q. or K; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i) or (ii).205. The AAV particle of embodiment 203 or 204, wherein X5 is S and / or X6 is G.206. The AAV particle of any one of embodiments 203-205, wherein [N3] comprises KS, KI, KT, KR, KH, KY, KL, KM, SG, IG, TG, RG, SA, SL, SE, SV, SR, SW, SN, HG, YG, SQ. IV, SK, LW, MG, or MA.207. The AAV particle of any one of embodiments 203-206, wherein [N3] is or comprises KSG, KIG, KTG, KRG, KSA, KSL, KSE, KSV, KSR, KSW, KSN, KHG, KYG, KSQ, KIV, KSK, KLW, KMG, or KMA.208. The AAV particle of any one of embodiments 203-207, wherein [N3] is or comprises KSG.209. The AAV particle of any one of embodiments 203-208, wherein [N2.]-[N3] comprises SPHKS (SEQ ID NO: 4704), SPHKI (SEQ ID NO: 4713), SPHKT (SEQ ID NO: 4711), SPHKR (SEQ ID NO: 4717). NPHKS (SEQ ID NO: 5661), SPHKH (SEQ ID NO: 4728), SPHKY (SEQ ID NO: 4715), SPHKL (SEQ ID NO: 4714), or SPHKM (SEQ ID NO: 4729).210. The AA V particle of any one of embodiments 203-209, wherein [N2]-[N3] is or comprises:(i) SPHKSG (SEQ ID NO: 946), SPHK1G (SEQ ID NO: 958), SPHKTG (SEQ ID NO: 4738), SPHKRG (SEQ ID NO: 974), NPHKSG (SEQ ID NO: 5662), SPHKSA (SEQ ID NO: 977), SPHKSL (SEQ ID NO: 4740), SPHKSE (SEQ ID NO: 4741), SPHKS V (SEQ ID NO: 4742), SPHKSR (SEQ ID NO: 951), SPHKSW (SEQ ID NO: 4743), SPHKSN (SEQ ID NO: 4744), SPHKHG (SEQ ID NO: 4745), SPHKYG (SEQ ID NO: 966), SPHKSQ (SEQ ID NO: 4746), SPHKIV (SEQ ID NO: 5663), SPHKSK (SEQ ID NO: 4747), SPHKLW (SEQ ID NO: 4748), SPHKMG (SEQ ID NO: 4750), or SPHKMA (SEQ ID NO: 4751);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4. or 5 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to airy of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).211. The AAV particle of any one of embodiments 203-210, wherein [N2]-[N3] is or comprises SPHKSG (SEQ ID NO: 946).212. The AAV particle of any one of embodiments 203-211, wherein the AAV capsid variant comprises an amino acid other than G at position 453 (e.g., A, K, W, R, L, I, M, N, T, E, Q, Y, H, F, or V), numbered according to SEQ ID NO: 138 or 981.213. The AAV particle of any one of embodiments 203-212, wherein the AA V capsid variant comprises the amino acid G at position 453, numbered according to SEQ ID NO: 138 or 981.214. The AAV particle of any one of embodiments 203-214, wherein:(i) XI of [ N 1] is G, A, K, W, R, L, I, M, N, T, E, Q, Y, H, F, or V;(ii) X2 of [N 1] is H, Y, R, Q, N, P. or D:(iii) X3 of [N1 ] is D, E, G, V, or N; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (i), (ii), or (iii).215. The AAV particle of any one of embodiments 203-214, wherein X2 of [N1] is H and X3 of [N1] is D.216. The AAV particle of any one of embodiments 203-215, wherein XI of [N1] is G, X2 of [N1] is H and X3 of [N1] is D.217. The AAV particle of any one of embodiments 203-216, wherein [N1] comprises GH, HD, GY,GR, GQ, AH, GN, KH, GP, WH, RH, LH, IH, MH, GD, NH, TH, EH, QH, YH, HH, FH, VH, YD,HE, RG, QD, RD, ND, PD, QV, DD, HN, or NG.218. The AAV capsid variant of any one of embodiments 203-217, wherein [Nl ] is or comprises GHD, GYD, GHE, GRG, GQD, GRD, AHD, GND, KHD, GPD, WHD, RHD, LHD, GQV, IHD, MHD, GDD, GHN, NHD, THD, GNG, EHD, QHD, YHD, HHD, FHD, or VHD.219. The AAV particle of any one of embodiments 203-218, wherein [N 1] is or comprises GHD.220. The AAV particle of any one of embodiments 203-219, wherein [N1]-[N2] comprises HDSPH (SEQ ID NO: 4703).221. The AAV particle of any one of embodiments 203-22.0, wherein [N1]-[N2] is or comprises:(i) GHDSPH (SEQ ID NO: 4784), GYDSPH (SEQ ID NO: 4829), GHESPH (SEQ ID NO: 4793), GRGSPH (SEQ ID NO: 4788), GHDNPH (SEQ ID NO: 5664), GQDSPH (SEQ ID NO: 4785), GRDSPH (SEQ ID NO: 4831), AHDSPH (SEQ ID NO: 5665), GNDSPH (SEQ ID NO: 4832), KHDSPH (SEQ ID NO: 5666), GPDSPH (SEQ ID NO: 4833). WHDSPH (SEQ ID NO: 5667), RHDSPH (SEQ ID NO: 5668), LHDSPH (SEQ ID NO: 5669), GQVSPH (SEQ ID NO: 4835), IHDSPH (SEQ ID NO: 5670), MHDSPH (SEQ ID NO: 5671), GDDSPH (SEQ ID NO: 4792), GHNSPH (SEQ ID NO: 4836), NHDSPH (SEQ ID NO: 5672), THDSPH (SEQ ID NO: 5673), GNGSPH (SEQ ID NO: 4805), EHDSPH (SEQ ID NO: 5674), QHDSPH (SEQ ID NO: 5675),(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof:(iii) an amino acid sequence comprising one, two, or three but no more titan four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).222. The AAV particle of any one of embodiments 203-221 , wherein [N1]-[N2]-[N3] is or comprises:(i) GHDSPHKSG (SEQ ID NO: 4698), GHDSPHKIG (SEQ ID NO: 4996), G YDSPH KSG (SEQ ID NO: 4997), GHESPHKSG (SEQ ID NO: 4998). GHDSPH KTG (SEQ ID NO: 4999), GRGSPHKRG (SEQ ID NO: 5000), GHDNPHKSG (SEQ ID NO: 5680), GQDSPHKSG (SEQ ID NO: 4908), GHDSPHKSA (SEQ ID NO: 4940), GHDSPHKSL (SEQ ID NO: 5001). GHDSPHKSE (SEQ ID NO: 5003), GRDSPHKSG (SEQ ID NO: 5004), AHDSPHKSG (SEQ ID NO: 5681). GNDSPHKSV (SEQ ID NO: 5005), AHDSPHKIG (SEQ ID NO: 5682), GHESPHKSA (SEQ ID NO: 4939), GQDSPHKIG (SEQ ID NO: 5006), GHDSPHKSV (SEQ ID NO: 5007), GHDSPHKSR (SEQ ID NO: 4942), KHDSPHKSG (SEQ ID NO: 5683), GPDSPHKIG (SEQ ID NO: 5008), GPDSPHKSG (SEQ ID NO: 5009), GHDSPHKSW (SEQ ID NO: 5010), WHDSPHKSG (SEQ ID NO: 5684), RHDSPHKSG (SEQ ID NO: 5685). GHDSPHKSN (SEQ ID NO: 5011), GHDSPHKRG (SEQ ID NO: 4937), GHDSPHKHG (SEQ ID NO: 5013). LHDSPHKSG (SEQ ID NO: 5686). GQVSPHKSG (SEQ ID NO: 5014), IHDSPHKSG (SEQ ID NO: 5687), MHDSPHKSG (SEQ ID NO: 5688), GDDSPHKSV (SEQ ID NO: 5015), GHNSPHKSG (SEQ ID NO: 5016), NHDSPHKSG (SEQ ID NO: 5689), THDSPHKSG (SEQ ID NO: 5690), GNGSPHKRG (SEQ ID NO: 5017), EHDSPHKSG (SEQ ID NO: 5691), GHDSPHKYG (SEQ ID NO: 5018). GHDSPHKSQ (SEQ ID NO: 5019), QHDSPHKSG (SEQ ID NO: 5692), RHDSPHK IV (SEQ ID NO: 5693), YHDSPI IKSG (SEQ ID NO: 5694), GNDSPHKIG (SEQ ID NO: 5020). HHDSPHKSG (SEQ ID NO: 5695), GHDSPHKSK (SEQ ID NO: 5021), FHDSPHKSG (SEQ ID NO: 5696). GHDSPHKLW (SEQ IDNO: 5022), VHDSPHKSG (SEQ ID NO: 5697), GHDSPHKMG (SEQ ID NO: 5024), GHDSPHKMA (SEQ ID NO: 5025), or GDDSPHKSG (SEQ ID NO: 4938);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).223. The AAV particle of any one of embodiments 203-222, wherein [N1]-[N2]-[N3] is or comprises GHDSPHKSG (SEQ ID NO: 4698).224. The AAV particle of any one of embodiments 203-223, wherein the AAV capsid variant comprises an amino acid other than Q at position 456 (e.g., R, P, H, K, L, V, A, E, or I), an amino acid other than N at position 457 (e.g., I, K, S, H, R, T, D, Y, L, W, F, A, Q, or M), an amino acid other than Q at position 458 (e.g., R, V, K, P, Y, H, L, I, E, or M), an amino acid other than Q at position 459 (e.g., H, L, E, P, W, D, I, V, S, K, R, C, M, or N), and / or an amino acid other than T at position 460 (e.g., A, E, K, S, I, P, G, orN), numbered according to SEQ ID NO: 138,225. The AAV particle of any one of embodiments 203-224, wherein the AAV capsid variant comprises an amino acid other than Q at position 462 (e.g.. R, P, II, K, L, V, A, E. or I), an amino acid oilier than N at position 463 (e.g., I, K, S, H, R, T, D, Y, L, W, F, A, Q. or M), an amino acid other than Q at position 464 (e.g., R. V, K, P, Y, II. L, I, E, or M), an amino acid other than Q at position 465 (e.g., H, L, E, P, W, D, I, V, S, K, R, C, M, or N), and / or an amino acid other than T at position 466 (e.g., A, E, K, S, I, P, G, orN), numbered according to SEQ ID NO: 982.226. The AAV particle of any one of embodiments 203-225, wherein the AAV capsid variant comprises the amino acid Q at position 456, the amino acid N at position 457, the amino acid Q at position 458, the amino acid Q at position 459, and / or the amino acid T at position 460, numbered according to SEQ ID NO: 138.22.7. The AAV particle of any one of embodiments 203-226, wherein the AA V capsid variant comprises the amino acid Q at position 462, the amino acid N at position 463, the amino acid Q at position 464, the amino acid Q at position 465, and / or the amino acid T at position 466, numbered according to SEQ ID NO: 138.228. The AAV particle of any one of embodiments 203-227, wherein the AAV capsid variant further comprises [N4], wherein [N4] comprises X7, X8, X9, X10, and XI 1, wherein:(a) X7 is Q, R, P, H, L, K, I, G, S, M, or E;(b) X8 is N, D, V, S, P, T, G. Y, W. E, R, H, K, F, A, I. L, or M;(c) X9 is Q, R, L, A. P, H, T, I, F, K. V, M, G, W, Y, S, E, N, D;(d) X10 is Q, H, K, A, L, P, E, M. I, S. N, R, Y, C. V, T, W, D, G; and(e) X11 is T, I, N, S, H, R, L, D, Y. A, Q; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(e).229. The AAV particle of embodiment 228, wherein [N4j is or comprises:(i) QNQQT (SEQ ID NO: 5412), QIRQT (SEQ ID NO: 5698), QNQHA (SEQ ID NO: 5699), QKQQT (SEQ ID NO: 5543), QSVQT (SEQ ID NO: 5700), RSQQT (SEQ ID NO: 5701), QNKLE (SEQ ID NO: 5702), QNQQK (SEQ ID NO: 5703), QHQQA (SEQ ID NO: 5704), QIQHT (SEQ ID NO: 5705), PRQQT (SEQ ID NO: 5706), HTQQT (SEQ ID NO: 5707), QRQHT (SEQ ID NO: 5708), QSQQT (SEQ ID NO: 5418), QNQQS (SEQ ID NO: 5709), RNQET (SEQ ID NO: 5710), QTQLT (SEQ ID NO: 5478), KNQQT (SEQ ID NO: 5711), QDQQT (SEQ ID NO: 5432), HNQQT (SEQ ID NO: 5426), QNQLT (SEQ ID NO: 5423), QTQQT (SEQ ID NO: 5712), QTQQI (SEQ ID NO: 5713). QSKQA (SEQ ID NO: 5714), QNQPP (SEQ ID NO: 5715), QSPQT (SEQ ID NO: 5716), QNYQT (SEQ ID NO: 5493), QNHQT (SEQ ID NO: 5431 ). QNRQT (SEQ ID NO: 5446), QNQQG (SEQ ID NO: 5717), QNHLT (SEQ ID NO: 5482). QYQHT (SEQ ID NO: 5447), QNQWT (SEQ ID NO: 5503), QNQHT (SEQ ID NO: 5718), QTRQT (SEQ ID NO: 5719), QNLHT (SEQ ID NO: 5720), LNQQT (SEQ ID NO: 5471), QNQET (SEQ ID NO: 5721), QIILQT (SEQ ID NO: 5513), LNQPT (SEQ ID NO: 5722), QNQDT (SEQ ID NO: 5723), RNQQT (SEQ ID NO: 5724), QNLLT (SEQ ID NO: 5725), QLVIT (SEQ ID NO: 5726), RTQET (SEQ ID NO: 5727), QTHQT (SEQ ID NO: 5728), QNQPA (SEQ ID NO: 5729), QDQHT (SEQ ID NO: 5730), QSQHT (SEQ ID NO: 5731), RNQQI (SEQ ID NO: 5732), VRQQT (SEQ ID NO: 5733), QNQHS (SEQ ID NO: 5734), AWQQT (SEQ ID NO: 5735), QSVPT (SEQ ID NO: 5736), QNIQP (SEQ ID NO: 5737), QNHLN (SEQ ID NO: 5738), LDQQT (SEQ ID NO: 5739), PDQQS (SEQ ID NO: 5740), ESQQT (SEQ ID NO: 5741), QNKQT (SEQ ID NO: 5742), QRQLT (SEQ ID NO: 5743), QIIVT (SEQ ID NO: 5744), QKQST (SEQ ID NO: 5745). QSHQT (SEQ ID NO: 5746), QFWT (SEQ ID NO: 5747), QNLQT (SEQ ID NO: 5428), QNQQT (SEQ TD NO: 5419), QSQPT (SEQ ID NO: 5748), QNEQT (SEQ ID NO: 5749), QSLQT (SEQ ID NO: 5516), RNRQT (SEQ ID NO: 5750), QSKQT (SEQ TD NO: 5751), QNPLT (SEQ ID NO: 5752), RDQKT (SEQ ID NO: 5753), HNQQN (SEQ ID NO: 5754). QWKRT (SEQ ID NO: 5755), QSQQI (SEQ ID NO: 5476), QAQQT (SEQ ID NO: 5462), QNHQI (SEQ ID NO: 5756), QNQQA (SEQ ID NO: 5757), QNQLN (SEQ ID NO: 5758), QTQPT (SEQ ID NO: 5759), INQQT (SEQ ID NO: 5560), QKQLT (SEQ ID NO: 5760), RNQLA (SEQ ID NO: 5761),RNQQS (SEQ ID NO: 5762), ISIQT (SEQ ID NO: 5763), QNQQN (SEQ ID NO: 5764), QSQQS (SEQ ID NO: 5765), QTVCT (SEQ ID NO: 5766), QYQQI (SEQ ID NO: 5767), QQIMT (SEQ ID NO: 5768), QNEQS (SEQ ID NO: 5769), LNHQT (SEQ ID NO: 5770), QMIHT (SEQ ID NO: 5771), RNHQS (SEQ ID NO: 5772), QKMNT (SEQ ID NO: 5773), QSQQN (SEQ ID NO: 5774), QYQHA (SEQ ID NO: 5465);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, or 4 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).230. The AAV particle of embodiment 228 or 229, wherein [N1]-[N2]-[N3 ]-[N4] is or comprises:(i) the amino acid sequence of any of SEQ ID NOs: 201 or 3160-3237;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more titan four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).231. The AAV particle of any one of embodiments 228-230, wherein [N1]-[N2]-[N3]-[N4] is or comprises GHDSPHKSGQNQQT (SEQ ID NO: 201).232. The AAV particle of any one of embodiments 203-231, wherein the AAV capsid variant comprises an amino acid other than K at position 449 (e.g., T), T at position 450 (e.g., A, S, 1, V, N,E, Y, C, G, W, or Q), an amino acid other than I at position 451 (e.g., E, V, S, T, N, D, C, G, Q, L, P,A), and / or an amino acid other than N at position 452 (e.g., S, Y, I, K, F, T, D, E, G, V, L, A, M, Q, H, P, or R), numbered according to SEQ ID NO: 138 or 982.233. The AAV particle of any one of embodiments 203-232, wherein the AAV capsid variant comprises the amino acid K at position 449, the amino acid T at position 450, the amino acid 1 at position 451, and / or the amino acid N at position 452, numbered according to SEQ ID NO: 138 or 982.234. The AAV particle of any one of embodiments 203-233, wherein the AA V capsid variant further comprises [N0], wherein [N0] comprises XA, XB, Xc, and XD, wherein:(a) XAis K or T;(b) XBis T, A, S, I, V, N. E, Y, C, G, W, or Q;(c) Xcis I, E. V, S. T, N, D, C, G, Q, L, P, A; and(d) XDis N, S, Y, I. K, F. T, D, E. G, V, L, A. M, Q, H, P, or R; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conservative substitution, of any of the aforesaid amino acids in (a)-(d).235. The AAV particle of embodiment 234, wherein [N0] is or comprises:(i) KAIN (SEQ ID NO: 5575), KTIN (SEQ ID NO: 5570). KTES (SEQ ID NO: 5601), TTIN (SEQ ID NO: 5571), KSIN (SEQ ID NO: 5572), KTVN (SEQ ID NO: 5568), KSIY (SEQ ID NO: 5775), KTSN (SEQ ID NO: 5578), KTTN (SEQ ID NO: 5602), KILN (SEQ ID NO: 5776), KTIS (SEQ ID NO: 5606), KAII (SEQ ID NO: 5777), KTIK (SEQ ID NO: 5612), KIEF (SEQ ID NO: 5624), KTIT (SEQ ID NO: 5620), KTNN (SEQ ID NO: 5604), KTID (SEQ ID NO: 5592), KAIS (SEQ ID NO: 5778), KTVD (SEQ ID NO: 5779), KITE (SEQ ID NO: 5780), KTEG (SEQ ID NO: 5647), KVIN (SEQ ID NO: 5623), KAVN (SEQ ID NO: 5645), KTIY (SEQ ID NO: 5781), KTDN (SEQ ID NO: 5576), KTCN (SEQ ID NO: 5583), KNW (SEQ ID NO: 5782), KIEL (SEQ ID NO: 5595), KTDA (SEQ ID NO: 5783), KTEV (SEQ ID NO: 5644), KSEL (SEQ ID NO: 5642), KTEM (SEQ ID NO: 5784), KTEQ (SEQ ID NO: 5632), KTII (SEQ ID NO: 5565), KIVN (SEQ ID NO: 5785), KTEK (SEQ ID NO: 5567), KTEN (SEQ ID NO: 5581), KIGN (SEQ ID NO: 5786), KEVM (SEQ ID NO: 5787), KYQV (SEQ ID NO: 5788), KTEA (SEQ ID NO: 5597), KATN (SEQ ID NO: 5586), KTEH (SEQ ID NO: 5584). KTVE (SEQ ID NO: 5789), KAID (SEQ ID NO: 5790), KTIM (SEQ ID NO: 5791), KEVG (SEQ ID NO: 5792), KSEM (SEQ ID NO: 5793), KAQQ (SEQ ID NO: 5794), KCGE (SEQ ID NO: 5795), KASN (SEQ ID NO: 5796), KTET (SEQ ID NO: 5594), KTIG (SEQ ID NO: 5797), KTDP (SEQ ID NO: 5798), KELV (SEQ ID NO: 5799), KELM (SEQ ID NO: 5800), KNE1 (SEQ ID NO: 5801), KTPN (SEQ ID NO: 5802), KIT N (SEQ ID NO: 5803), KTDI (SEQ ID NO: 5804), KTDQ (SEQ ID NO: 5805), KGIN (SEQ ID NO: 5806), KSEI (SEQ ID NO: 5807), KSEK (SEQ ID NO: 5627), KWSA (SEQ ID NO: 5808), KELA (SEQ ID NO: 5809), KQTQ (SEQ ID NO: 5810), KGAD (SEQ ID NO: 5811), KVGE (SEQ ID NO: 5812), KANE (SEQ ID NO: 5813), KTDT (SEQ ID NO: 5814), KTCI (SEQ ID NO: 5815). KELR (SEQ ID NO: 5816), KCQI (SEQ ID NO: 5817), KGVM (SEQ ID NO: 5818), KA CD (SEQ ID NO: 5819), KNEL (SEQ ID NO: 5820), KAAE (SEQ ID NO: 5821). KGQN (SEQ ID NO: 5822), KNEF (SEQ ID NO: 5823), KTSI (SEQ ID NO: 5824), KAEH (SEQ ID NO: 5616), KCDQ (SEQ ID NO: 5825), KEIL (SEQ ID NO: 5826), KTER (SEQ ID NO: 5573). KNAI (SEQ ID NO: 5650), KTDK (SEQ ID NO: 5588), KTPD (SEQ ID NO: 5827), KTIH (SEQ ID NO: 5659), orKTEI (SEQ ID NO: 5591);(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, or 3 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (1); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).236. The AAV particle of embodiment 234 or 235, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 3606-3836;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11. 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof:(iii) an amino acid sequence comprising one, two, or three but no more titan four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).237. The AAV particle of any one of embodiments 234-236, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTINGHDSPHKSGQNQQT (SEQ ID NO: 5828).238. The AAV particle of any one of embodiments 234-236, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754).239. The AAV particle of any one of embodiments 234-236, wherein [N0]-[N1]-[N2]-[N3]-[N4] is or comprises KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241).240. The AAV particle of any one of embodiments 168-239, wherein [N1]-[N2]-[N3] is present in loop IV, e.g., numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.241. The AAV particle of any one of embodiments 198-202 or 234-240, wherein [N0] and [N4] are present in loop IV. e.g., numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.242. The AAV particle of any one of embodiments 198-202 or 2.34-241 , wherein [N0] is present immediately subsequent to position 448, numbered according to the amino acid sequence of SEQ IDNO: 4. 36, 138, 981, or 982.243. The AAV particle of any one of embodiments 198-202 or 234-242, wherein [N0] replaces positions 449-452 (e.g., K449, T450, 1451, and N4.52), numbered according to SEQ ID NO: 4, 36,138, 981, or 982.244. The AAV particle of any one of embodiments 198-202 or 234-243. wherein [N0] is present immediately subsequent to position 448 and wherein [N0] replaces positions 449-452 (e.g., K449. T450. 1451, and N452), numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.245. The AAV particle of any one of embodiments 198-202 or 234-244, wherein [N0] corresponds to positions 449-452 (e.g., K449, T450, 1451, and N452) of any one of SEQ ID NOs: 4, 36, 138, 981, or 982.246. The AAV particle of any one of embodiments 168-245, wherein [N1] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 4, 36, 138, 981, or 982.247. The AAV particle of any one of embodiments 168-246, wherein [Nl] replaces positions 453-455 (e.g., G453, S454, and G455), numbered according to SEQ ID NO: 4, 36, 138. 981, or 982.248. The AAV particle of any one of embodiments 168-246, wherein [N1] replaces position 453 (e.g.,G453), numbered according to SEQ ID NO: 4. 36, 138, 981, or 982.249. The AAV particle of any one of embodiments 168-177, 179-181, 183-185, 187-193, 195-200, 202, or 240-246, wherein:(i) XI of [N l] replaces position 453 (e.g., G453);(ii) X2 of [N1] corresponds to position 454 (e.g., S454): and(iii) X3 of [N1] corresponds to position 455 (e.g., G455), wherein (i), (ii), and (iii) are numbered according to SEQ ID NO: 138 or SEQ ID NO: 981.250. The AAV particle of any one of embodiments 168-176, 178-201, or 240-246, wherein:(i) XI of [N1] corresponds to position 453 (e.g., G453);(ii) X2. of [N1] corresponds to position 454 (e.g,, S454); and(iii) X3 of [N1] corresponds to position 455 (e.g., G455); wherein (i), (ii), and (iii) are numbered according to SEQ ID NO: 138 or SEQ ID NO: 981.251. The AAV particle of any one of embodiments 203-248, wherein:(i) XI of [N1] corresponds to position 453 (e.g., G453):(ii) X2 of [N1] replaces position 454 (e.g., S454): arid(iii) X3 of [N1] replaces position 455 (e.g., G455), wherein (i), (ii), and (iii) are numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.252. The AAV particle of any one of embodiments 203-248 or 251, wherein [N1] corresponds to positions 453-455 (e.g., G453, H454, D455) of SEQ ID NO 982.253. The AAV particle of any one of embodiments 168-176, 178-201, 240-247, or 250. wherein [N1] corresponds to positions 453-455 (e.g., G453, S454, G455) of SEQ ID NO: 138 or 981 .254. The AAV particle of any one of embodiments 168-253, wherein [N2] is present immediately subsequent to position 455, numbered according to of SEQ ID NO: 4, 36, 138, 981, or 982.255. The AAV particle of any one of embodiments 168-254, wherein [N2] corresponds to positions456-458 (e.g., S456, P457, and H458) of SEQ ID NO: 981 or 982.256. The AAV particle of any one of embodiments 168-254, wherein [N2] corresponds to positions 456-458 (e.g., S456, P457, and H458) of any one of SEQ ID NOs: 4 or 36-59.257. The AAV particle of any one of embodiments 168-256, wherein [N2] is present immediately subsequent to [N1],258. The AAV particle of any one of embodiments 168-202, 240-247, or 249-257, wherein [N3] corresponds to positions 459-460 (e.g., S459, K460, A461) of SEQ ID NO: 981.259. The AAV particle of any one of embodiments 168-202, 240-247, or 249-257, wherein [N3] corresponds to positions 459-460 (e.g., S459, K460, A461) of SEQ ID NO: 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 57, or 59.260. The AAV particle of any one of embodiments 168-259, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to any one of SEQ ID NOs: 4, 36, 138, 981, or 982,261. The AAV particle of any one of embodiments 168-259, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 981.262. The AAV particle of any one of embodiments 168-261, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of SEQ ID NO: 981.263. The AAV particle of any one of embodiments 168-262, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, S459, K460, A461) of any one of SEQ ID NOs: 36, 38, 39, 40, 41. 42, 43, 44, 45, 46, 47, 48. 49, 50, 51, 52, 53, 54, 55. 57, or 59.264. The AAV particle of any one of embodiments 203-257 or 259-261 , wherein [N3] corresponds to positions 459-460 (e.g,, K459, S460, G461) of SEQ ID NO: 982.265. The AAV particle of any one of embodiments 203-257 or 259-261, wherein [N3] corresponds to positions 459-460 (e.g., K459, S460. G461) of SEQ ID NO: 37.266. The AAV particle of any one of embodiments 203-265, wherein [N2]-[N3] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 982.267. The AAV particle of any one of embodiments 203-246, 248, 252, 255, 257, 260, 263-266, wherein [N3] replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ IDNO: 138.268. The AAV particle of any one of embodiments 203-246, 248, 252, 255, 257, 260, 263-267, wherein [N3] is present immediately subsequent to [N2] and replaces positions 454 and 455 (e.g..S454 and G455), numbered according to SEQ ID NO: 138.269. The AAV particle of any one of embodiments 203-246, 248, 252, 255, 257, 260, 263-268, wherein [N3] is present immediately subsequent to [N1]-[N2] and replaces positions 454 and 455 (e.g., S454 and G455), numbered according to SEQ ID NO: 138.270. The AAV particle of any one of embodiments 203-257, 260, 264-269, wherein [N2]-[N3] corresponds to positions 456-461 (e.g., S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.271. The AAV particle of any one of embodiments 203-257, 260, 264-270, wherein [N2]-[N3] corresponds to positions 456-461 (e.g,, S456, P457, H458, K459, S460, G461) of SEQ ID NO: 37.272. The AAV particle of any one of embodiments 191 -202 or 2.28-271 , wherein [N4] is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.273. The AAV particle of any one of embodiments 191-202 or 228-272, wherein [N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.274. The AAV particle of any one of embodiments 191-202 or 228-273, wherein [N4] corresponds to positions 462-466 (e.g., Q462, N463, Q464. Q465, and T466) of SEQ ID NO: 981 or 982.275. The AAV particle of any one of embodiments 191 -202 or 228-273, wherein [N4] corresponds to positions 462-466 of any one of SEQ ID NOs: 4 or 36-59.276. The AAV particle of any one of embodiments 191-202 or 228-274, wherein [N4] corresponds to positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460) of SEQ ID NO: 138.277. The AAV particle of any one of embodiments 191-202 or 228-276, wherein [N2]-[N3]-[N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.278. The AAV particle of any one of embodiments 191-202. or 228-277, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455, and wherein [N2]-[N3]-[N4] replaces positions 456-460 (e.g., Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.279. The AAV particle of any one of embodiments 191-202 or 228-278, wherein [N1]-[N2]-[N3]- [N4] replaces positions 453-460 (e.g., G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.280. The AAV particle of any one of embodiments 191-202 or 228-279, wherein [N1]-[N2]-[N3]- [N4] is present immediately subsequent to position 452, and wherein [NT]-[N2]-[N3]-[N4] replaces positions 453-460 (e.g., G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.281. The AAV particle of any one of embodiments 191-202, 240-247, 249, 250, 253-263, 266, or272-280, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 453-466 (e.g., G453, S454, G455, S456, P457, H458, S459, K460. A461, Q462, N463, Q464. Q465, and T466) of SEQ ID NO: 981.282. The AAV particle of any one of embodiments 168-202, 240-247, 249, 250, 253-263, 266, or 272-280, wherein [N1]-[N2]-[N3] corresponds to positions 453-461 (e.g., G453, S454, G455. S456,P457, H458, S459, K460, A461) of SEQ ID NO: 981.283. The AAV particle of any one of embodiments 228-257, 260, 261, 264-282, wherein [NT]-[N2J- [N3]-[N4] corresponds to positions 453-466 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461 , Q462, N463, Q464, Q465, T466) of SEQ ID NO: 982.284. The AAV particle of any one of embodiments 203-257, 260, 261, 264-283, wherein [N1]-[N2]- [N3] corresponds to positions 453-461 (e.g., G453, H454, D455, S456, P457, H458, K459, S460, G461) of SEQ ID NO: 982.285. The AAV particle of any one of embodiments 228-257, 260, 261, 264-282, wherein [N1]-[N2]- [N3]-[N4] corresponds to positions 453-466 of any one of SEQ ID NOs: 4 or 36-59.286. The AAV particle of any one of embodiments 198-202 or 234-286, wherein [N0]-[N1]-[N2]- [N3]-[N4] replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and T460), numbered according to SEQ ID NO: 138.287. The AAV particle of any one of embodiments 198-202 or 234-286, wherein [N0]-[N1]-[N2]~[N3]-[N4] is present immediately subsequent to position 448, and wherein [N0]-[N1]-[N2]-[N3]-[N4] replaces positions 449-460 (e.g,, K449, T450, 1451, N452, G453, S454, G455, Q456, N457. Q458,Q459, and T460), numbered according to SEQ ID NO: 138.288. The AA V particle of any one of embodiments 198-202, 240-247, 249, 2.50, 253-2.63, 266, 2.72- 2.81, 286, or 287. wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 (e.g.. K449, T450, 1451, N452, G453, S454, G455, S456, P457, H458, S459, K460, A461, Q462, N463, Q464, Q465, T466) of SEQ ID NO: 981.289. The AAV particle of any one of embodiments 234-257, 260, 261, 264-284, 286, or 287, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 (e.g., K449, T450, 1451, N452, G453, H454, D455, S456, P457, H458. K459, S460, G461, Q462, N463, Q464, Q465, T466) of SEQ ID NO: 982.290. The AAV particle of any one of embodiments 234-257, 260, 261, 264-284, 286, or 2.87, wherein [N0]-[N1]-[N2]-[N3]-[N4] corresponds to positions 449-466 of any one of SEQ ID NOs: 4 or 36-59.291. The AAV particle of any one of embodiments 191-202 or 228-290, wherein [N4] is present immediately subsequent to position 461, numbered according to SEQ ID NO: 4, 36, 981, or 982.292. The AAV particle of any one of embodiments 191-202 or 228-291, wherein [N4] replaces positions 462-466 (e.g., Q462, N463, Q464, Q465, and T466), numbered according to SEQ ID NO: 4, 36, 981, or 982.293. The AAV particle of any one of embodiments 191 -202 or 228-292, wherein [N2]-[N3]-[N4] replaces positions 462-466 (e.g., Q462. N463, Q464, Q465, and T466). numbered according to SEQ ID NO: 4, 36, 981. or 982.294. The AAV particle of any one of embodiments 191-202 or 228-293, wherein [N2]-[N3]-[N4] is present immediately subsequent to position 455. and wherein [N2]-[N3]-[N4] replaces positions 462- 466 (e.g., Q462, N463, Q464, Q465, and T466), numbered according to SEQ ID NO: 4, 36, 981, or 982.295. The AAV particle of any one of embodiments 168-294, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N2]-[N3],296. The AAV particle of any one of embodiments 168-295, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N1]-[N2]-[N3].297. The AAV particle of any one of embodiments 168-296, wherein the AAV capsid variant comprises, from N-terminus to C-terminus. [N0]-[N1]-[N2]-[N3].298. The AAV particle of any one of embodiments 168-297, wherein the AAV capsid variant comprises, fromN-terminus to C-terminus, [N1]-[N2]-[N3]-[N4].299. The AAV particle of any one of embodiments 168-298, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [N0]-[N1]-[N2j-[N3]-[N4],300. An adeno-associated vims (AAV) particle comprising an AAV capsid variant (e.g., an AAV capsid variant) and viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRN A, optionally wherein the modulatory polynucleotide comprises anRNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises the formula [A]-[B] (SEQ ID NO: 4696). wherein:(i) [A] comprises GSGSPH (SEQ ID NO: 4695); and(ii) [B] comprises XI X2, X3, X4, and X5, wherein:(a) XI is S, I, F, V, C, Y, W, R, P, L, Q, M, K, or G;(b) X2 is K, M, R, F, V, C, P, Y, L, W, G, N, S, T, 1, or A;(c) X3 is A, Y, L. R, W, C, T, F, H, I, P, M, K, S, V. G, Q, or N;(d) X4 is Q, M, F, K, H, R, C. W, P. V, L, G, S, Y, I. A, T, D, N, or E; and(e) X5 is A, N, Y, R, K, L, I, M, Q. S, C, W, F, T, G, V, or P; optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conseivative substitution, of any of the aforesaid amino acids in (a)-(e).301. The AAV particle of embodiment 300, wherein:(a) XI is S, L, R, V, or P;(b) X2 is K, C. F, L, P, R. S, or V;(c) X3 is A, C, F, I, K, L, M, P, R, T, W, or Y;(d) X4 is Q, R, S, T, C, F, K, L, P or Y; and(e) X5 is N, R, S, T, K, M, Q or Y: optionally wherein the AAV capsid variant comprises an amino acid modification, e.g., a conseivative substitution, of any of the aforesaid amino acids in (a)-(e).302. The AAV particle of embodiment 300 or 301 , wherein [B] comprises SKA, SMY, SKL, SKR, SKW, SRC, SFT, SKF, IVW, SKY, SCH, FPW, SKI, VYY, SLY, SKP, SRF, SRM, SVK, SWA, SLW, SFR, SKK, SYA, SCS, SGA, SFP. SFF, SMC. SKT, SGK, FYR, CRV, YGI, VNC, SLA, WSY. RWL, PSC, SSW, SKG, VPW, SGC, STT, PKR, SKC, WVP, SFW, RIK, SKM, LRW, LPT, SYM, LLC, RCC, LCV, SYL, QGC, MAF, SFQ. SLC, RPW, RPR, SCP, SVR, SLP. VYH. SYT, LVY, YRY. SWL, CPA, SPP, RWT, PRK, PFV, SKS, WVA, SKV, CAL, SSC, SKN, LCT, STC, SKQ. KSG, SYY, SLT, SCQ, FPF, SVF, GRY, AQA, AQN, YMN, AFY, LKR, RHR, AQK, WRL, CRN, TCN, FFI, AQY, WQN, YFM, ARQ, HQN, IRR, YQN, YWN, AFS, FWN, AQC, MRN, KK.N, APN, WKN, ARW, RPN, KVF, AFN, ACS, RLW, SRN, CPN, ACN, FRQ, PFN, FGN, CQN, LFW, TRK, KRN, RQN, VQN, IQN, AQR, PFR, AWN, RSY, LQN, WLN, RRA, AQT, GCT, RYT, TPN, ARM, CFL, PQN, WSN, FKN, KQN, APR, RYN, MIC, TQN, WKS, AAR, LTR, 1RG, LVN, FQN, ACQ, WGL, ILR, QIN, AC1, ALR, AHA, CLN, AFV, AQF, RCN, MPC, KTS, PYN, AQS, TRN, LKN, AQM, CTN, PDN, RNY, ACR, CSV, ARI, LPK, SEQ, VRM, NSR, RKR, ARN, QRP, RW, GQN, YSN, QSN, AKG, CTS, FEN, AKK, KAQ, MYM, KAF, KLK, KRH, KWR, RCR, FTC, KFF, VWQ, KYF. KAR, CHQ, PWQ, KIR, YYQ, LYW, KPK, RFW, RMR, VKK, WAP, LWK, FRP, KKV, YAF, KAC, KRL, CSR. RCP, GAC, KFR, FFG, MCQ, KLF, KTR, GKR, YRQ, RVQ, GIQ, NCQ, KPF, LAW, KRS, SYQ, WLQ, KRR, KGC, KRY, GCQ, FTP, TTC, KRQ, KCF, VPQ, FWS, KFK. IKQ, KAP. FRY, KMI, RWQ, PTQ, KWK. YMR, KAA, LCQ, CCQ, CVQ, KLT, KLC, YLV, AFQ, KWG, KIL, FQI, KAL, KAH, LCL, PRQ, CPQ, VRY, VRC, KMP. KKT, LPY. YI-IQ, YTR, VYQ, RYQ, WLK, PAQ, MCT, PPD. WTQ, RKQ, KCS, FVQ, KLP, KSE, VAQ. LYQ,KVR, ALQ, SCT, KNS, KRK, CTQ, TCL, YAR, KQR, KRV, SGQ, YYS, LTC, CQS, KAK, KPQ, PFQ, KCT, or VFE.303. The AAV particle of any one of embodiments 300-302, wherein [B] comprises SKAQ (SEQ ID NO: 5829), SMYM (SEQ ID NO: 5830), SKAF (SEQ ID NO: 5831), SKLK (SEQ ID NO: 5832), SKRH (SEQ ID NO: 5833), SKWR (SEQ ID NO: 5834), SRCR (SEQ ID NO: 5835), SFTC (SEQ ID NO: 5836), SKFF (SEQ ID NO: 5837), IVWQ (SEQ ID NO: 5838), SKYF (SEQ ID NO: 5839), SKAR (SEQ ID NO: 5840), SCHQ (SEQ ID NO: 5841), FPWQ (SEQ ID NO: 5842), SKIR (SEQ ID NO: 5843), VYYQ (SEQ ID NO: 5844). SLYW (SEQ ID NO: 5845). SKPK (SEQ ID NO: 5846), SRFW (SEQ ID NO: 5847), SRMR (SEQ ID NO: 5848), SVKK (SEQ ID NO: 5849), SWAP (SEQ ID NO: 5850), SLWK (SEQ ID NO: 5851), SFRP (SEQ ID NO: 5852), SKKV (SEQ ID NO: 5853), SYAF (SEQ ID NO: 5854), SKAC (SEQ ID NO: 5855), SKRL (SEQ ID NO: 5856), SCSR (SEQ ID NO: 5857), SRCP (SEQ ID NO: 5858), SGAC (SEQ ID NO: 5859), SKFR (SEQ ID NO: 5860), SFPF (SEQ ID NO: 5861), SFFG (SEQ ID NO: 5862), SMCQ (SEQ ID NO: 5863), SELF (SEQ ID NO: 5864), SKTR (SEQ ID NO: 5865), SGKR (SEQ ID NO: 5866). FYRQ (SEQ ID NO: 5867), CRVQ (SEQ ID NO: 5868), YGIQ (SEQ ID NO: 5869), VNCQ (SEQ ID NO: 5870), SKPF (SEQ ID NO: 5871), SLAW (SEQ ID NO: 5872), SKRS (SEQ ID NO: 5873), WSYQ (SEQ ID NO: 5874), RWLQ (SEQ ID NO: 5875), PSCQ (SEQ ID NO: 5876), SSWL (SEQ ID NO: 5877), SKRR (SEQ ID NO: 5878). SKGC (SEQ ID NO: 5879), WWQ (SEQ ID NO: 5880), SKRY (SEQ ID NO: 5881), SGCQ (SEQ ID NO: 5882). SFTP (SEQ ID NO: 5883), STTC (SEQ ID NO: 5884), PKRQ (SEQ IDSKWK (SEQ ID NO: 5896), SYMR (SEQ ID NO: 5897), SKAA (SEQ ID NO: 5898), LLCQ (SEQ ID NO: 5899), RCCQ (SEQ ID NO: 5900), LCVQ (SEQ ID NO: 5901), SKLT (SEQ ID NO: 5902), SKLC (SEQ ID NO: 5903), SYLV (SEQ ID NO: 5904), QGCQ (SEQ ID NO: 5905), MAFQ (SEQ ID NO: 5906), SKWG (SEQ ID NO: 5907), SKIL (SEQ ID NO: 5908), SFQI (SEQ ID NO: 5909), SKAL (SEQ ID NO: 5910), SKAH (SEQ ID NO: 5911). SLCL (SEQ ID NO: 5912), RPWQ (SEQ ID NO: 5913), RPRQ (SEQ ID NO: 5914), SCPQ (SEQ ID NO: 5915), SVRY (SEQ ID NO: 5916), SVRC (SEQ ID NO: 5917), SKMP (SEQ ID NO: 5918), SKKT (SEQ ID NO: 5919). SLPY (SEQ ID NO: 592.0), VYHQ (SEQ ID NO: 5921), SYTR (SEQ ID NO: 592.2), LVYQ (SEQ ID NO: 5923), YRYQ (SEQ ID NO: 592.4), SWLK (SEQ ID NO: 592.5), CPAQ (SEQ ID NO: 5926), SMCT (SEQ ID NO: 592.7), SPPD (SEQ ID NO: 5928), SKRN (SEQ ID NO: 592.9), RWTQ (SEQ ID NO: 5930), PRKQ (SEQ ID NO: 5931), SKCS (SEQ ID NO: 5932). PFVQ (SEQ ID NO: 5933), SKIP (SEQ ID NO: 5934), SKSE (SEQ ID NO: 5935), WVAQ (SEQ ID NO: 5936), SLYQ (SEQ ID NO: 5937), SKVR (SEQ ID NO: 5938), CALQ (SEQ ID NO: 5939), SSCT (SEQ ID NO: 5940). SKNS (SEQ ID NO: 5941), SKRK (SEQ ID NO: 5942), LCTQ (SEQ ID NO: 5943), STCL (SEQ ID NO: 5944),SYAR (SEQ ID NO: 5945), SKQR (SEQ ID NO: 5946), SKRV (SEQ ID NO: 5947), KSGQ (SEQ IDID NO: 5962), KRHR (SEQ ID NO: 5963), K AQK (SEQ ID NO: 5964), KWRL (SEQ ID NO: 5965), RCRN (SEQ ID NO: 5966), FTCN (SEQ ID NO: 5967), KFFI (SEQ ID NO: 5968), K AQY (SEQ ID NO: 5969), VWQN (SEQ ID NO: 5970), KYFM (SEQ ID NO: 5971), KARQ (SEQ ID NO: 5972), CHQN (SEQ ID NO: 5973), PWQN (SEQ ID NO: 5974), KIRR (SEQ ID NO: 5975). YYQN (SEQ ID NO: 5976), LYWN (SEQ ID NO: 5977), KPKR (SEQ ID NO: 5978), KAFS (SEQ ID NO: 5979), RFWN (SEQ ID NO: 5980), KAQC (SEQ ID NO: 5981), RMRN (SEQ ID NO: 5982), VKKN (SEQ ID NO: 5983), WAPN (SEQ ID NO: 5984), LWKN (SEQ ID NO: 5985), KARW (SEQ ID NO: 5986), FRPN (SEQ ID NO: 5987), KKVF (SEQ ID NO: 5988), YAFN (SEQ ID NO: 5989), KACS (SEQ ID NO: 5990), KRLW (SEQ ID NO: 5991), CSRN (SEQ ID NO: 5992), RCPN (SEQ ID NO: 5993), GACN (SEQ ID NO: 5994), KFRQ (SEQ ID NO: 5995), FPFN (SEQ ID NO: 5996), FFGN (SEQ ID NO: 5997), MCQN (SEQ ID NO: 5998), KLFW (SEQ ID NO: 5999). KTRK (SEQ ID NO: 6000), GKRN (SEQ ID NO: 6001), YRQN (SEQ ID NO: 6002). RVQN (SEQ ID NO: 6003), GIQN (SEQ ID NO: 6004), KAQR (SEQ ID NO: 6005). NCQN (SEQ ID NO: 6006). KPFR (SEQ ID NO: 6007), LAWN (SEQ ID NO: 6008), KRSY (SEQ ID NO: 6009), SYQN (SEQ ID NO: 6010), WLQN (SEQ ID NO: 6011), SCQN (SEQ ID NO: 6012). SWEN (SEQ ID NO: 6013). KRRA (SEQ ID NO: 6014), KAQT (SEQ ID NO: 6015), KGCT (SEQ ID NO: 6016), KRYT (SEQ ID NO: 6017), GCQN (SEQ ID NO: 6018), FTPN (SEQ ID NO: 6019). TTCN (SEQ ID NO: 6020). KARM (SEQ ID NO: 6021), KRQN (SEQ ID NO: 6022), KCFL (SEQ ID NO: 6023), VPQN (SEQ ID NO: 6024). FWSN (SEQ ID NO: 6025), KFKN (SEQ ID NO: 6026), IKQN (SEQ ID NO: 6027), KAPR (SEQ ID NO: 6028), FRYN (SEQ ID NO: 6029), KMIC (SEQ ID NO: 6030), RWQN (SEQ ID NO: 6031), PT'QN (SEQ ID NO: 6032), KWKS (SEQ ID NO: 6033), YMRN (SEQ ID NO: 6034), KAAR (SEQ ID NO: 6035), LCQN (SEQ ID NO: 6036), CCQN (SEQ ID NO: 6037), CVQN (SEQ ID NO: 6038), KLTR (SEQ ID NO: 6039), KLCT (SEQ ID NO: 6040), KIRG (SEQ ID NO: 6041), YLVN (SEQ ID NO: 6042), AFQN (SEQ ID NO: 6043), KACQ (SEQ ID NO: 6044), KWGL (SEQ ID NO: 6045), KILR (SEQ ID NO: 6046), FQIN (SEQ ID NO: 6047), KACI (SEQ ID NO: 6048). KALR (SEQ ID NO: 6049), KARA (SEQ ID NO: 6050), LCLN (SEQ ID NO: 6051), KAFV (SEQ ID NO: 6052). PRQN (SEQ ID NO: 6053), CPQN (SEQ ID NO: 6054), KAQF (SEQ ID NO: 6055), VRYN (SEQ ID NO: 6056), VRCN (SEQ ID NO: 6057). KMPC (SEQ ID NO: 6058). KKTS (SEQ ID NO: 6059). LPYN (SEQ ID NO: 6060), YHQN (SEQ ID NO: 6061), KAQS (SEQ ID NO: 6062), YTRN (SEQ ID NO: 6063), VYQN (SEQ ID NO: 6064), RYQN (SEQ ID NO: 6065), WLKN (SEQ ID NO: 6066),KAQM (SEQ ID NO: 6067), PAQN (SEQ ID NO: 6068), MCTN (SEQ ID NO: 6069), PPDN (SEQ ID NO: 6070), KRNY (SEQ ID NO: 6071), WTQN (SEQ ID NO: 6072), KACR (SEQ ID NO: 6073),RKQN (SEQ ID NO: 6074), KCSV (SEQ ID NO: 6075), KARI (SEQ ID NO: 6076), FVQN (SEQ ID NO: 6077), KLPK (SEQ ID NO: 6078), KSEQ (SEQ ID NO: 6079), VAQN (SEQ ID NO: 6080), LYQN (SEQ ID NO: 6081), KVRM (SEQ ID NO: 6082), ALQN (SEQ ID NO: 6083), SCTN (SEQ ID NO: 6084), KNSR (SEQ ID NO: 6085), KRKR (SEQ ID NO: 6086), CTQN (SEQ ID NO: 6087). TCLN (SEQ ID NO: 6088), YARN (SEQ ID NO: 6089), KQRP (SEQ ID NO: 6090), KRW (SEQ ID NO: 6091), SGQN (SEQ ID NO: 6092), YYSN (SEQ ID NO: 6093), LTCN (SEQ ID NO: 6094), CQSN (SEQ ID NO: 6095), KAKG (SEQ ID NO: 6096), KPQN (SEQ ID NO: 6097), PFQN (SEQ ID NO: 6098), KCTS (SEQ ID NO: 6099). VFEN (SEQ ID NO: 6100), or KAKK (SEQ ID NO: 6101).304. The AAV particle of any one of embodiments 300-303, wherein [B] is or comprises:(i) SKAQA (SEQ ID NO: 6102), SKAQN (SEQ ID NO: 6103), SMYMN (SEQ ID NO: 6104), SKAFY (SEQ ID NO: 6105), SKLKR (SEQ ID NO: 6106), SKRHR (SEQ ID NO: 6107), SKAQK (SEQ ID NO: 6108), SKWRL (SEQ ID NO: 6109), SRCRN (SEQ ID NO: 6110), SFTCN (SEQ ID NO: 6111), SKFFI (SEQ ID NO: 6112), SKAQY (SEQ ID NO: 6113), IVWQN (SEQ ID NO: 6114), SKYFM (SEQ ID NO: 6115), SKARQ (SEQ ID NO: 6116), SCHQN (SEQ ID NO: 6117), FPWQN (SEQ ID NO: 6118), SK1RR (SEQ ID NO: 6119). VYYQN (SEQ ID NO: 6120), SLYWN (SEQ ID NO: 612.1), SKPKR (SEQ ID NO: 6122), SKAFS (SEQ ID NO: 612.3), SRFWN (SEQ ID NO: 6124), SKAQC (SEQ ID NO: 6125), SR.MRN (SEQ ID NO: 6126), SVKKN (SEQ ID NO: 6127). SWAPN (SEQ ID NO: 612.8), SLWKN (SEQ ID NO: 612.9), SKARW (SEQ ID NO: 6130), SFRPN (SEQ ID NO: 6131), SKKVF (SEQ ID NO: 6132), SYAFN (SEQ ID NO: 6133). SKACS (SEQ ID NO: 6134). SKRLW (SEQ ID NO: 6135), SCSRN (SEQ ID NO: 6136), SRCRN (SEQ ID NO: 6137), SGACN (SEQ ID NO: 6138). SKFRQ (SEQ ID NO: 6139), SFPFN (SEQ ID NO: 6140), SFFGN (SEQ ID NO: 6141), SMCQN (SEQ ID NO: 6142), SKLFW (SEQ ID NO: 6143), SKTRK (SEQ ID NO: 6144), SGKRN (SEQ ID NO: 6145), FYRQN (SEQ ID NO: 6146), CRVQN (SEQ ID NO: 6147), YGIQN (SEQ ID NO: 6148), SKAQR (SEQ ID NO: 6149), VNCQN (SEQ ID NO: 6150), SKPFR (SEQ ID NO: 6151), SLAWN (SEQ ID NO: 6152), SKRSY (SEQ ID NO: 6153), WSYQN (SEQ ID NO: 6154), RWLQN (SEQ ID NO: 6155), PSCQN (SEQ ID NO: 6156), SSWLN (SEQ ID NO: 6157), SKRRA (SEQ ID NO: 6158). SKAQT (SEQ ID NO: 6159), SKGCT (SEQ ID NO: 6160), VPWQN (SEQ ID NO: 6161), SKRYT (SEQ ID NO: 6162), SGCQN (SEQ ID NO: 6163), SFTPN (SEQ ID NO: 6164), STTCN (SEQ ID NO: 6165), SKARM (SEQ ID NO: 6166), PKRQN (SEQ ID NO: 6167), SKCFL (SEQ ID NO: 6168), WVPQN (SEQ ID NO: 6169), SFWSN (SEQ ID NO: 6170), SKFKN (SEQ ID NO: 6171), RIKQN (SEQ ID NO: 6172), SKAPR (SEQ ID NO: 6173), SFRYN (SEQ ID NO: 6174), SK MIC (SEQ ID NO: 6175), LRWQN (SEQ ID NO: 6176), LPTQN (SEQ ID NO: 6177), SKWKS (SEQ ID NO: 6178), SYMRN (SEQ ID NO: 6179), SKAAR (SEQ ID NO: 6180), LLCQN (SEQ ID NO: 6181), RCCQN (SEQ ID NO: 6182), LCVQN (SEQ ID NO: 6183), SKLTR (SEQ ID NO: 6184), SKLCT (SEQ ID NO: 6185),SKIRG (SEQ ID NO: 6186), SYLVN (SEQ ID NO: 6187), QGCQN (SEQ ID NO: 6188), MAFQN (SEQ ID NO: 6189), SKACQ (SEQ ID NO: 6190), SKWGL (SEQ ID NO: 6191), SKIER (SEQ ID NO: 6192), SFQIN (SEQ ID NO: 6193), SKACI (SEQ ID NO: 6194), SKALR (SEQ ID NO: 6195), SKAHA (SEQ ID NO: 6196), SLCLN (SEQ ID NO: 6197), SKAFV (SEQ ID NO: 6198), RPWQN (SEQ ID NO: 6199), RPRQN (SEQ ID NO: 6200), SCPQN (SEQ ID NO: 6201), SKAQF (SEQ ID NO: 6202), SVRYN (SEQ ID NO: 6203), SVRCN (SEQ ID NO: 6204), SKMPC (SEQ ID NO: 62.05), SKKTS (SEQ ID NO: 62.06). SLPYN (SEQ ID NO: 6207), VYHQN (SEQ ID NO: 62.08), SKAQS (SEQ ID NO: 6209), SYTRN (SEQ ID NO: 62.10), LVYQN (SEQ ID NO: 6211), YRYQN (SEQ ID NO: 6212), SWLKN (SEQ ID NO: 6213), SKAQM (SEQ ID NO: 6214), CPAQN (SEQ ID NO: 6215), SMCTN (SEQ ID NO: 6216), SPPDN (SEQ ID NO: 6217), SKRNY (SEQ ID NO: 6218), RWTQN (SEQ ID NO: 6219), SKACR (SEQ ID NO: 6220), PRKQN (SEQ ID NO: 6221), SKCSV (SEQ ID NO: 6222), SKARI (SEQ ID NO: 6223), PFVQN (SEQ ID NO: 6224), SKEPK (SEQ ID NO: 6225), SKSEQ (SEQ ID NO: 6226), WVAQN (SEQ ID NO: 6227), SLYQN (SEQ ID NO: 6228), SKVRM (SEQ ID NO: 6229), CALQN (SEQ ID NO: 6230), SSCTN (SEQ ID NO: 6231), SKNSR (SEQ ID NO: 6232), SKRKR (SEQ ID NO: 6233), LCTQN (SEQ ID NO: 6234), STCLN (SEQ ID NO: 6235), SYARN (SEQ ID NO: 6236), SKQRP (SEQ ID NO: 6237), SKRVV (SEQ ID NO: 6238), KSGQN (SEQ ID NO: 6239), SYYSN (SEQ ID NO: 6240), SLTCN (SEQ ID NO: 6241), SCQSN (SEQ ID NO: 62.42). SKAKG (SEQ ID NO: 6243), SKPQN (SEQ ID NO: 6244), FPFQN (SEQ ID NO: 6245), SKCTS (SEQ ID NO: 6246), SWEN (SEQ ID NO: 6247), SKAKK (SEQ ID NO: 62.48). or GRYQN (SEQ ID NO: 6249):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i). e.g., any 2, 3, or 4 amino acids, e.g.. consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more than four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, rela tive to any one of the amino acid sequences in (i).305. The AAV particle of any one of embodiments 300-304, wherein [A]-[B] is or comprises:(i) GSGSPHSKAQA (SEQ ID NO: 6250), GSGSPHSKAQN (SEQ ID NO: 6251), GSGSPHSMYMN (SEQ ID NO: 6252), GSGSPHSKAFY (SEQ ID NO: 6253), GSGSPHSKLKR (SEQ ID NO: 6254), GSGSPHSKRHR (SEQ ID NO: 62.55), GSGSPHSKAQK (SEQ ID NO: 6256), GSGSPHSKWRL (SEQ ID NO: 6257). GSGSPHSRCRN (SEQ ID NO: 6258), GSGSPHSFTCN (SEQ ID NO: 6259), GSGSPHSKFFI (SEQ ID NO: 6260), GSGSPHSKAQY (SEQ ID NO: 6261), GSGSPHIVWQN (SEQ ID NO: 6262), GSGSPHSKYFM (SEQ ID NO: 6263), GSGSPHSKARQ (SEQ ID NO: 6264), GSGSPHSCHQN (SEQ ID NO: 6265), GSGSPHFPWQN (SEQ ID NO: 6266), GSGSPI ISKIRR (SEQ ID NO: 6267), GSGSPHVYYQN (SEQ ID NO: 6268), GSGSPHSLYWN (SEQ ID NO: 6269), GSGSPHSKPKR (SEQ ID NO: 6270), GSGSPHSKAFS (SEQ ID NO: 6271),GSGSPHSRFWN (SEQ ID NO: 6272), GSGSPHSKAQC (SEQ ID NO: 6273), GSGSPHSRMRN (SEQ ID NO: 6274), GSGSPHSVKKN (SEQ ID NO: 6275), GSGSPHSWAPN (SEQ ID NO: 6276), GSGSPHSLWKN (SEQ ID NO: 6277), GSGSPHSKARW (SEQ ID NO: 6278), GSGSPHSFRPN (SEQ ID NO: 6279), GSGSPHSKKVF (SEQ ID NO: 6280), GSGSPHSYAFN (SEQ ID NO: 6281), GSGSPHSKACS (SEQ ID NO: 6282), GSGSPHSKRLW (SEQ ID NO: 6283), GSGSPHSCSRN (SEQ ID NO: 6284), GSGSPHSRCPN (SEQ ID NO: 6285), GSGSPHSGACN (SEQ ID NO: 6286), GSGSPHSKFRQ (SEQ ID NO: 6287), GSGSPHSFPFN (SEQ ID NO: 6288), GSGSPHSFFGN (SEQ ID NO: 6289), GSGSPHSMCQN (SEQ ID NO: 6290), GSGSPHSKLFW (SEQ ID NO: 6291), GSGSPHSKTRK (SEQ ID NO: 6292), GSGSPHSGKRN (SEQ ID NO: 6293). GSGSPHFYRQN (SEQ ID NO: 6294), GSGSPHCRVQN (SEQ ID NO: 6295). GSGSPH YGIQN (SEQ ID NO: 6296), GSGSPHSKAQR (SEQ ID NO: 6297), GSGSPH VNCQN (SEQ ID NO: 6298), GSGSPHSKPFR (SEQ ID NO: 6299), GSGSPHSLAWN (SEQ ID NO: 6300), GSGSPHSKRSY (SEQ ID NO: 6301), GSGSPHWSYQN (SEQ ID NO: 6302), GSGSPHRWLQN (SEQ ID NO: 6303), GSGSPHPSCQN (SEQ ID NO: 6304), GSGSPHSSWLN (SEQ ID NO: 6305), GSGSPHSKRRA (SEQ ID NO: 6306), GSGSPHSKAQT (SEQ ID NO: 6307), GSGSPHSKGCT (SEQ ID NO: 6308), GSGSPHVPWQN (SEQ ID NO: 6309), GSGSPHSKRYT (SEQ ID NO: 6310), GSGSPHSGCQN (SEQ ID NO: 6311), GSGSPHSFTPN (SEQ ID NO: 6312). GSGSPHSTTCN (SEQ ID NO: 6313). GSGSPHSKARM (SEQ ID NO: 6314), GSGSPHPKRQN (SEQ ID NO: 6315), GSGSPHSKCFL (SEQ ID NO: 6316), GSGSPHWVPQN (SEQ ID NO: 6317), GSGSPHSFWSN (SEQ ID NO: 6318), GSGSPHSKFKN (SEQ ID NO: 6319), GSGSPHRIKQN (SEQ ID NO: 6320), GSGSPHSKAPR (SEQ ID NO: 6321), GSGSPHSFRYN (SEQ ID NO: 6322), GSGSPHSKMIC (SEQ ID NO: 6323). GSGSPHLR WQN (SEQ ID NO: 6324), GSGSPHLPTQN (SEQ ID NO: 6325), GSGSPHSKWKS (SEQ ID NO: 6326), GSGSPHSYMRN (SEQ ID NO: 6327), GSGSPHSK A A R (SEQ ID NO: 6328). GSGSPHLLCQN (SEQ ID NO: 6329), GSGSPHRCCQN (SEQ ID NO: 6330), GSGSPHLCVQN (SEQ ID NO: 6331), GSGSPHSKLTR (SEQ ID NO: 6332), GSGSPHSKLCT (SEQ ID NO: 6333), GSGSPHSK1RG (SEQ ID NO: 6334), GSGSPHSYLVN (SEQ ID NO: 6335), GSGSPHQGCQN (SEQ ID NO: 6336), GSGSPHMAFQN (SEQ ID NO: 6337), GSGSPHSKACQ (SEQ ID NO: 6338), GSGSPHSKWGL (SEQ ID NO: 6339), GSGSPHSKILR (SEQ ID NO: 6340), GSGSPHSFQIN (SEQ ID NO: 6341), GSGSPHSKACT (SEQ ID NO: 6342), GSGSPHSKALR (SEQ ID NO: 6343). GSGSPHSKAHA (SEQ ID NO: 6344), GSGSPHSLCLN (SEQ ID NO: 6345), GSGSPHSKAFV (SEQ ID NO: 6346), GSGSPI IRPWQN (SEQ ID NO: 6347), GSGSPHRPRQN (SEQ ID NO: 6348), GSGSPHSCPQN (SEQ ID NO: 6349), GSGSPHSK AQF (SEQ ID NO: 6350), GSGSPHSVRYN (SEQ ID NO: 6351), GSGSPHSVRCN (SEQ ID NO: 6352), GSGSPHSKMPC (SEQ ID NO: 6353), GSGSPHSKKTS (SEQ ID NO: 6354), GSGSPHSLPYN (SEQ ID NO: 6355), GSGSPH V YHQN (SEQ ID NO: 6356), GSGSPHSKAQS (SEQ ID NO: 6357). GSGSPHSYTRN (SEQ ID NO: 6358), GSGSPHLVYQN (SEQ ID NO: 6359), GSGSPH YRYQN (SEQ ID NO: 6360), GSGSPHSWLKN (SEQ ID NO: 6361), GSGSPHSKAQM (SEQ ID NO: 6362), GSGSPHCPAQN (SEQ ID NO: 6363), GSGSPHSMCTN(SEQ ID NO: 6364), GSGSPHSPPDN (SEQ ID NO: 6365), GSGSPHSKRNY (SEQ ID NO: 6366), GSGSPHRWTQN (SEQ ID NO: 6367), GSGSPHSKACR (SEQ ID NO: 6368), GSGSPHPRKQN (SEQ ID NO: 6369), GSGSPHSKCSV (SEQ ID NO: 6370), GSGSPHSKARI (SEQ ID NO: 6371), GSGSPHPFVQN (SEQ ID NO: 6372), GSGSPHSKLPK (SEQ ID NO: 6373), GSGSPHSKSEQ (SEQ ID NO: 6374), GSGSPHWVAQN (SEQ ID NO: 6375), GSGSPHSLYQN (SEQ ID NO: 6376), GSGSPHSKVRM (SEQ ID NO: 6377), GSGSPHCALQN (SEQ ID NO: 6378), GSGSPHSSCTN (SEQ ID NO: 6379), GSGSPHSKNSR (SEQ ID NO: 6380), GSGSPHSKRKR (SEQ ID NO: 6381), GSGSPHLCTQN (SEQ ID NO: 6382), GSGSPHSTCLN (SEQ ID NO: 6383). GSGSPHSYARN (SEQ ID NO: 6384), GSGSPHSKQRP (SEQ ID NO: 6385), GSGSPHSKRW (SEQ ID NO: 6386), GSGSPI IKSGQN (SEQ ID NO: 6387), GSGSPHSYYSN (SEQ ID NO: 6388), GSGSPI ISLTCN (SEQ ID NO: 6389), GSGSPHSCQSN (SEQ ID NO: 6390), GSGSPHSKAKG (SEQ ID NO: 6391), GSGSPHSKPQN (SEQ ID NO: 6392), GSGSPHFPFQN (SEQ ID NO: 6393), GSGSPHSKCTS (SEQ ID NO: 6394), GSGSPHSVFEN (SEQ ID NO: 6395), GSGSPHSKAKK (SEQ ID NO: 6396), or GSGSPHGR YQN (SEQ ID NO: 6397):(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more th an four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i)306. The AA V particle of any one of embodiments 300-305, wherein [A]-[B] does not comprise the amino acid sequence of GSGSPHSKAQN (SEQ ID NO: 6251).307. The AAV particle of any one of embodiments 300-306, wherein the AAV capsid variant comprises one, two, or all of an amino acid other than Q at position 458 (e.g., R, C, S, W, L, F, Y, H, I, V, A, or P), an amino acid other tlian Q at position 459 (e.g., K, I, R, L or S), and / or an amino add other than T at position 460 (e.g., R), numbered according to SEQ ID NO: 138.308. The AAV particle of any one of embodiments 300-307, wherein the AAV capsid variant comprises:(i) the amino acid R at position 458;(ii) the amino acid W at position 458;(iii) the amino acid Y at position 458;(iv) the amino acid F at position 458;(v) the amino acid S at position 458;(vi) the amino acid C at position 458;(vii) the amino acid I at position 458;(viii) the amino acid L at position 458;(ix) the amino acid P at position 458;(x) the amino acid I at position 459;(xi) the amino acid H at position 458; or(xii) the amino acid V at position 458; wherein (i)-(xii) are numbered according to SEQ ID NO: 138,309. The AAV particle of any one of embodiments 300-307, wherein the AA V capsid variant comprises:(i) the amino acid R at position 458 and the amino acid K at position 459;(ii) the amino acid C at position 458 and the amino acid I at position 459;(iii) the amino acid S at position 458 and the amino acid R at position 459’(iv) the amino acid L at position 458 and the amino acid K at position 459;(v) the amino acid F at position 458 and the amino acid K at position 459;(vi) the amino acid C at position 458 and the amino acid R at position 459;(vii) the amino acid H at position 458 and the amino acid R at position 459;(viii) the amino acid I at position 458 and the amino acid L at position 459;(ix) the amino acid V at position 458 and the amino acid R at position 459;( X ) the amino acid A at position 458 and the amino acid K at position 459;(xi) the amino acid I at position 458 and the amino acid K at position 459;(xii) the amino acid C at position 458 and the amino acid S at position 459; or(xiii) the amino acid C at position 458 and the amino acid L at position 459 wherein (i)-(xiii) are numbered according to SEQ ID NO: 138.310. The AAV particle of any one of embodiments 300-307, wherein the AAV capsid variant comprises the amino acid F at position 458, the amino acid K at position 459, and the amino acid R at position 460, numbered according to SEQ ID NO: 138.311. The AAV particle of any one of embodiments 300-310, wherein the A AV capsid variant comprises one, two, or all of an amino acid other than T at position 450 (e.g., Y, P, W, R, K, S, or F), an amino acid other than I at position 451 (e.g., R, S, Y, I,, V, H, P, A, or F), and / or an amino acid other than N at position 452 (e.g,,W, A, T, F, Y, L, R, H, S, or M), numbered according to SEQ ID NO: 138.312. The AAV particle of any one of embodiments 300-311 , wherein the AA V capsid variant comprises the amino acid V at position 452. numbered according to SEQ ID NO: 138.313. The AAV particle of any one of embodiments 300-312, wherein the AAV capsid variant comprises the amino acid Y at position 450 and the amino acid V at position 452, numbered according to SEQ ID NO: 138.314. The AAV particle of any one of embodiments 300-312, wherein the AAV capsid variant comprises the amino acid R at position 450 and the amino acid Y at position 451 , numbered according to SEQ ID NO: 138.315. The AAV particle of any one of embodiments 300-311, wherein the AAV capsid variant comprises:(i) the amino acid P at position 450, the amino acid R at position 451, and the amino acid W at position 452;(ii) the amino acid Y at position 450, the amino acid S at position 451, and the amino acid A at position 452;(iii) the amino acid Y at position 450, the amino acid Y at position 451, and the amino acid T at position 452;(iv) the amino acid P at position 450, the amino acid R at position 451, and the amino acid F at position 452;(v) the amino acid W at position 450, the amino acid L at position 451. and the amino acid T at position 452;(vi) the amino acid R at position 450, the amino acid S at position 451, and the amino acid Y at position 452;(vii) the amino acid Y at position 450, the amino acid V at position 451, and the amino acid F at position 452;(viii) the amino acid K at position 450, the amino acid H at position 451, and the amino acid L at position 452;(ix) the amino acid P at position 450, the amino acid P at position 451, and the amino acid L at position 452;(x) the amino acid P at position 450, the amino acid A at position 451 , and the amino acid R at position 452;(xi) the amino acid S at position 450, the amino acid R at position 451, and the amino acid R at position 452;(xii) the amino acid F at position 450, the amino acid F at position 451, and the amino acid H al position 452;(xiii) the amino acid R al position 450, the amino acid F at position 451, and the amino acid S al position 452;(xiv) the amino acid Y at position 450, the amino acid S at position 451, and the amino acid M at position 452; or(xv) the amino acid P at position 450, the amino acid F at position 451, and the amino acid L at position 452; wherein (i)-(xv) is numbered according to SEQ ID NO: 138.316. The AAV particle of any one of embodiments 300-315, wherein the AA V capsid variant comprises:(i) the amino acid sequence of any one of SEQ ID NOs: 3849-3982, 2984-4010, 4681-4693;(ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 amino acids, e.g., consecutive amino acids, thereof;(iii) an amino acid sequence comprising one, two, or three but no more titan four modifications relative to any of the amino acid sequences in (i); or(iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i).317. The AAV particle of any one of embodiments 300-316, wherein the A AV capsid variant does not comprise the amino acid sequence of GSGSPHSKAQNQQ (SEQ ID NO: 1801 ) or GSGSPHSKAQNQQT (SEQ ID NO: 200).318. The AAV particle of any one of embodiments 300-317, wherein [A]-[B] is present in loop IV.319. The AAV particle of any one of embodiments 300-318, wherein [A] is present immediately subsequent to position 452, numbered according to SEQ ID NO: 138 or 981.320. The AAV particle of any one of embodiments 300-319, wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138 or 981.321. The AAV particle of any one of embodiments 300-320, wherein [A] is present immediately subsequent to position 452. and wherein [A] replaces positions 453-455 (e.g., G453, S454, G455), numbered according to SEQ ID NO: 138 or 981.322. The AAV particle of any one of embodiments 300-321, wherein [B] is present immediately subsequent to [A],323. The AAV particle of any one of embodiments 300-322, wherein [B] replaces positions 456 and457 (e.g., Q456, N457), numbered according to SEQ ID NO: 138.324. The AAV particle of any one of embodiments 300-323, wherein [A]-[B] replaces positions 453-457 (e.g., G453, S454, G455, Q456, N457), numbered according to SEQ ID NO: 138.32.5. The AAV particle of any one of embodiments 300-324, wherein [A]-[B] is present immediately subsequent to position 452. and wherein [A]-[B] replaces positions 453-457 (e.g., G453, S454, G455,Q456, N457), numbered according to SEQ ID NO: 138.326. The AAV particle of any one of embodiments 300-325, wherein the AAV capsid variant comprises, from N-terminus to C-terminus, [A] [B],327. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises at least one, at least two, at least three, or at least four (e.g., from 1-4 to 1-5) charged amino acid residues (e.g., acidic and / or basic amino acid residues) relative to SEQ ID NO: 138, which is present N-terminal to the amino acid sequence of SPH (e.g., within 1 , 2, 3, 4, 5, or 6 amino acids from the start of the SPH amino acid sequence (e.g.. within positions 450-455 numbered according to SEQ ID NO: 138)), optionally wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.328. The AA V particle of embodiment 327, wherein the amino acid sequence of SPII is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.329. The AAV particle of embodiment 327 or 328, wherein the AAV capsid variant comprises less than four, less than three, less than two (e.g., two or one) charged amino acid residues (e.g., acidic and / or basic amino acid residues) relative to SEQ ID NO: 138.330. The AAV particle of any one of embodiments 327-329, wherein the AAV capsid variant comprises one charged amino acid residues (e.g., an acidic or basic amino acid residue) relative to SEQ ID NO: 138, optionally at any one of positions 450-455 numbered relative to SEQ ID NO: 138,331. The AAV particle of any one of embodiments 327-330, wherein the charged amino acid residue is an acidic amino acid (e.g., D orE).332. The AAV particle of any one of embodiments 327-331, wherein the charged amino acid residue is a negatively charged amino acid (e.g., D or E).333. The AAV particle of any one of embodiments 327-332, wherein the charged amino acid residue is D.334. The AAV particle of any one of embodiments 327-333, wherein the charged amino acid residue is E,335. The AAV particle of any one of embodiments 327-334, wherein the charged amino acid residue is a basic amino acid (e.g., K, R, or H).336. The AAV particle of any one of embodiments 327-335, wherein the charged amino acid residue is a positively charged amino acid (e.g., K, R, or H).337. The AAV particle of any one of embodiments 327-336, wherein the charged amino acid residue is H.338. The AAV particle of any one of embodiments 327-337, wherein the charged amino acid residue is R.339. The AAV particle of any one of embodiments 327-338, wherein the charged amino acid residue is K.340. The AAV particle of any one of embodiments 327-339, wherein the AAV capsid variant comprises an acidic amino acid (e.g., E or D) and a basic amino acid (e.g., R, K, or H).341. The AAV particle of any one of embodiments 327-340, wherein at least one, two, three or four charged amino acid residues is present within 1, 2, 3, 4, 5, or 6 (e.g., 1-6) amino acids from the start of the SPH amino acid sequence.342. The AAV particle of any one of embodiments 327-341, wherein the AAV capsid variant comprises two charged amino acid residues immediately preceding the amino acid sequence of SPH (e.g,, at positions 454 and 455, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982).343. The AAV particle of any one of embodiments 327-342, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., E) within 1, 2, 3. 4, 5 (e.g., 5) amino acids from the start of the SPH amino acid sequence.344. The AAV particle of any one of embodiments 327-343 , wherein the AAV capsid variant comprises a charged amino acid residue (e.g., E) at position 451, numbered according to any one of SEQ ID NO: 138, 981, or 982.345. The AAV particle of any one of embodiments 327-344, wherein the AAV capsid variant comprises E at position 451 , numbered according to any one of SEQ ID NOs: 138, 981, or 982.346. The AAV particle of any one of embodiments 327-345, wherein the AA V capsid variant comprises a charged amino acid residue (e.g., R or K) at position 452, numbered according to any one of SEQ ID NOs: 138. 981, or 982.347. The AAV particle of any one of embodiments 327-346, wherein the AAV capsid variant comprises R at position 452, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.348. The AAV particle of any one of embodiments 327-347, wherein the AAV capsid variant comprises E at position 451 and R at position 452, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.349. The AAV particle of any one of embodiments 327-348, wherein the AAV capsid variant has decreased tropism for a liver cell or tissue, relative to the tropism of an AA V capsid comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981.350. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid vanant comprises at least one, at least two, at least three, or at least four (e.g., from 1-4 to 1-5) charged amino acid residues (e.g., basic amino acid residues) relative to SEQ ID NO: 138, which is present C- terminal to the amino acid sequence of SPH (e.g., within 1, 2, 3, 4, 5, 6, or 7 amino acids from the end of the SPH amino acid sequence (e.g., within positions 459-465 numbered according to any one of SEQ ID NOs: 36-59, or 981)), optionally wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.351. The AAV particle of embodiment 350, wherein the amino acid sequence of SPH is present at positions 456-458 numbered according to any one of SEQ ID NOs: 36-59, 981 , or 982.352. The AAV particle of embodiment 350 or 351, wherein the AAV capsid variant comprises less than four, less than three, less than two (e.g., two or one) charged amino acid residues (e.g., basic amino acid residues) relative to SEQ ID NO: 138.353. The AAV particle of any one of embodiments 350-352, wherein the AAV capsid variant comprises one charged amino acid residues (e.g., a basic amino acid residue) relative to SEQ ID NO: 138, optionally at any one of positions 456-460 numbered relative to SEQ ID NO: 138 or at positions 462-466 numbered according to any one of SEQ ID NOs: 36-59, 981, or 982.354. The AAV particle of any one of embodiments 350-353, wherein the charged amino acid residue is a basic amino acid (e.g,, R or K).355. The AAV particle of any one of embodiments 350-354, wherein the charged amino acid residue is a positively charged amino acid (e.g., R or K).356. The AAV particle of any one of embodiments 350-355, wherein the charged amino acid residue is R.357. The AAV particle of any one of embodiments 350-355, wherein the charged amino acid residue is K.358. The AAV particle of any one of embodiments 350-357, wherein at least one, two, three or four charged amino acid residues is present within 1, 2, 3, 4, 5, 6, 7 (e.g., 1 -7) amino acids from the end of the SPH amino acid sequence.359. The AA V particle of any one of embodiments 350-358, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., K orR) immediately after the SPH sequence (e.g., at position 459 numbered according to SEQ ID NO: 981).360. The AAV particle of any one of embodiments 350-359, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., K or R) at position 459, numbered according to SEQ ID NO: 138 or SEQ ID NO: 982.361. The AAV particle of any one of embodiments 350-360, wherein the AAV capsid variant comprises K at position 459, numbered according to SEQ ID NO: 981.362. The AAV particle of any one of embodiments 350-360, wherein the AA V capsid variant comprises R at position 459, numbered according to SEQ ID NO: 981.363. The AAV particle of any one of embodiments 350-362, wherein the AAV capsid variant comprises a charged amino acid residue (e.g., R or K) at one. two three, four, five, or all of positions 460, 461, 462, 463, 464, and / or 465, numbered according to SEQ ID NO: 138 or 981.364. The AAV particle of any one of embodiments 300-326 or 350-363, wherein the AAV capsid variant has increased tropism for a liver cell or tissue, relative to the tropism of an A AV capsid comprising the amino acid sequence of SEQ ID NO: 138.365. The AAV particle of any one of embodiments 300-326 or 350-364, wherein the AAV capsid vanant is enriched al least about 10, 15, 20. 25, 30, 35, 40, 45, 50, 55. 60, 65, 70, 75, 80, 85, 90. 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 150, 160, 170, 180, 190, or 200-fold, in the liver compared to an AAV capsid comprising SEQ ID NO: 138, e.g., when measured by an assay as described in Example 4.366. The AAV particle of any one of embodiments 300-326, 364, or 365, wherein the AAV capsid variant has reduced tropism for a CNS cell or tissue, e.g., a brain cell, brain tissue, spinal cord cell, or spinal cord tissue, relative to the tropism of an AAV capsid comprising the amino acid sequence of SEQ ID NO: 138.367. The AAV particle of any one of embodiments 300-326 or 364-366, wherein the AAV capsid variant shows preferential transduction in a liver region relative to the transduction in the brain and / or dorsal root ganglia (DRG).368. The adeno-associated virus (AAV) particle of any one of embodiments 300-326 or 364-367, wherein the AAV capsid variant shows preferential transduction in a liver region relative to the transduction in the heart and / or muscle (e.g., quadriceps).369. An adeno-associated vims (AAV) particle comprising an AAV capsid variant (e.g.. an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory poly nucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the A AV capsid variant comprises:(a) the amino acid sequence of any of the sequences provided in Table 1, 2A, 2B, or 20-26;(b) an amino acid sequence comprising at least 3, al least 4, at least 5. at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, al least 13, at least 14, at least 15, at least 16. or atleast 17 consecutive amino acids from any one of the sequences provided in Table 1, 2A, 213, or 20- 26; or(c) an amino acid sequence comprising at least one. at least two, or at least three but no more titan four different amino acids, relative to any one of the sequences provided in Table 1, 2 A, 2B, or 20-26; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of the sequences provided in Table 1, 2 A, 2B, or 20-26.370. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducmg or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises:(a) the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986;(b) an amino acid sequence comprising at least 3, at least 4, or at least 5 consecutive amino acids from any one of SEQ ID NOs: 945-980 or 985-986; or(c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985-986;(d) an amino sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 945-980 or 985- 986.371. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA. optionally wherein the modulatory’ polynucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises:(a) the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201 , 941, 943, 204, 208, 404, or 903-909;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204. 208, 404. or 903-909;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909; or(d) an amino acid sequence comprising at least one, at least two. or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.372. An adeno-associated virus (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA. optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises:(a) the amino acid sequence of any one of SEQ ID NOs : 3849-4051 or 4681 -4693 ;(b) an amino acid sequence comprising at least 3. at least 4, at least 5, at least 6, at least 7. at least 8. at least 9, at least 10, at least 11 , at least 12. at least 13, at least 14, at least 15, at least 16 or at least 17 consecutive amino acids from any one of SEQ ID NOs: 3849-4051 or 4681-4693;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 3849- 4051 or 4681-4693; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 3849-4051 or 4681-4693.373. An adeno-associated vims (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and a viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises:(a) the amino acid sequence of any one of SEQ ID NOs: 4052-4092;(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14. at least 15. at least 16 or at least 17 consecutive amino acids from any one of SEQ ID NOs: 4052-4092;(c) an amino acid sequence comprising at least one. at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 4052- 4092; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 4052-4092.374. An adeno-associated vims (AAV) particle comprising an AAV capsid variant (e.g., an AAV9 capsid variant) and viral genome comprising a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRN A, optionally wherein the modulatory polynucleotide comprises anRNAi agent targeting DMPK mRNA; and wherein the AAV capsid variant comprises:(a) the amino acid sequence of any one of SEQ ID NOs: 4056. 4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097:(b) an amino acid sequence comprising at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 consecutive amino acids from any one of SEQ ID NOs: 4056, 4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097;(c) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 4056,4058, 4059, 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097; or(d) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 4056, 4058,4059. 4062-4064, 4066, 4067, 4080, 4084, 4090, or 4095-4097.375. The AAV particle of embodiment 369 or 371. wherein the AAV capsid variant comprises an amino acid sequence comprising at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, or at least 13 consecutive amino acids from any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.376. The AAV particle of any one of embodiments 369-374, wherein the at least 3 consecutive amino acids comprise SPH.377. The AAV particle of any one of embodiments 369-371 or 376, wherein the at least 4 consecutive amino acids comprise SPHS (SEQ ID NO: 4700).378. The AAV particle of any one of embodiments 369-371, 376, or 377, wherein the at least 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 4701).379. The AAV particle of any one of embodiments 369-371 or 376-378, wherein the at least 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941).380. The AAV particle of embodiment 369-371, wherein the at least 3 consecutive amino acids comprise HDS.381. The AAV particle of any one of embodiments 369-371 or 380, wherein the at least 4 consecutive amino acids comprise HDSP (SEQ ID NO: 4702).382. The AAV particle of any one of embodiments 369-371, 380, or 381, wherein the at least 5 consecutive amino acids comprise HD SPH (SEQ ID NO: 4703).383. The AAV particle of any one of embodiments 369-371 or 380-382, wherein the at least 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2).384. The AAV particle of any one of embodiments 369-371 , wherein:(i) the at least 3 consecutive amino acids comprise SPH;(ii) the at least 4 consecutive amino acids comprise SPHK (SEQ ID NO: 6398);(iii) the at least 5 consecutive amino acids comprise SPHKY (SEQ ID NO: 4715); and / or(iv) the at least 6 consecutive amino acids comprise SPHK YG (SEQ ID NO: 966).385. The AAV particle of embodiment 369 or 371. wherein the AAV capsid variant comprises an amino acid sequence comprising at least one. at least two, or at least three but no more than four modifications relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.386. The AAV particle of any one of embodiments 369, 371, or 385, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two. or at least three but no more than four modifications relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941).387. The AAV particle of any one of embodiments 369, 371, or 385, wherein the AA V capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2),388. The AAV particle of any one of embodiments 369-371, 384, or 385, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications relative to the amino acid sequence of SPHKYG (SEQ ID NO: 966).389. The AAV particle of embodiment 370, wherein the AAV capsid variant comprises:(i) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589);(ii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754)(iii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241);(iv) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ ID NO: 4100); or(v) an amino acid sequence comprising at least one, at least two, or at least three but no more than four modifications, relative to the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062).390. The AAV particle of embodiment 369 or 371, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 2, 200, 201, 941, 943, 204, 208, 404, or 903-909.391. The AAV particle of any one of embodiments 369, 371, or 390, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941).392. The AAV particle of any one of embodiments 369, 371, or 390, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2).393. The AAV particle of any one of embodiments 369, 371, 384, or 390, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one. at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of SPHKYG (SEQ ID NO: 966).394. The AAV particle of embodiment 369, wherein the AAV capsid variant comprises:(i) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589);(ii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754);(iii) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative io the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241);(iv) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KT1NGHDSPHSKAQNLQT (SEQ ID NO: 4100); or(v) an amino acid sequence comprising at least one, at least two, or at least three but no more than four different amino acids relative to the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062).395. The AAV particle of any one of embodiments 1-129, 269, 271, 375-388, or 390-394, wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 2, 2.00, 201, 941, 943, 204, 208, 404, or 903-909.396. The AAV particle of any one of embodiments 295-297, 301-305, 313, 314, 318, 319, or 323, wherein the AAV capsid variant comprises the amino acid sequence of ERVSGSPHSKA (SEQ ID NO: 6399), optionally wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., 1451, N542, G453, S454, G455), numbered according to SEQ ID NO: 138.397. The AAV particle of any one of embodiments 369-371, 375-379, 385, 386, 389-391, or 394-396, wherein the AAV capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.398. The AAV particle of any one of embodiments 269-371, 375, 380-383, 385, 387, 389, 390, 393, or 394, wherein the AAV capsid variant comprises the amino acid sequence of AEIGHDSPHKSG (SEQ ID NO: 6400), optionally wherein the amino acid sequence is present immediately subsequent to position 449 and replaces positions 450-455 (e.g., T450, 1451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138.399. The AAV particle of any one of embodiments 369-371, 375, 380-383, 385, 387, 389, 390, 393, 394, or 398, wherein the AAV capsid variant comprises the amino acid sequence of KAEIGHDSPHKSGQNQQT (SEQ ID NO: 1754), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456. N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.400. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391, or 395, wherein tire AAV capsid variant comprises tire amino acid sequence of EKMSGSPHSKA (SEQ ID NO: 6401), optionally wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., 1451, N452, G453, S454, G455), numbered according to SEQ ID NO: 138.401. The AAV particle of any one of embodiments 369-371 , 375-379, 390, 391 , or 395, wherein the AAV capsid variant comprises the amino acid sequence of KTEKMSGSPHSKAQNQQT (SEQ ID NO: 3241), optionally wherein the amino acid sequence is present immediately subsequent to position448 and replaces positions 449-460 (e.g., K449, T450, 1451, N452, G453. S454, G455, Q456, N457,Q458, Q459, T460), numbered according to SEQ ID NO: 138.402. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391, or 395, wherein the AAV capsid variant comprises the amino acid sequence of HDSPHSKAQNL (SEQ ID NO: 6402), optionally wherein the amino acid sequence is present immediately subsequent to position 453 and replaces positions 456-458 (e.g., Q456, N457, Q458), numbered according to SEQ ID NO: 138.403. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391, or 395, wherein theAAV capsid variant comprises the amino acid sequence of KTINGHDSPHSKAQNLQT (SEQ IDNO: 4100), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451 , N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.404. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391, or 395, wherein the AAV capsid variant comprises the amino acid sequence of VNGHDSPHSKA (SEQ ID NO: 6403), optionally wherein the amino acid sequence is present immediately subsequent to position 450 and replaces positions 451-455 (e.g., 1451. N452, G453, S454. G455). numbered according to SEQ ID NO: 138.405. The AAV particle of any one of embodiments 369-371, 375-379, 390, 391, or 395, wherein the AAV capsid variant comprises the amino acid sequence of KTVNGHDSPHSKAQNQQT (SEQ ID NO: 4062), optionally wherein the amino acid sequence is present immediately subsequent to position 448 and replaces positions 449-460 (e.g., K449, T450, 1451 , N452, G453, S454, G455, Q456, N457, Q458, Q459, T460), numbered according to SEQ ID NO: 138.406. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69-89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202. 240-247, 249, 250. 253-263, 266, 272.-281, 286, 288, 291-299. 327-363, 369-371, 375-379, 385, 386, 390, 391, or 395, wherein the AAV capsid vanant comprises an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 942: a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 942.407. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26. 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97. 100-103, 105, 110, 111, 113-12.9, 203-248, 2.51, 252, 2.54-257, 2.60, 261, 2.64-280, 283-287, 2.89-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, or 395, wherein theAAV capsid variant comprises an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 3; a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g.. substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 3: or a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 3.408. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69-89, 91,94-99, 102-104, 107, 1 10-112, 1 15-129. 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286,288, 2.91-299, 327-363, 369-371 , 375-379, 385, 386, 390, 391 , 395, or 406, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g.. conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, at leasttwo, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 942.409. The AAV particle of any one of embodiments 1-9. l i , 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-2.80, 283-287, 289-299, 327-363, 369, 369, 371. 380-383, 385, 386, 390, 392. 395, or 407, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 3; a nucleotide sequence comprising at least one, at least two. at least three, at least four, al least five, at least six. or at least seven modifications, e.g., substitutions (e.g., conservative substitutions), but no more than ten modifications, e.g., substitutions (e.g., conservative substitutions), relative to the nucleotide sequence of SEQ ID NO: 3; or a nucleotide sequence comprising at least one, at least two, at least three, at least four, at least five, at least six, or at least seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 3.410. The AAV particle of any one of embodiments 369-409, wherein the amino acid sequence is present in loop IV, e.g., relative to the amino acid sequence of SEQ ID NO: 138.411. The AAV particle of any one of embodiments 369-410, wherein the amino acid sequence is present immediately subsequent to position 448, 449, 450, 451, 452, 453, 454, or 455, numbered according to SEQ ID NO: 138.412. The AAV particle of any one of embodiments 369-411, wherein the amino acid sequence replaces amino acids 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, and / or 460 (e.g., K449, T450, 1451, N452, G453, S454, G455, Q456, N457, Q458, Q459, and / or T460), numbered according SEQ ID NO: 138.413. The AAV particle of any one of embodiments 369-412, wherein the amino acid sequence is present immediately subsequent to position 455. numbered according to SEQ ID NO: 138.414. The AAV particle of any one of embodiments 369-413, wherein the amino acid sequence is present immediately subsequent to position 453, numbered according SEQ ID NO: 138.415. The AAV particle of any one of embodiments 1-2.3, 26-29, 32, 35-43, 46-51 , 54-72. 69-89, 91, 94-99, 102-104, 107, 110-112, 115-129. 168-202, 02, 240-247, 249, 250. 253-263, 266, 272.-281, 286, 288, 2.91-299. 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, or 410-413, wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein theamino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.416. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69-89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363. 369-371 , 375-379, 385, 386, 390, 391. 395, 406. 408, 410-413, or 415, wherein the AAV capsid variant the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 981.417. The AAV particle of embodiment 415 or 416, wherein the AAV capsid variant further comprises an amino acid other than I at position 451, an amino acid other than N at position 452, and an amino acid other than G at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981.418. The AAV particle of any one of embodiments 415-417, wherein the AAV capsid variant further comprises E at position 451, R at position 452, and V at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981.419. The AAV particle of any one of embodiments 415-418, wherein the AAV capsid variant further comprises the substitutions 145 IE, N452R, and G453V, numbered according to any one of SEQ ID NOs: 36, 138, or 981.420. The AAV particle of any one of embodiments 415-419, wherein the AAV capsid variant comprises:(i) E at position 451, R at position 452, and V at position 453, numbered according to any one of SEQ ID NOs: 36, 138, or 981; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to any one of SEQ ID NOs: 36, 138, or 981.42.1. The AAV particle of embodiment 415 or 416, wherein the AAV capsid variant farther comprises an amino acid other than I at position 451, an amino acid other than N at position 452, and / or G at position 453, numbered according to SEQ ID NO: 39 or 138.422. The AAV particle of any one of embodiments 415, 416, or 421, wherein the AAV capsid variant further comprises E at position 451, K at position 452, and / or M at position 453, numbered according to SEQ ID NO: 138 or 39.423. The AAV particle of any one of embodiments 415, 416, 421 , or 422, wherein the AAV capsid variant further comprises the substitutions 1451E, N452K, and G453M, numbered according to SEQ ID NO: 39 or 138.424. The AAV particle of any one of embodiments 415, 416, or 421-423, wherein the AAV capsid variant comprises:(i) E at position 451 , K at position 452, and M at position 453, numbered according to SEQ ID NO: 39 or 138; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 39 or 138.425. The AAV particle of embodiment 415 or 416, wherein the AAV capsid variant further comprises an amino acid other than S at position 454, an amino acid other than G at position 455, and / or Q at position 458, numbered according to SEQ ID NO: 138.426. The AAV particle of any one of embodiments 415, 416, or 425, wherein the AAV capsid variant further comprises H at position 454, D at position 455, and / or L at position 458, numbered according to SEQ ID NO: 138.427. The AAV particle of any one of embodiments 415, 416, 425, or 426, wherein the AAV capsid variant further comprises the substitutions S454H, G455D, and Q458L. numbered according to SEQ ID NO: 138.428. The AAV particle of any one of embodiments 415, 416, or 425-427, wherein the AAV capsid variant comprises:(i) H at position 454, D at position 455, and / or L at position 458, numbered according to SEQ ID NO: 138; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 138.429. The AAV particle of embodiment 415 or 416, wherein the AAV capsid variant further comprises an amino acid other than I at position 451, an amino acid other than S at position 454, and / or an amino acid other than G at position 455, numbered according to SEQ ID NO: 52 or 138.430. The AAV particle of any one of embodiments 415, 416, or 429, wherein the AAV capsid variant further comprises V at position 451, H at position 454, and / or D at position 455, numbered according to SEQ ID NO: 52 or 138.431. The AAV particle of any one of embodiments 415, 416, 429, or 430, wherein the AAV capsid variant further comprises the substitutions 1451V, S454H. and / or G455D, numbered according to SEQ ID NO: 52 or 138.432. The AAV particle of any one of embodiments 415, 416, or 429-431, wherein the AAV capsid vanant comprises:(i) V at position 451, H at position 454, and / or D at position 455, numbered according to SEQ ID NO: 52 or 138; and(ii) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to SEQ ID NO: 52 or 138.433. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97. 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 2.83-287. 289-299. 327-363, 369, 369, 371, 380-383, 385, 386, 390. 392, 395. 407, 409-412, or 414, wherein the AAV capsid variant the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to tire amino acid sequence of SEQ ID NO: 138.434. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, or 433, comprising the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 982.435. The AAV particle of any one of embodiments 1-9, 11. 12-22, 2.4, 2.6, 28, 30, 33, 35-42. 44, 46- 50, 52. 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-2.48, 251, 2.52, 254-2.57, 260, 2.61, 264-2.80, 283-287, 289-299, 327-363, 369, 369, 371. 380-383, 385, 386, 390, 392. 395, 407. 409-412, 414, 433, or 434, wherein the AAV capsid variant the amino acid sequence of SPHKSG (SEQ ID NO: 946), wherein the amino acid sequence is present immediately subsequent to position 455, numbered relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 982.436. The AAV particle of any one of embodiments 369-435, wherein the AAV capsid variant comprises:(i) the amino acid sequence of HDSPHSKA (SEQ ID NO: 4486), which is present immediately subsequent to position 453; and(ii) a deletion of amino acids SG at position 454 and 455; wherein (i) and (ii) are numbered according to SEQ ID NO: 138.437. The AAV particle of any one of embodiments 369-436, wherein the AA V capsid variant comprises the amino acids HD at position 454 and 455, and further comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), which is present immediately subsequent to position 455, numbered relative to SEQ ID NO: 138.438. The AAV particle of any one of embodiments 433-435, wherein the AAV capsid variant further comprises an amino acid other titan T at position 450, an amino acid other than I at position 451, and an amino acid other than N at position 452, numbered according to SEQ ID NO: i 38 or 982.439. The AAV particle of any one of embodiments 433-435 or 438, wherein the AAV capsid variant further comprises A at position 450, E at position 451 , and I at position 452, numbered according to SEQ ID NO: 138 or 982.440. The AAV particle of any one of embodiments 433-435, 438, or 439, wherein tire AAV capsid variant further comprises the substitutions T450A, 145 IE, and N452I, numbered according to SEQ ID NO: 138 or 982.441. The AAV particle of any one of embodiments 433, 434, or 438-440, wherein the AAV capsid variant comprises:(i) A at position 450, E at positron 451, and I at position 452, numbered according to SEQ ID NO: 138 or 982; and(ii) the amino acid sequence of HDSPHK (SEQ ID NO: 2), which is present immediately subsequent to positions 453, numbered according to SEQ ID NO: 138 or 982.442. The AAV particle of any one of embodiments 1-2.2, 25-27, 31, 34-42, 45-50, 53-63. 69, 79, 83- 86, 91-98. 102, 103. 110, 111, 1 18-129. 369-371 , 384, 385. 390, 393. 395, 410-413, wherein the AAV capsid variant the amino acid sequence of SPHKYG (SEQ ID NO: 966), wherein tire amino acid sequence is present immediately subsequent to position 455, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.443. An adeno-associated vims (AAV) particle comprising an AAV capsid variant comprising the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 982, wherein the AAV particle further comprises a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA.444. An A adeno-associated virus (AAV) particle comprising an AAV capsid variant and a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and wherein the AAV capsid variant comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of SEQ ID NO: 981 .445. An adeno-associated virus (AAV) particle comprising an AAV capsid variant comprising the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to the amino acid sequence of SEQ ID NO: 37, and optionally further comprising:(i) one, two. or all of an amino acid other than T at position 450, an amino acid other than I at position 541, and / or an amino acid other than N at position 452, numbered according to SEQ ID NO: 138 or 37;(ii) one, two, or all of A at position 450, E at position 451, and / or I at position 452, numbered according to SEQ ID NO: 138 or 37; wherein the AAV particle further comprises a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA.446. An adeno-associated virus (AAV) particle comprising an AAV capsid variant comprising the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to position 455, numbered according to the amino acid sequence of any one of SEQ ID NO: 36, 38-55, 57, or 59, wherein the A AV particle further comprises a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dy stropilia myotonica protein kinase (DMPK) mRNA, optionally wherein tire modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA.447. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant further comprises:(i) a modification in loop I, II, VI and / or VIII; and / or(ii) a substitution at position K449, e.g., a K449R substitution, numbered according to SEQ ID NO: 138.448. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, not more than 20, or not more than 10 modifications, e.g.. substitutions (e.g., conservative substitutions), relative to the amino add sequence of SEQ ID NO: 138.449. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two, or at least three, but no more than 30, not more than 20, or not more than 10 different amino acids relative to the amino acid sequence of SEQ ID NO: 138.450. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO:138.451. The AA V particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence with at least 98% identity to SEQ ID NO: 138.452. The AAV particle of any one of the preceding embodiments, wherein the AAV capsrd variant comprises an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO:137.453. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the capsid variant comprises a sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%. at least 97%, at least 98%, or at least 99%) sequence identity to SEQ ID NO: 137.454. The AAV particle of any one of the preceding embodiments, wherein tire AAV capsid variant comprises a VP1 protein, a VP2 protein, a VP 3 protein, or a combmation thereof.455. The AAV particle of any one of embodiments 1 -454, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 138-742, e.g., a VP2, of SEQ ID NO: 981, 982, 36, or 4, or a sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity’ thereto.456. The AAV particle of any one of embodiments 1-455, wherein the A AV capsid variant comprises the amino acid sequence corresponding to positions 203-742, e.g,, a VP3, of SEQ ID NO: 981 , 982, 36, or 4, or a sequence with at least 80% (e.g., at least 80%, at least 85%. at least 90%, at least 95%, al least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.457. The AAV particle of any one of embodiments 1-456, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 138-736, e.g., a VP2, of SEQ ID NO: 138, or a sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.458. The AAV particle of any one of embodiments 1-457, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 203-736, e.g., a VP3, of SEQ ID NO: 138, or a sequence with at least 80% (e.g., at least 80%, at least 85%, at: least: 90%, at least 95%, at least 96%. at least 97%, at least 98%, or at least 99%) sequence identity thereto.459. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43. 46-51, 54-72, 69-89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371 , 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, or 446-458, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein:(i) the at least 3 consecutive amino acids comprise SPH;(ii) the at least 4 consecutive amino acids comprise SPHS (SEQ ID NO: 4700);(iii) the at least 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 4701); or(iv) the at least 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203- 742 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences in (a)-(c).460. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69-89, 91, 94-99, 102-104, 107, 1 10-112, 1 15-129. 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299. 327-363, 369-371 , 375-379, 385, 386, 390, 391 , 395, 406, 408, 410-413, 415-432, 444, or 446-459, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of SPHSKA (SEQ ID NO: 941 ), wherein:(i) the at least 3 consecutive amino acids comprise SPH;(ii) the at least 4 consecutive amino acids comprise SPHS (SEQ ID NO: 4700):(iii) the at least 5 consecutive amino acids comprise SPHSK (SEQ ID NO: 4701); or(iv) the at least 6 consecutive amino acids comprise SPHSKA (SEQ ID NO: 941): wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to the amino acid sequence of SEQ ID NO: 981.461. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69-89, 91, 94-99, 102-104, 107, 1 10-1 12, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-2.99, 327-363, 369-371, 375-379, 385, 386, 390. 391, 395. 406, 408. 410-413. 415-432, 444, or 446-460, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the AAV capsid variant comprises:(a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 981;(b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 981;(c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 981; or(d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences in (a)- (c).462. The AAV particle of any one of embodiments 1-2.3, 26-29, 32, 35-43, 46-51 , 54-72. 69-89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202. 240-247, 249, 250. 253-263, 266, 272-281, 286, 288, 291 -299, 327-363. 369-371 , 375-379, 385, 386. 390, 391. 395, 406. 408, 410-413, 415-432, 444, or 446-461, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least 90%, at least 95%, at least96%. at least 97%, at least 98%, or at least 99%) identical to the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981.463. The AAV particle of any one of embodiments 459-462, wherein the amino acid sequence is present immediately subsequent to position 455. numbered according to SEQ ID NO: 138 or 981.464. The AAV particle of any one of embodiments 1-9, 11, 12-22, 2.4, 26, 28, 30, 33, 35-42. 44, 46- 50, 52. 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-2.57, 260, 2.61, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435. 438-441, 443, 445. or 447-458, wherein the AAV capsid variant an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein:(i) the at least 3 consecutive amino acids comprise HDS;(ii) the at least 4 consecutive amino acids comprise HDSP (SEQ ID NO: 4702);(iii) the at least 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 4703); or(iv) the at least 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982; (b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982; (c) a VP3 protein comprising the amino acid sequence of positions 203- 742. of SEQ ID NO: 982; or (d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%. or at least 99%) sequence identity to any of the amino acid sequences in (a)-(c).465. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, or 464, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, at least 4, at least 5, or at least 6 consecutive amino acids from the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein:(i) the at least 3 consecutive amino acids comprise HDS;(ii) the at least 4 consecutive amino acids comprise HDSP (SEQ ID NO: 4702);(iii) the at least 5 consecutive amino acids comprise HDSPH (SEQ ID NO: 4703); or(iv) the at least 6 consecutive amino acids comprise HDSPHK (SEQ ID NO: 2); wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least about 95, 96, 97. 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 982.466. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371 , 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441 , 443, 445, 447-458, 464, or 465, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises:(a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982;(b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982:(c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982: or(d) an amino acid sequence with at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to any of the amino acid sequences in (a ) (c).467. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 11 1, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287. 289-299. 327-363, 369, 369, 371, 380-383, 385, 386, 390. 392, 395. 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, or 464-466, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2). wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the amino acid sequence of SEQ ID NO: 982.468. The AAV particle of any one of embodiments 464-468, wherein the amino acid sequence is present immediately subsequent to position 453, numbered according to SEQ ID NO: 138 or 982.469. The AAV particle of any one of embodiments 1 -468, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981 or 982, or an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%. at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.470. The AAV particle of any one of embodiments 1-469, wherein the A AV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, not more than 20 or not more than 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981 or 982.471. The AAV particle of any one of embodiments, 1 -470, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three, but not more than 30, not more than 20 or not more than 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 981 or 982.472. The AAV particle of any one of embodiments 1-2.3, 26-2.9, 32, 35-43, 46-51 , 54-72. 69-89, 91, 94-99, 102-104, 107, 110-112, 115-12.9, 168-202. 2.40-247, 249, 250. 2.53-263, 266, 272.-281, 2.86, 288, 2.91-299. 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, or 469-471, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981, or an amino acid sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.473. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69-89, 91, 94-99, 102-104, 107, 1 10-1 12, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463. or 469-472, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one. at least two or at least three modifications, e.g,, substitutions (e.g.. conservative substitutions), but not more than 30, not more than 20 or not more than 10 modifications, e.g,, substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981.474. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43. 46-51, 54-72, 69-89, 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371 , 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, or 469-473, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three, but not more than 30, not more than 20 or not more than 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 981 .475. The AAV particle of any one of embodiments 1-9, 11 , 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52. 54-77, 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-2.57, 260, 2.61, 264-2.80, 283-2.87, 289-2.99, 327-363, 369, 369, 371. 380-383, 385, 386, 390, 392. 395, 407. 409-412, 414, 433-435, 438-441 , 443, 445, 447-458, or 464-471, wherein the AA V capsid variant comprises the amino acid sequence of SEQ ID NO: 982, or an amino acid sequence with at least 80% (e.g.. at least 80?% at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.476. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77. 83-88, 90-97, 100-103, 105, 110, 111 , 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371 , 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441 , 443, 445, 447-458, 464-471 , or 475, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three modifications, e.g., substitutions (e.g,, conservative substitutions), but not more than 30, not more than 20 or not more than 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 982.477. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44. 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441, 443, 445, 447-458, 464-471, 475, or 476, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, at least two or at least three, but not more than 30, not more than 20 or not more than 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 982.478. The AAV particle of any one of embodiments 1-477, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 983 or 984, or a nucleotide sequence with at least 80% (e.g.. at least 80%, at least 85%, at least 90%, at least 95%, at least 96%. at least 97%, at least 98?% or at least 99%) sequence identity thereto.479. The AAV particle of any one of embodiments 1-478. wherein tire nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NOs: 983 or 984, or a nucleotide sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity' thereto.480. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51 , 54-72, 69-89, 91, 94-99, 102-104, 107, 110-112, 1 15-129. 168-202, 02, 240-247, 249, 250. 253-263, 266, 272-281, 286, 288, 291-299. 327-363, 369-371 , 375-379, 385, 386, 390, 391 , 395, 406, 408, 410-413, 415-432, 444, 446-463, 469-474, 478, or 479, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence with at least 80% (e.g,, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%. or at least 99%) sequence identity thereto.481. The AAV particle of any one of embodiments 1-9, 11, 12-22. 24, 26, 28, 30, 33, 35-42, 44. 46-50, 52, 54-77. 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261,264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441 , 443, 445, 447-458, 464-471, or 475-479, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence with at least 80% (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity thereto.482. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the capsid variant is codon optimized.483. The AAV particle of any one of embodiments 1-23, 26-29, 32, 35-43, 46-51, 54-72, 69-89. 91, 94-99, 102-104, 107, 110-112, 115-129, 168-202, 02, 240-247, 249, 250, 253-263, 266, 272-281, 286, 288, 291-299, 327-363, 369-371, 375-379, 385, 386, 390, 391, 395, 406, 408, 410-413, 415-432, 444, 446-463, 469-474, 478-480, or 482, and further comprising an amino acid sequence at least 95% identical to SEQ ID NO: 981.484. An adeno-associated virus (AAV) particle comprising an AAV capsid variant and a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK ) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981 .485. The AA V particle of embodiment 483 or 484, wherein the nucleotide sequence encoding theAAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence at least 90%, at least 95%, or at least 99% identical thereto.486. The AAV particle of any one of embodiments 1-9, 11, 12-22, 24, 26, 28, 30, 33, 35-42, 44, 46- 50, 52, 54-77, 83-88, 90-97, 100-103, 105, 110, 111, 113-129, 203-248, 251, 252, 254-257, 260, 261, 264-280, 283-287, 289-299, 327-363, 369, 369, 371, 380-383, 385, 386, 390, 392, 395, 407, 409-412, 414, 433-435, 438-441 , 443, 445, 447-458, 464-471 , 475-479, 481, or 482, and further comprising an amino acid sequence at least 95% identical to SEQ ID NO: 982.487. An adeno-associated virus ( AAV) particle comprising an AAV capsid variant and a nucleic acid encoding modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein tire modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982.488. The AAV particle of embodiment 486 or 487. wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 984, or a nucleotide sequence at least 90%, at least 95%, or at least 99% identical thereto.489. An adeno-associated vims (AAV) particle comprising an AAV capsid variant and a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NOs: 983 or 984, or a nucleotide sequence at least 95% identical thereto.490. An adeno-associated vims (AAV) particle comprising an AAV capsid variant and a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 4 or 36-59, optionally wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 4 or 36.491. An adeno-associated virus (AA V) particle comprising an AAV capsid variant and a nucleic acid encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protem kinase (DMPK) mRNA. optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and wherein the AAV capsid variant comprises an amino acid sequence encoded by tire nucleotide sequence of any one of SEQ ID NOs: 12-35. or a nucleotide sequence at least 95% identical thereto.492. The AAV particle of 490 or 491, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of any one of SEQ ID NOs: 12-35, or a nucleotide sequence at least 95% identical thereto.493. The AAV particle of any one of embodiments 1-299, 369-371, or 375-492, which has an increased tropism for a CNS cell or tissue, e.g., a brain cell, brain tissue, spinal cord cell, or spinal cord tissue, relative to the tropism of an AAV particle comprising a capsid comprising the amino acid sequence of SEQ ID NO: 138.494. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-493, which transduces a brain region, e.g., a midbrain region (e.g., the hippocampus, or thalamus) or the brain stem, optionally wherein the level of transduction is at least 5, at least 10, at least 15, at least 20, atleast 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, or at least 65- fold greater as compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR assay, e.g., as described in Example 2.495. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-494, which transduces a brain region, e.g., a midbrain region (e.g,, the hippocampus, or thalamus ) or the brain stem, optionally wherein the level of transduction is at least 30, at least 35, at least 40. at least 45. at least 50, at least 55, at least 60. or at least 65-fold greater as compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an inmwnohistochemistiy assay or a qPCR assay, e.g., as described in Example 2.496. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-495, which is enriched at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10-fold, in the brain compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 .497. The AAV particle of any one of embodiments 1 -12.9, 168-299. 369-371 , or 375-496, which is enriched at least 20. at least 2.5. at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80 or at least 85-fold, in the brain compared to anAAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1.498. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-497, which is enriched in the brain of at least two to at least three species, e.g., a non-human primate and rodent (e.g., mouse), e.g., as compared to an AAV particle comprising a capsid of SEQ ID NO: 138.499. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, or 375-498, which is enriched at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100, at least 105, at least 115, at least 120. at least 125, at least 130. at least 135, at least 140, at least 145, at least 150, at least 155, at least 160, at least 165, at least 170, at least 175, at least 180, at least 190, at least 200, at least 205, or at least 210-fold, in the brain of at least two to at least three species, e.g.. a non-human primate and rodent (e.g., mouse), compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 5.500. The AAV particle of embodiment 498 or 499, wherein the at least two to at least three species are Macaca fascicularis, C.hlorocebus sabaeus, Callithrixjacchus , and / or mouse (e.g., BALB / c mice,C57B1 / 6 mice, and / or CD-1 outbred mice).501. The AAV particle of any one of embodiments 130-146, 369, 410-414, 447-454, 457, 458, 482, or 493, which is enriched at least 2, at least 2.5, at least 3, at least 3.5. at least 4, at least 4.5, at least 5, at least 5.5, at least 6, at least 6,5, at least 7, at least 7.5, or at least 8-fold, in the brain compared to an AAV particle comprising a capsid of SEQ ID NO: 981, e.g,, when measured by an assay as described in Example 3.502. The AAV particle of any one of embodiments 147-167, 369, 410-414, 447-454, 457, 458, 482, or493, which is enriched at least 2, at least 2.5, at least 3, at least 3.5, at least 4, at least 4.5, at least 5, or at least 5.5-fold, in the brain compared to an AAV particle comprising a capsid of SEQ ID NO: 982, e.g., when measured by an assay as described in Example 3.503. The AAV particle of any one of embodiments 1-129, 168-299, 369-371 , or 375-500, which delivers an increased level of a payload to a brain region, optionally wherein the level of the payload is increased by at least 10, at least 12. at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65. or at least 70-fold, as compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT- PCR or a qPCR assay (e.g., as described in Example 2 or 8).504. The AAV particle of any one of embodiments 1-129. 168-299. 369-371, 375-500, or 503, which delivers an increased level of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 5, at least 10, at least 15, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50-fold, as compared to anAAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2 or 8).505. The AAV particle of embodiment 504 or 504, wherein the brain region is a midbrain region (e.g., the hippocampus or thalamus), frontal cortex, temporal cortex, motor cortex, cerebral cortex, caudate, putamen. dentate nucleus, substantia nigra, or the brainstem.506. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-505, which is enriched at least 4. at least 5, at least 10, at least 15. at least 20, at least 25, at least 30, or at least 35-fold, in the spinal cord compared to an AAV particle comprising a capsid of SEQ ID NO:138, e.g., when measured by an assay as described in Example 1 or 8, optionally wherein the region ofthe spinal cord is a thoracic spinal cord region, cervical spinal cord region, C5 ventral horn region, lumbar spinal cord region, orL5 ventral horn region.507. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-506, which show's preferential transduction in a brain region relative to the transduction in the dorsal root ganglia (DRG).508. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-507, which shows preferential transduction in a brain region relative to the liver.509. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-508, which shows preferential transduction in a brain region relative to the transduction in the heart.510. The AAV particle of any one of embodiments 1-129, 168-299, 369-371, 375-500, or 503-509, which shows preferential transduction in a brain region relative to the transduction in the dorsal root ganglia (DRG) and the heart.511. The AAV particle of any one of the preceding embodiments, which is capable of transducing non-neuronal cells, e.g., glial cells (e.g.. oligodendrocytes or astrocytes).512. The AA V particle of embodiment 511, wherein the non-neuronai cells comprise glial cells, oligodendrocytes (e.g., Olig2 positive oligodendrocytes), or astrocytes (e.g., OIig2 positive astrocytes).513. The AAV particle of any one of the preceding embodiments, which is capable of transducing Olig2 positive ceils, e.g., Olig2 positive astrocytes or Olig2 positive oligodendrocytes.514. The AAV particle of any one of embodiments 369, 373, 447-454, 457, 458, or 482, which has increased tropism for a heart cell or tissue, e.g., a heart ventricle or heart atrium, relative to the tropism of an AAV particle comprising a capsid of SEQ ID NO: 138.515. The AAV particle of any one of embodiments 369, 373, 447-454, 457, 458, 482. or 514, which is enriched at least 4, at least 5, at least 8, at least 10, at least 11, at least 12, at least 13. at least 14, at least 18, at least 19, at least 20. at least 21, at least 22, at least 24, at least 25, al least 27, at least 31, at least 33, or at least 34-fold, in the heart compared to an AAV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 4.516. The AAV particle of any one of embodiments 369, 374, 447-454, 457, 458, 482, which has an increased tropism for a muscle cell or tissue (e.g., a quadriceps cell or a quadriceps tissue), relative to the tropism of an AAV particle comprising a capsid comprising the amino acid sequence of SEQ ID NO: 138.517. The AAV particle of any one of embodiments 369, 374, 447-454, 457, 458, 482. which is enriched at least 4, at least 5, at least 8, at least 12, at least 17, at least 18, at least 20. at least 26, at least 27, at least 28. at least 30, or at least 36-fold, in the muscle compared to an A AV particle comprising a capsid of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 4.518. The AAV particle of embodiment 516 or 517, wherein the muscle cell or tissue is a heart muscle (e.g., a heart ventricle or a heart atrium, or both), a quadriceps muscle, or both.519. The AAV particle of any one of the preceding embodiments, which is isolated and / or recombinant.[Embodiments 520-576 are intentionally absent.]577. The AAV particle of any one of the preceding embodiments, wherein the modulatory polynucleotide comprises an RNAi agent, optionally a dsRNA, siRNA, shRNA, pre-miRNA, pri- miRNA, miRNA, siRNA, IncRNA, piRNA, or snoRNA. or a combination thereof.[Embodiments 578-583 are intentionally absent.]584. The AAV particle of embodiment 577, wherein the modulatory polynucleotide comprises an siRNA.[Embodiments 585 is intentionally absent.]586. The AAV particle of any one of the preceding embodiments, wherein the viral genome comprises a promoter operably linked to the nucleic acid sequence encoding the modulatory polynucleotide.587. The AAV particle of embodiment 586, wherein the promoter is human elongation factor la- subunit (EFla), cytomegalovirus (CMV) immediate-early enhancer and / or promoter, chicken β-actin(CBA), CAG, CAG derivative, β glucuronidase (GU SB), or ubiquitin C (UBC), neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B-chain(PDGF-p), intercellular adhesion molecule 2 (1CAM-2), synapsin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca2+ / calmodulin-dependent protein kinase II (CaMKII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light (NFL) or heavy (NFH), β-globin minigene np2, preproenkephalin (PRE), enkephalin (Enk) and excitatory' amino acid transporter 2 (E AAT2), glial fibrillary' acidic protein (GFAP), myelin basic protein (MBP), a cardiovascular promoter (e.g., αMHC, cTnT, and CA4V-MLC2k), a liver promoter (e.g., hAAT, TBG), a skeletal muscle promoter (e.g., desmin, MCK, C512) or a fragment, e.g., a truncation, or a functional variant thereof.[Embodiments 588 and 589 are intentionally absent.]590. The AAV particle of any one of embodiments 586-589, wherein the viral genome further comprises a polyadenylation (poly A) sequence.591. The AAV particle of any one of embodiments 586-599. wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.592. The AAV particle of any one of embodiments 586-591 , wherein the viral genome comprises anITR sequence positioned 5 relative to the nucleic acid sequence encoding the modulatory polynucleotide.593. The AA V particle of any one of embodiments 586-592, wherein the viral genome comprises anITR sequence positioned 3 relative to the nucleic acid sequence encoding the modulatory' polynucleotide.594. The AAV particle of any one of embodiments 586-593, wherein the viral genome comprises anITR sequence positioned 5 relative to the nucleic acid sequence encoding the modulatory polynucleotide and an ITR sequence positioned 3 relative to the nucleic acid sequence encoding the modulatory polynucleotide595. The AAV particle of any one of embodiments 586-594, wherein the viral genome further comprises an enhancer, a Kozak sequence, an intron region, and / or an exon region.[Embodiments 596-613 are intentionally absent.]614. The AAV particle of any one of embodiments 586-595, wherein the viral genome is singh stranded.615. The AAV particle of any one of embodiments 586-595, wherein the viral genome is self- complementary.616. The AAV particle of any one of embodiments 586-615, wherein the viral genome further comprises a nucleotide sequence encoding a Rep protein, e.g., a non-structural protein, wherein the Rep protein comprises a Rep78 protein, a Rep68 protein, a Rep52 protein, and / or a Rep40 protein (e.g,, a Rep78 and a Rep52 protein).617. The AAV particle of any one of embodiments 586-615, wherein the AAV particle further comprises a nucleotide sequence encoding a Rep protein, e.g., a non-structural protein, wherein the Rep protein comprises a Rep78 protein, a Rep68 protein, a Rep52 protein, and / or a Rep40 protein (e.g., a Rep78 and a Rep52 protein).618. The AAV particle of embodiment 616 or 617, wherein the Rep78 protein, the Rep68 protein, theRep52 protein, and / or the Rep40 protein are encoded by at least one Rep gene.619. The AAV particle of any one of embodiments 586-618, wherein the viral genome further comprises a nucleic acid sequence encoding the AAV capsid variant of the AAV particle of any one of embodiments 1-519, 566, or 574.620. The AAV particle of any one of embodiments 575-519, wherein the AAV particle is an isolated and / or recombinant AAV particle.[Embodiment 621 is intentionally absent.]622. A cell, e.g., a host cell, comprising the AAV particle of any one of the preceding embodiments.623. The cell of embodiment 622, wherein the cell is a mammalian cell or an insect ceil.[Embodiment 624 is intentionally absent.]625. The cell of embodiment 62.2 or 623, wherein the cell is a muscle cell (e.g., a cell of the heart, diaphragm, or quadriceps).[Embodiment 626 is intentionally absent.]627. A method of making an AAV particle, comprising(i) providing a host cell comprising a viral genome; and(ii) incubating the host ceil under conditions suitable to encapsulate the viral genome in the AAV capsid variant as described in any one of embodiments 1 -519, 566, or 574; thereby making the AAV particle.628. The method of embodiment 627, further comprising, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the host cell.629. The method of embodiment 628. wherein the host cell comprises a second nucleic acid encoding the capsid variant.630. The method of embodiment 629, wherein the second nucleic acid molecule is introduced into the host cell prior to, concurrently with, or after tire first nucleic acid molecule.631. A pharmaceutical composition comprising the AAV particle of any one of embodiments 1-620, and a pharmaceutically acceptable excipient.632. A method of delivering a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA to a cell or tissue (e.g., a muscle cell, or a muscle tissue), comprising administering an effective amount of the pliarmaceutical composition of embodiment 631 or the AA V particle of any one of embodiments 1-620.[Embodiments 633-635 are intentionally absent.]636. The method of embodiment 632, wherein the cell or tissue is within a subject.637. The method of embodiment 636, wherein the subject has, has been diagnosed with having, or is at risk of having a genetic disorder, e.g., a monogenic disorder or a polygenic disorder.638. The method of embodiment 636 or 637, wherein the subject has, has been diagnosed with having, or is at risk of a DMPK-related disorder.639. The method of any one of embodiments 636-638. wherein the subject has, has been diagnosed with having, or is at risk of having a muscular disorder or a neuromuscular disorder.640. The method of any one of embodiments 636-639, wherein the subject has, has been diagnosed with having, or is at risk of having myotonic dystrophy type 1 (DM1).641. A method of treating a subject having or diagnosed with having a genetic disorder, e.g., a monogenic disorder or a polygenic disorder, comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620.642. A method of treating a subject having or diagnosed with a DMPK-related disorder, comprising administering to the subject an effective amount of the pliarmaceutical composition of embodiment 631 or the AAV particle of tiny one of embodiments 1-620.643. A method of treating a subject having or diagnosed with having a myotonic dystrophy type 1 (DM1). comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620.[Embodiments 644 and 645 are intentionally absent.]646. The method of any one of embodiments 641-643, where treating comprises prevention of progression of tire disease or disorder in the subject.647. The method of embodiment 636-646, wherein tire subject is a human.648. The method of any one of embodiments 636-647, w herein the AAV particle is administered to the subject intravenously, intrathecally, intraarterially, or intramuscularly.649. The method of any one of embodiments 636-648, wherein the AAV particle is administered to the subject via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.650. The method of any one of embodiments 636-649, wherein the AAV particle is administered to the subject intravenously.[Embodiment 651 is intentionally absent.]652. The method of any one of embodiments 636-651. wherein the AAV particle is administered to the subject intraarterially.653. The method of any one of embodiments 648-652, wherein administration of the AAV particle results in a decreased presence, level, and / or activity of a DMPK gene, mRNA, protein, or combination thereof, optionally wherein administration of the AAV particle results in decreased or eliminated mutated DMPK mRNA.[Embodiment 654 is intentionally absent.]655. The pharmaceutical composition of embodiment 631 or the AA V particle of any one of embodiments 1-620 for use in a method of delivering a payload (e.g.. a modulatory polynucleotide for reducing or elimination expression of mutated DMPK mRNA) to a cell or tissue.656. The pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620 for use in a method of treating a genetic disorder, a muscular disorder, or a neuromuscular disorder.657. The pharmaceutical composition of embodiment 63 i or the AAV particle of any one of embodiments 1-620 for use in the manufacture of a medicament.658. Use of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620 in the manufacture of a medicament.659. Use of the pharmaceutical composition of embodiment 631 or the AAV particle of any one of embodiments 1-620 in the manufacture of a medicament for treating a genetic disorder, a muscular disorder, or a neuromuscular disorder.660. The AAV particle, pharmaceutical composition, cell, method, or use or any one of the preceding embodiments for reducing or eliminating expression of mutated DMPK mRNA.[Embodiments 661-664 are intentionally' absent.]665. The AAV particle of embodiment 660, wherein the AAV capsid variant comprises (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or a sequence at least 90% identical thereto; (b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or a sequence at ieast 90% identical thereto; or (c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or a sequence at least 90% identical thereto; or wherein the AAV capsid variant is encoded by the nucleotide sequence of SEQ ID NO: 984 or a sequence at least 90% identical thereto.666. The AAV particle of any one of embodiments 660-664, wherein the AAV capsid variant comprises no more than three amino acid substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 982.[Embodiments 667-674 are intentionally absent.]675. The AAV particle of any one of the preceding embodiments, wherein the encoded modulatory polynucleotide comprises a molecular scaffold comprising a 5 flanking region, a loop region, and a 3 flanking region, optionally wherein(a) the 5 flanking region comprises any one of SEQ ID NOs: 6413-6416; or a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99% identical to any one of SEQ ID NOs: 6413-6416;(b) the loop region comprises any one of SEQ ID NOs: 6417-6421 ; or a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95% at least 96%, at least 97%, at least 98%, at least 99% identical to any one of SEQ ID NOs: 6417-6421; and(c) the 3 flanking region comprises any one of SEQ ID NOs: 6422-6427; or a nucleotide sequence at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%. at least 98%, at least 99% identical to any one of SEQ ID NOs: 6422-6427.676. The AA V particle of embodiment 675, wherein:(a) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414 or SEQ ID NO: 6415;(b) the loop region of the molecular scaffold comprises SEQ ID NO: 6417, SEQ ID NO: 6418, or SEQ ID NO: 6421; and(c) the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6423, SEQ ID NO: 6424, or SEQ ID NO: 6425.677. The AAV particle of embodiment 675, wherein:(a) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 642.3;(b) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6415, the loop region of the molecular scaffold comprises SEQ ID NO: 6421. and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6425; or(c) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6424; or(d) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6418, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 642.3.677a. The AAV particle of embodiment 677. wherein the modulatory polynucleotide comprises an siRNA comprising a passenger strand and a guide strand, wherein the passenger and guide strands are substantially complementary, and wherein the guide strand targets (e.g., reduces expression or silences expression of) DMPK mRNA, e.g., DMPK mRNA comprising a trinucleotide repeat expansion.677b. The AAV particle of embodiment 677a, wherein the passenger strand and the guide strand are located, respectively, on a 5 arm and a 3 arm of a stem loop structure, wherein the passenger strand is located between the 5 flanking region of the molecular scaffold and the loop region of the molecular scaffold and the guide strand is located between the loop region of the molecular scaffold and the 3 flanking region of the molecular scaffold.677c. The AAV particle of embodiment 677a, wherein the guide strand and the passenger strand are located, respectively, on a 5 arm and a 3 arm of a stem loop structure, wherein the guide strand is located between the 5 flanking region of the molecular scaffold and the loop region of the molecular scaffold and the passenger strand is located between the loop region of the molecular scaffold and the 3 flanking region of the molecular scaffold.677d. The AAV particle of any one of embodiments, 677a-677c, wherein the passenger strand is 15-30 nucleotides in length, optionally 21-25 nucleotides in length.677e. The AAV particle of any one of embodiments, 677a-677d, the guide strand is 15-30 nucleotides in length, optionally 21-25 nucleotides in length.677f. The AAV particle of embodiment 677e, wherein the passenger strand and guide strand are at least 70% complementary' .677g. The AAV particle of any one of embodiments 677a-677f, wherein the modulatory' polynucleotide (e.g., the guide strand of the modulatory polynucleotide) binds to a coding region of DMPK mRNA.677h. The AAV particle of any one of embodiments 677a-677g, wherein the modulatory polynucleotide (e.g., the guide strand of the modulatory polynucleotide) binds to a noncoding region of DMPK mRNA.678. The AAV particle of any one of embodiments 667-677h, wherein the viral genome further comprises a promoter operably linked to the modulatory polynucleotide.679. The AAV particle of any one of embodiments 667-678, wherein the viral genome further comprises an enhancer.[Embodiments 680-681 are intentionally absent.]682. The AAV particle of embodiment 678 or 679, wherein the promoter comprises a tissue-specific promoter.683. The AAV particle of embodiment 678 or 679, wherein the promoter comprises a ubiquitous promoter.684. The AAV particle of any one of embodiments 678-683, wherein the promoter comprises:(i) an EF-la promoter, a CB promoter, a chicken [3-actin (CBA) promoter, a CAG promoter, a CAG derivative promoter, a CMV immediate-early enhancer and / or promoter, a β glucuronidase (GUSB) promoter, a ubiquitin C (UBC) promoter, a neuron-specific enolase (NSE) promoter, a platelet-derived growth factor (PDGF) promoter, a platelet-derived growth factor B-chain (PDGF-β) promoter, an intercellular adhesion molecule 2 (ICAM-2) promoter, a synapsin (Syn) promoter, a methyl-CpG binding protein 2 (MeCP2) promoter, a Ca2+ / calmodulin-dependent protein kinase II (CaMKII) promoter, a metabotropic glutamate receptor 2 (mGluR2) promoter, a neurofilament light (NFL) or heavy (NFH) promoter, a p-globin minigene nβ 2 promoter, a preproenkephalin (PPE) promoter, an enkephalin (Enk) and excitatory amino acid transporter 2 (E AAT2) promoter, a glial fibrillary acidic protein (GFAP) promoter, a myelin basic protein (MBP) promoter, a cardiovascular promoter (e.g., άMHC, cTnT, and CMV-MLC2k), a liver promoter (e.g., hAAT, TBG), a skeletal muscle promoter (e.g., desmin, MCK, C512) or a fragment, e.g., a truncation, or a functional variant thereof.[Embodiments 685-712 are intentionally absent.]713. The AAV particle of any one of embodiments 667-684, wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.714. The AAV particle of embodiment 713, wherein the ITR sequence is positioned 5 relative to the nucleic acid encoding the modulatory’ polynucleotide.715. The AAV particle of embodiment 713 or embodiment 714, wherein the ITR sequence is positioned 3 relative to the nucleic acid encoding the modulatory polynucleotide.716. The AAV particle of any one of embodiments 713-715, wherein the viral genome comprises an ITR positioned 5 relative to the nucleic acid encoding the modulatory polynucleotide and an ITR positioned 3 relative to the nucleic acid encoding the modulatory polynucleotide.[Embodiments 717-721 are intentionally absent.]722. The AAV particle of any one of embodiments 667-716, wherein the viral genome further comprises a polyadenylation (poly A) signal region.724. The AAV particle of any one of embodiments 667-716, wherein the viral genome further comprises an intron region.[Embodiments 725 and 726 are intentionally absent.]727. The AAV particle of any one of embodiments 667-724, wherein the viral genome further comprises an exon region, e.g., at least one, at least two, or at least three exon regions.728. The AAV particle of any one of embodiments 667-727, wherein the viral genome further comprises a Kozak sequence.[Embodiments 729-748 are intentionally’ absent.]749. An AAV particle comprising an AA V capsid variant and a viral genome, wherein the capsid variant comprises:(a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or a sequence 90% identical thereto;(b) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO:982 or a sequence 90% identical thereto; and / or(c) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or a sequence 90% identical thereto and wherein the viral genome encodes a modulatory polynucleotide (e,g., siRNA) comprising a stem-loop structure comprising:(i) a 5 flanking region, a passenger strand, a loop region, a guide strand that targets DJMPK, and a 3 flanking region; or(ii) a 5 flanking region, a guide strand that targets DMPK, a loop region, a passenger strand, and a 3 flanking region.750. The AAV particle of embodiment 749, wherein the AAV capsid variant comprises no more than three amino acid substitutions relative to the amino acid sequence of HDSPHK (SEQ ID NO: 2), wherein the AAV capsid variant comprises an amino acid sequence that is at least 99% identical to SEQ ID NO: 982.751. The AAV particle of embodiment 749, wherein the AAV capsid variant is encoded by the nucleotide sequence of SEQ ID NO: 984 or a sequence at least 90% identical (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%. at least 99%, or 100% identical) thereto.[Embodiments 752-761 are intentionally absent.]762. The AA V particle of any one of embodiments 660-751, further comprising a nucleic acid encoding a Rep protein, wherein the Rep protein comprises a Rep78 protein, a Rep68, Rep52 protein, and / or a Rep40 protein.763. The AAV particle of embodiment 762, wherein the Rep78 protein, the Rep68 protein, the Rep52 protein, and / or the Rep40 protein are encoded by at least one Rep gene.764. A vector encoding the AAV particle of any one of embodiments 660-763.765. A cell comprising the A AV particle of any one of embodiments 660-763 or the vector of embodiment 764.766. The cell of embodiment 765. which is a mammalian cell, e.g., an HEK2.93 cell, an insect cell, e.g., an Sf9 cell, or a bacterial cell.767. A method of making a recombinant AAV particle, the method comprising(i) providing a host cell comprising a viral genome comprising the nucleotide sequence encoding a modulatory polynucleotide of the disclosure; and(ii) incubating the host ceil under conditions suitable to enclose the viral genome in a capsid variant comprising the amino acid sequence of SEQ ID NO: 982; thereby making the recombinant AAV particle.768. The method of embodiment 767, further comprising, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the host cell.769. The method of embodiment 767 or embodiment 768, wherein the host cell comprises a second nucleic acid encoding the capsid variant.770. The method of embodiment 769, further comprising introducing the second nucleic acid into the cell.771. The method of embodiment 769 or embodiment 770, wherein the second nucleic acid molecule is introduced into the host cell prior to, concurrently with, or after the first nucleic acid molecule.772. The method of any one of embodiments 767-772, wherein the host cell comprises a mammalian ceil, e.g., an HEK293 cell, an insect cell, e.g., an Sf9 cell, or a bacterial cell.773. A pharmaceutical composition comprising the AAV particle of any one of embodiments 660-763 and a pharmaceutically acceptable excipient.774. A method of delivering a modulatory polynucleotide to a subject comprising administering an effective amount of the pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 660-763, thereby delivering the nucleic acid encoding a modulatory polynucleotide to the subject.775. The method of embodiment 774, wherein the subject has, has been diagnosed with having, or is at risk of having a DMPK-related disorder.776. The method of embodiment 774 or embodiment 775, wherein the subject has, has been diagnosed with having, or is at risk of having a myotonic dystrophy type 1 (DM1).777. A method of treating a subject having or diagnosed with having a DMPK-related disorder comprising administering to the subject an effective amount of the pharmaceutical composition ofembodiment 773 or the AAV particle of any one of embodiments 660-763, thereby treating theDMPK-related disorder.780. A method of treating a subject having or diagnosed with having DM1 comprising administering to the subject an effective amount of the pharmaceutical composition of embodiment 773 or the AAV particle of any one of embodiments 660-773, thereby treating DM1 in the subject.781. The method of embodiment 779 or embodiment 780, wherein the subject has one or more mutations in DMPK.782. The method of any one of embodiments 779-781, wherein the DM1 is mild DM1.783. The method of any one of embodiments 779-781, wherein the DM1 is classic DM1.784. The method of any one of embodiments 799-781, wherein the DM1 is childhood DM1.785. The method of any one of embodiments 799-781, wherein the DM1 is congenital DM1.786. The method of any of embodiments 799-785, wherein the DMPK gene has 50 or more CTG repeats (SEQ ID NO: 6434),787. The method of embodiment 786, wherein the DMPK gene has 800 or more CTG repeats (SEQ ID NO: 6435).788. The method of embodiment 787, wherein the DMPK gene has 1000 or more CTG repeats (SEQ ID NO: 6436).[Embodiments 789-790 are intentionally absent.]791. The method of any one of embodiments 777-790, wherein treating results in amelioration of at least one biomarker or symptom of the disease associated with mutated DMPK mRNA or mutated DMPK mRNA expression or activity,792. The method of embodiment 791, wherein the at least one biomarker or symptom comprises increased levels of mutated DMPK mRNA, protein clumping within cells, interfered protein production, muscle cell weakness, or a combination thereof.793. The method of any one of embodiments 774-792, wherein the subject is a human.794. The method of any one of embodiments 774-793, wherein the subject is a juvenile, e.g., between 6 years of age to 20 years of age.795. The method of any one of embodiments 774-793. wherein the subject is an adult, e.g., above 20 years of age.796. The method of any one of embodiments 774-795, wherein the subject has one or more mutations in a DMPK gene, DMPK mRNA, and / or DMPK protein.797. The method of any one of embodiments 774-796, wherein the AAV particle is administered to the subject intravenously, intracerebrally, via intrathalamic (ITH) administration, intramuscularly, intrathecally, intracerebroventricularly, via intraparenchymal administration, via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration, or via intra-cistema magna injection (ICM).798. The method of any one of embodiments 774-796, wherein the A AV particle is administered via dual ITH and ICM administration.799. The method of any one of embodiments 774-796, wherein the AAV particle is administered via intravenous injection, optionally' wherein the intravenous injection is via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.[Embodiments 800-802 are intentionally absent.]803. The method of any one of embodiments 774-799, birther comprising performing a blood test, performing an imaging test, collecting a tissue biopsy, or collecting a blood or serum sample.804. The method of any one of embodiments 774-803, which further comprises evaluating, e.g., measuring, the level of mutated DMPK expression, e.g., mutated DMPK gene and / or DMPK mRNA, in the subject, e.g.. in a cell, tissue, or fluid, of the subject,805. The method of embodiment 804. wherein measuring the level of DMPK expression is performed prior to, during, or subsequent to treatment with the AAV particle.806. The method of embodiment 804 or embodiment 805, wherein the cell or tissue is a peripheral cell or tissue (e.g., the liver, heart, skeletal muscle, and / or spleen).807. The method of any one of embodiments 774-806, wherein the administration results in decreased level of mutated DMPK mRNA expression in a cell or tissue of the subject, relative to a reference level, e.g., a subject that has not received treatment, e.g.. has not been administered the AAV particle.808. The method of any one of embodiments 774-807, which further comprises evaluating, e.g.. measuring, the level of DMPK activity in the subject, e.g.. in a cell or tissue of the subject, optionally wherein the level of DMPK activity is measured by an assay described herein.808a. The method of any one of embodiments 774-808, wherein the administration results in an increase in the level of viral genomes (VG) per cell in a muscle cell or tissue, e.g., heart and / or skeletal muscle cell and / or tissue, of the subject.809. The method of any one of embodiments 774-808a, wherein the administration results in a decrease in at least one of:(i) the level of DMPK activity in a cell, tissue, and / or fluid, e.g., a muscle cell or tissue, of the subject; and / or(ii) the level of DMPK mRNA expression in a cell, tissue, and / or fluid, e.g., a muscle cell or tissue, of the subject.810. The method of any one of embodiments 774-809, further comprising administration of an additional therapeutic agent and / or therapy suitable for treatment or prevention of the DMPK-related disorder, e.g., myotome dystrophy type 1.811. The method of embodiment 810. wherein the additional therapeutic agent comprises an antidiabetic drug, an anti-myotonic drag (e.g., mexiletine), a non-steroidal anti-inflammatory drug, or a combination thereof.812. The pharmaceutical composition of embodiment 773 or the AA V particle of any one of embodiments 660-763 for use in the treatment of a DMPK-related disorder, e.g,, myotonic dystrophy type 1.813. Use of an effective amount of the pharmaceutical composition of embodiment 773 or the AA V particle of any one of embodiments 660-763 in tire manufacture of a medicament for the treatment ofa DMPK-related disorder, e.g., myotonic dystrophy type 1.
[0084] The details of various aspects or embodiments of the present disclosure are set forth below. Other features, objects, and advantages of the disclosure will be apparent from the description and the claims. In the description, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art in the field of this disclosure. In the case of conflict, the present description will control.BRIEF DESCRIPTION OF THE DRAWINGS
[0885] FIG, 1 depicts biodistribution (VG / cell) in the motor cortex, frontal cortex, putamen, substantia nigra, dentate nucleus, cervical spinal cord ventral horn, DRG, liver, and heart in cynomolgus monkeys at 28 days post-IV injection of TTM-002,GBA_VG17-HA, AAV9.GBA__VG17-HA, or vehicle control.
[0086] FIG. 2 depicts mRNA expression of the GBA1 transgene in the motor cortex, frontal cortex, putamen, substantia nigra, dentate nucleus, cervical spinal cord ventral horn, DRG, liver, and heart in cynomolgus monkeys at 28 days post-IV injection of TTM-002.GBA VG17-HA, AAV9.GBA VG17-HA, or vehicle control.
[0087] FIG. 3 A is a graph showing the percentage of HA positive cells (percent of cells transduced by the indicated capsid variant) in the cortex in mice on the Y axis at the indicated doses on the X-axis (from highest dose to lowest dose: 1e14 vg / kg, 3.2el3 vg / kg, 1e13 vg / kg, 3.2e12 vg / kg, or lei 2 vg / kg) at 28 days post-intravenous administration of AAV particles comprising the TTM-002 or TTM-027 AAV capsid variant. FIG. 3B is a graph showing the mRNA transgene expression relative to the housekeeping gene in the brains of the mice on the Y axis at the indicated doses on the X-axis (from highest to lowest dose: 1e14 vg / kg, 3.2e13 vg / kg, le13 vg / kg, 3.2e12 vg / kg, or 1e12 vg / kg) al 28 days post-intravenous administration of AAV particles comprising the TTM-002 or TTM-027 AAV capsid variant.
[0088] FIG. 4 A is a graph showing the percentage of transduced cells having HA+ nuclei as measured by co-localization of nuclear H2B-HA staining and hematoxylin (%HA+ cells) in the indicated brain regions (temporal cortex, caudate, thalamus, or hippocampus) of African green monkeys. Measurements are at day 28 post-intravenous injection of AAV particles comprising the TTM-002 capsid variant or the AAV9 capsid control and a self-complementary genome encoding a histone 2B protein with an HA-tag at a dose of le 13 VG / kg. FIG. 4B is a graph showing the percentage of HA-t- cells among ceils positive for the indicated marker (NeuN+ neurons, SM311+ Neurons, GFAP+ astrocytes, or Sox9+ astrocytes) in the indicated brain regions (temporal cortex, caudate, thalamus, or hippocampus) of African green monkeys. Measurements are at day 28 post-intravenous injection of AAV particles comprising the TTM-002 capsid variant and a self- complementary genome encoding a histone 2B protein with an HA-tag at a dose of 1e13 VG / kg. Plotted data in FIGs. 4A-4B represent one slice per monkey (n=2). Quantitative image analysis was performed on 1e3 to le5 cells according to region size. All P values are derived from an unpaired two-tailed t-test.
[0089] FIGs. 5A-5D are a series of graphs showing tropism of TTM-001 and TTM-002. relative to the AAV9 control in the brain and liver at 28 days post-intravenous administration in mice at a dose of 1 e 13 VG / kg. FIG. 5 A shows the viral genomes (VG) / diploid genomes (DG) in the brain for the AAV9 control, TTM-001, or TTM-002; FIG. 5B shows brain RNA (fold vs AAV9) for the AAV9 control, TTM-001, or TTM-002; FIG. 5C shows the VG / DG in the liver for the AAV9 control, TTM- 001, or TTM-002; and FIG. 5D shows the liver RNA (fold vs AAV9) for the AAV9 control, TTM- 001, or TTM-002. Each data point represents an individual mouse and all plotted values represent mean ± SD (n=3). P values are derived from an unpaired two-tarled t-test.DETAILED DESCRIPTIONOverview
[0090] Described herein, inter alia, are compositions comprising an AAV capsid variant comprising a sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated DMPK mRNA. In some embodiments, the present disclosure provides a method of delivering the AAV capsid variant comprising the sequence encoding the modulatory polynucleotide for reducing or eliminating expression of mutated DMPK mRNA to a cell or tissue in a subject. In some embodiments, the present disclosure provides a method for treating myotonic dy strophy type 1 (DM1) or another DMPK-related disorder). In various embodiments, AAV capsid variants disclosed herein have enhanced tropism for a cell or tissue, for example a cell or tissue of the muscle, heart, and / or brain. In some embodiments, the AAV capsid variants described herein have enhanced tropism for a cell or tissue of the heart. In some embodiments, the AAV capsid variants described herein have enhanced tropism for a cell or tissue of muscle. In some embodiments, tire AAV capsid variants described herein have enhanced tropism for a cell or tissue of cardiac muscle. In some embodiments, the AAV capsid variants described herein have enhanced tropism for a cell or tissue of skeletal muscle (e.g., quadriceps, vastus lateralis, and / or gastrocnemius). In some embodiments, the AAV capsid variants described herein have enhanced tropism for a cell or tissue of smooth muscle. In some embodiments, the AAV capsid variants described herein have enhanced tropism for more than one tissue (e.g., heart and brain).
[0091] AAVs have proven to be useful as a biological tool due to their relatively simple structure, their ability to infect a wide range of cells (including quiescent and dividing cells) without integration into the host genome and without replicating, and their relatively benign immunogenic profile. Forexample, engineered adeno-associated virus (AAV) capsids with improved brain tropism represent an atractive solution to the limitations of CNS delivery. AAV -derived vectors are promising tools for clinical gene transfer because of their non-pathogenic nature, their low immunogenic profile, low rate of integration into the host genome, and long-term transgene expression in non-dividing cells. However, the transduction efficiency of naturally occurring AAVs in certain organs is too low for clinical applications, and capsid neutralization by pre-existing neutralizing antibodies may prevent treatment of a large proportion of patients. For these reasons, considerable efforts have been devoted to obtaining capsid variants with enhanced properties. Of many approaches tested so far, significant advances have resulted from directed evolution of AAV capsids using in vitro or in vivo selection of capsid variants created by capsid sequence randomization using either error-prone PCR, shuffling of various parent serotypes, or insertion of fully randomized short peptides at defined positions.
[0092] The genome of the vims may be modified to contain a minimum of components for the assembly of a functional recombinant vims, or viral particle, which is loaded with or engineered to target a particular tissue and express or deliver a modulatory polynucleotide, e.g., a modulatory polynucleotide for reducing or eliminating expression of mutated DMPK mRNA, and the viral particle comprising said genome may be delivered to a target cell, tissue, or organism. In some embodiments, the target cell or tissue is in the muscle, heart, and / or brain. In some embodiments, the target cell is a muscle cell, i.e., a skeletal muscle, smooth muscle, and / or cardiac muscle cell. In some embodiments, the target tissue is a muscle tissue, i.e.. a skeletal muscle (e.g., quadriceps, vastus lateralis, and / or gastrocnemius), smooth muscle, and / or cardiac muscle tissue. In some embodiments, the target cell or tissue is in the brain.
[0093] Gene therapy presents an alternative approach for treating DM1 and related diseases sharing single-gene etiology. AAVs are commonly used in gene therapy approaches as a result of a number of advantageous features. Without wishing to be bound by theory, it is believed in some embodiments, that an AAV particle described herein can be used to administer and / or deliver a modulatory polynucleotide, in order to achieve sustained, high concentrations, allowing for longer lasting efficacy, fewer dose treatments, broad biodistribution, and / or more consistent levels of the modulatory polynucleotide, relative to a non-AAV therapy.
[0094] Provided herein are compositions and methods which may provide for improved features compared to prior AAV-mediated gene knockdown approaches, including (i) increased biodistribution throughout the muscle and / or heart tissue, (ii) elevated modulatory polynucleotide expression in muscle and / or heart tissue; (iii) preferential biodistribution in muscle and / or heart tissue over other tissues or cells such as the liver and / or DRG; (iv) increased biodistribution throughout the CNS; and (v) elevated modulatory polynucleotide expression in multiple brain regions (e.g., cortex, thalamus, and brain stem); and (vi) preferential biodistribution in the CNS over the liver and / or DRG.
[0095] The modulatory polynucleotides provided herein modulate mutated DMPK by altering levels of mutated protein and / or mRNA in cells and / or tissues. In some embodiments, the modulator,polynucleotides may reduce or eliminate the expression of the mutated DMPK mRNA by reducing its amount and / or activity. In some embodiments, the modulatory polynucleotides reduce or eliminate expression of mutated DMPK mRNA, e.g., by binding to mutated DMPK mRNA and thereby reducing its level in a subject (e.g.. via RISC-mediated degradation). In some embodiments, the modulatory polynucleotides reduce or eliminate one or more effects of mutated DMPK mRNA. In some embodiments, the modulatory polynucleotides reduce or eliminate expression of mutated DMPK by reducing or eliminating translation of the mutated mRNA into protein. In some embodiments, the modulatory polynucleotides reduce or eliminate expression of mutated DMPK by reducing or eliminating effects on DMPK protein. In some embodiments, the modulatory polynucleotide may reduce or eliminate formation of hairpin loops, ribonuclear foci, sequestration of RNA-binding proteins, and / or alterations in splicing, translation, localization, polyadenylation and mRNA stability of RNA-binding proteins. In some embodiments, the modulatory polynucleotide may reduce or eliminate aggregation of mutant protein, disruption of ribosome function, and / or disruption of mRNA metabolism, e.g., including translation, stability, and degradation.
[0096] Also provided herein, are compositions comprising an AAV capsid variant, e.g., an AAV capsid variant described herein for delivery, e.g., vectorized delivery, of a modulatory polynucleotide described herein, and methods of making and using the same. As demonstrated in the Examples below, certain AAV capsid variants described herein show multiple advantages over wild-type AAV9, including (i) increased penetrance through the blood brain barrier following intravenous administration, (ii) wider distribution throughout the multiple brain regions, e.g,, frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, and / or hippocampus, ( iii) elevated payload expression in multiple brain regions, and / or iv) wider distribution of a modulatory polynucleotide in one or more peripheral tissues, e.g., the heart and / or muscle (e.g., skeletal muscle (e.g., quadriceps, vastus lateralis, and / or gastrocnemius), smooth muscle, and / or cardiac muscle), and / or (v) elevated expression of a modulatory polynucleotide in one or more peripheral tissues. Without being bound by theory, these advantages may be due, in part, to the dissemination of the AAV capsid variants through the brain vasculature. In some embodiments, the AAV capsids described herein enhance the delivery of a modulatory' polynucleotide to multiple regions of the brain including for example, the frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, and / or hippocampus.
[0097] In some embodiments, the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA. In some embodiments, the modulatory polynucleotide comprises an siRNA targeting DMPK mRNA.
[0098] Thus, the compositions and methods described herein can be used in the treatment of a DMPK-related disorders. In some embodiments, the disclosure provides an AAV particle comprising an AAV capsid variant disclosed herein and an AAV viral genome comprising a nucleotide sequence comprising a promoter and a sequence encoding a modulatory' polynucleotide for use in treating aDMPK-related disorder. In some embodiments, the modulatory polynucleotide reduces or eliminates expression of mutated DMPK mRNA. In some embodiments, the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA. In some embodiments, the RNAi agent comprises siRNA. In some embodiments, the DMPK-related disorder is DM1. In some embodiments, the DM1 is congenital DM1 .I. CompositionsAdeno-associated viral (AAV ) Particles
[0099] AA Vs have a genome of about 5,000 nucleotides in length and contain two open reading frames encoding the proteins responsible for replication (Rep) and the structural protein of the capsid (Cap). The open reading frames are flanked by two Inverted Terminal Repeat (ITR) sequences, which serve as the origin of replication of the viral genome. The wild-type AAV viral genome comprises nucleotide sequences for two open reading frames, one for the four non-structural Rep proteins (Rep78, Rep68, Rep52, Rep40, encoded by Rep genes) and one for the three capsid, or structural, proteins (VP1 , VP2, VP3, encoded by capsid genes or Cap genes). The Rep proteins are important for replication and packaging, while the capsid proteins are assembled to create the protein shell of the AAV, or AAV capsid. Alternative splicing and alternate initiation codons and promoters result in the generation of four different Rep proteins from a single open reading frame and the generation of three capsid proteins from a single open reading frame. Though it varies by AAV serotype, as a nonlimiting example, for AAV9 / hu.l4 (SEQ ID NO: 123 of US 7,906,111, the contents of which are herein incorporated by reference in their entirety) VP1 refers to amino acids 1-736, VP2 refers to amino acids 138-736, and VP3 refers to amino acids 203-736. In some embodiments, with reference to the amino acid sequence of SEQ ID NO: 982, 36, or 4, VP1 comprises amino acids 1-742, VP2 comprises amino acids 138-742, and VP3 comprises amino acids 203-742. In other words, VP1 is the full-length capsid protein sequence, while VP2 and VP3 are shorter components of the whole. As a result, changes in the sequence in the VP3 region are also changes to VP1 and VP2; however, the percent difference as compared to the parent sequence will be greatest for VP3 since it is the shortest sequence of the three. Though described here in relation to the amino acid sequence, the nucleic acid sequence encoding these proteins can be similarly described. Together, the three capsid proteins assemble to create the AAV capsid. Without being bound by theory, the AAV capsid typically comprises a molar ratio of 1: 1: 10 of VP1:VP2:VP3.
[0100] The AAV particle typically requires a co-helper (e.g. , adenovirus) to undergo productive infection in cells. In the absence of such helper functions, the AAV virions essentially enter host cells but do not integrate into the cells’ genome.
[0101] AAV particles have been investigated for delivery of gene therapeutics because of several unique features. Non-limiting examples of the features include (i) tire ability to infect both dividing and non-dividing cells; (ii) a broad host range for infectivity, including human cells; (iii) wild-typeAAV has not been associated with any disease and has not been shown to replicate in infected cells; (iv) the lack of cell-mediated immune response against the particle, and (v) the non-integrative nature in a host chromosome thereby reducing potential for long-term genetic alterations. Moreover, infection with AAV particles has minimal influence on changing the pattern of cellular gen...
Claims
CLAIMSWhat is claimed is:1 . An adeno-associated vims (AAV) particle comprising: a) an AAV capsid variant comprising an amino acid sequence having the following formula: [N1]-[N2.]-[N3], wherein:(i) optionally [N1] comprises X1, X2, and X3, wherein at least one of XI, X2, or X3 is G;(ii) [N2] comprises the amino acid sequence of SPH; and(iii) [N3] comprises X4, X5, and X6. wherein at least one of X4, X5, or X6 is a basic amino acid; and b) a vrrai genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRN A, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA.
2. The AAV particle of claim 1, wherein the amino acid sequence [N1]-[N2]~[N3] is in hypervariable loop IV of the AAW capsid variant.
3. The AAV particle of claim 1 or claim 2, wherein the AAV capsid variant is an AAV9 capsid vanant.
4. The AAV particle of any one of claims 1-3, wherein [N1] comprises XI, X2, and X3, wherein at least one of XI, X2, or X3 is G.
5. The AAV particle of any one of claims 1-4, wherein [N2]-[N3] comprises the amino acid sequence of SPHSKA (SEQ ID NO: 941).
6. An adeno-associated virus (AA V) particle comprising (a) a viral genome comprising a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and (b) an AAV9 capsid variant comprising the amino acid sequence of SPHSKA (SEQ ID NO: 941).
7. The AA V particle of claim 6, wherein the amino acid sequence of SPHSKA (SEQ ID NO: 941) is in hypervariable loop IV of the AAV9 capsid variant.
8. The AAV particle of claim 6 or claim 7, wherein the amino acid sequence of SPHSKA (SEQ IDNO: 941 ) is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 4 or SEQ ID NO: 36.
9. The AAV particle of any one of claims 6-8, wherein the AAV9 capsid variant further comprises one, two. or all of: an N at an amino acid position corresponding to position 452. an E at an amino acid position corresponding to position 451, and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 4,10. The AAV particle of claim any one of claims 6-9. wherein the AAV9 capsid variant comprises the amino acid sequence of KTENVSGSPHSKAQNQQT (SEQ ID NO: 3272).
11. The AAV particle of any one of claims 6-10, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 4;(ii) a VP2 protein comprising an amino acid sequence having at least 90% identity to positions 138-742 of SEQ ID NO: 4; and / or(iii) a VP3 protein comprising an amino acid sequence liaving at least 90% identity to positions 203-742 of SEQ ID NO: 4.
12. The AAV particle of any one of claims 6-11, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having al least 95% identity to SEQ ID NO: 4;(ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 4; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 4.
13. The AAV particle of any one of claims 6-12, wherein the A AV9 capsid variant comprises :(i) a VP I protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 4;(ii) a VP2 protein comprising an amino acid sequence having at least 99% identity to positions 138-742 of SEQ ID NO: 4: and / or(iii) a VP3 protein comprising an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 4.
14. The AAV particle of any one of claims 6-13, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4; and / or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4.
15. Tire AAV particle of any one of claims 6-13, wherein the AAV9 capsid variant comprises:(i) the amino acid sequence of SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 4;(ii) an E at an amino acid position corresponding to position 451 and a V at an amino acid position corresponding to position 453 of SEQ ID NO: 4; and(iii) no other modifications relative to wild type AA V9.
16. The AAV particle of any one of claims 6-8, wherein the AA V9 capsid variant further comprises one, two, or all of: an E at an amino acid position corresponding to position 451 , an R at an amino acid position corresponding to position 452, and / or a V at an amino acid position corresponding to position 453 of SEQ ID NO: 36.
17. The AAW particle of any one of claims 6-8 and 16, wherein the AAV9 capsid variant comprises the amino acid sequence of KTERVSGSPHSKAQNQQT (SEQ ID NO: 3589).
18. The AAV particle of any one of claims 6-8, 16, and 17, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 36;(ii) a VP2 protein comprising an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 36; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 36.
19. The AA V particle of any one of claims 6-8 and 16-18, wherein the A AV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 36;(ii) a VP2 protein comprising an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 36; and / or(iii) a VP3 protein comprising an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 36.
20. The AAV particle of any one of claims 6-8 and 16-19, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 36;(ii) a VP2 protein comprising an amino acid sequence iraving at least 99% identity to positions 138-742 of SEQ ID NO: 36; and / or(iii) a VP3 protein comprising an amino acid sequence leaving at least 99% identity to positions 203-742 of SEQ ID NO: 36.
21. The AAV particle of any one of claims 6-8 and 16-20, wherein the AAV9 capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO:36; and / or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36.
22. The AAV particle of any one of claims 6-8 and 16-20, wherein the AAV9 capsid variant comprises:(i) the amino acid sequence SPHSKA (SEQ ID NO: 941), wherein the amino acid sequence is present immediately subsequent to an amino acid position corresponding to position 455 of SEQ ID NO: 36;(ii) an E at an amino acid position corresponding to position 451, an R at an amino acid position corresponding to position 452, and a V at an amino acid position corresponding to position 453 of SEQ ID NO: 36; and(iii) no other modifications relative to wild type AAV9.
23. The AA V particle of any one of claims 1-4, wherein [N1]-[N2]-[N3] is present immediately subsequent to a position corresponding to the amino acid position 452 of SEQ ID NO: 982; and wherein the AAV capsid variant comprises an amino acid sequence at least 90% identical, e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical, to the amino acid sequence of SEQ ID NO: 982, e.g., to positions 203-742 of SEQ ID NO: 982.
24. The AAV particle of claim 23, wherein [N1] comprises GHD.
25. The AAV particle of claim 23 or claim 24, wherein [N1] comprises the amino acid G at a position corresponding to position 453, the amino acid H at position 454, and the amino acid D at position 455 of SEQ ID NO: 138 or SEQ ID NO: 982.
26. The AA V particle of any one of claims 23-25, wherein [N3] comprises KSG.
27. The AAV particle of any one of claims 23-26, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity to positions 203-742 of SEQ ID NO: 982.
28. The AAV particle of any one of claims 23-27, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 95% identity to positions 203-742 of SEQ ID NO: 982.
29. The AAV particle of any one of claims 23-28, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 982 or an amino acid sequence having at least 99% identity to positions 203-742 of SEQ ID NO: 982.
30. The AA V particle of any one of claims 23-29, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO:982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO:982.31 . The AAV particle of any one of claims 1-30, wherein the modulatory polynucleotide comprises a molecular scaffold, wherein the molecular scaffold comprises:(a) a 5 flanking region, optionally comprising any one of SEQ ID NOs: 6413-6416;(b) a loop region, optionally comprising any one of SEQ ID NOs: 6417-6421 ; and(c) a 3 flanking region, optionally comprising any one of SEQ ID NOs: 6422-6427.
32. The AAV particle of claim 31, wherein:(a) the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414 or SEQ IDNO: 6415:(b) the loop region of the molecular scaffold comprises SEQ ID NO: 6417, SEQ ID NO: 6418, or SEQ ID NO: 6421; and(c) the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6423, SEQ ID NO: 6424, or SEQ ID NO: 6425.
33. The AAV particle of claim 31 or claim 32, wherein the 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3' flanking region of the molecular scaffold comprises SEQ ID NO: 6423,34. The AAV particle of claim 31 or claim 32, wherein lite 5 flanking region of the molecular scaffold comprises SEQ ID NO: 6415, the loop region of the molecular scaffold comprises SEQ ID NO: 6421, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6425.
35. The AAV particle of claim 31 or claim 32, wherein the 5 flanking region of the molecular' scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6417, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6424.
36. The AAV particle of claim 3 i or claim 32, wherein the 5 ’ flanking region of the molecular scaffold comprises SEQ ID NO: 6414, the loop region of the molecular scaffold comprises SEQ ID NO: 6418, and the 3 flanking region of the molecular scaffold comprises SEQ ID NO: 6423.
37. The AAV particle of any one of claims 1-36, wherein the modulatory polynucleotide further comprises siRNA or sliRNA.
38. The AAV particle of claim 37, wherein the modulator}' polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more DMPK mRNA transcripts (e.g., one or more mutated DMPK mRNA transcripts), and wherein the passenger strand and the guide strand are located, respectively, on a 5" arm and a 3 arm of a stem loop structure, wherein the passenger strand is located between the 5 flanking region and the loop region and the guide strand is located between the loop region and the 3 flanking region.
39. The AAV particle of claim 37, wherein the modulatory polynucleotide further comprises a passenger strand and a guide strand, wherein the guide strand binds to and reduces or eliminates expression of one or more DMPK mRN A transcripts (e.g., one or more mutated DMPK mRNA transcripts), and wherein the guide strand and the passenger strand are located, respectively, on a 5 arm and a 3 arm of a stem loop structure, wherein the guide strand is located between the 5 flanking region and the loop region and the passenger strand is located between the loop region and the 3 flanking region.
40. The AAV particle of any claim 38 or claim 39, wherein the passenger strand is 15-30 nucleotides in length,41. The AAW particle of any one of claims 38-40, wherein the guide strand is 15-30 nucleotides in length.
42. The AAV particle of claim 41, wherein the guide strand is 21-25 nucleotides in length and / or the passenger strand is 21-25 nucleotides in length.
43. The AAV particle of any one of claims 38-42, wherein the passenger strand is at least 70% complementary' to the guide strand.
44. The AAV particle of any one of claims 38-43, wherein the one or more DMPK mRNA transcripts comprises SEQ ID NO: 6428 or SEQ ID NO: 6429, or a trinucleotide repeat expansion thereof.
45. The AA V particle of any one of claims 1-44, wherein the viral genome comprises a promoter operably linked to the nucleic acid sequence encoding the modulatory' polynucleotide.
46. The AAV particle of any one of claims 1-45, wherein the viral genome further comprises an inverted terminal repeat (ITR) sequence.
47. The AAV particle of claim 46, wherein the viral genome comprises an ITR sequence positioned 5 relative to the nucleic acid sequence encoding the modulatory polynucleotide.
48. The AAV particle of claim 46 or claim 47, wherein the viral genome comprises an ITR sequence positioned 3 relative to the nucleic acid sequence encoding the modulatory polynucleotide.
49. The AA V particle of any one of claims 46-48, wherein the viral genome comprises an ITR sequence positioned 5 relative to the nucleic acid sequence encoding the modulatory polynucleotide, and an ITR sequence positioned 3 relative to the nucleic acid sequence encoding the modulatory polynucleotide.
50. An adeno-associated vims (AAV) particle comprising a viral genome comprising (a) a nucleic acid sequence encoding a modulatory polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RN Ai agent targeting DMPK mRNA, and (b) an AAV capsid variant comprising:(i) a ATI protein comprising the amino acid sequence of SEQ ID NO: 4;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4; and / or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4.
51. An adeno-associated virus (AAV) particle comprising a viral genome comprising (a) a nucleic acid sequence encoding a modulatory' polynucleotide for reducing or eliminating expression of mutated dystrophia myotonica protein kinase (DMPK) mRNA, optionally wherein the modulatory polynucleotide comprises an RNAi agent targeting DMPK mRNA, and (b) an AAV capsid variant comprising:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 36; and / or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO:36.
52. A cell comprising the AA V particle of any one of claims 1-51, optionally wherein tire cell is a mammalian cell (e.g., an HEK293 cell), an insect cell (e.g., an Sf9 cell), or a bacterial cell.
53. A method of making the AAV particle of any one of claims 1-51, the method comprising:(i) providing a cell comprising the viral genome comprising a nucleic acid sequence encoding a modulatory' polynucleotide for reducing or eliminating expression of mutated DMPK roRNA and a nucleic acid encoding the AAV capsid variant; and(ii) incubating the cell under conditions suitable to encapsulate the viral genome in the AAV capsid variant; thereby making the AAV particle.
54. The method of claim 53, wherein: the A AV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 4;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 4; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 4 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 4.
55. The method of claim 54, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 4, the amino acid sequence of positions 138-742 of SEQ ID NO: 4, and / or the amino acid sequence of positions 203-742 of SEQ ID NO: 4.
56. The method of claim 53, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 36;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742. of SEQ ID NO: 36 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%. at least 92%, at least 93%, at least 94%. at least 95%, at: least 96%, at least 97%, at least 98%. or at least 99% identity ) to positions 138-742 SEQ ID NO: 36; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO: 36 or an amino acid sequence having at ieast 90% identity (e.g., at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 36.
57. The method of claim 56, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 36, the amino acid sequence of positions 138-742 of SEQ ID NO: 36, and / or the amino acid sequence of positions 203-742 of SEQ ID NO: 36.
58. The method of claim 53, wherein the AAV capsid variant comprises:(i) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, al least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to SEQ ID NO: 982;(ii) a VP2 protein comprising the amino acid sequence of positions 138-742 of SEQ ID NO: 982 or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity) to positions 138-742 SEQ ID NO: 982; or(iii) a VP3 protein comprising the amino acid sequence of positions 203-742 of SEQ ID NO:
982. or an amino acid sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%. at least 93%, at least 94%, at least 95%, at least 96%. at least 97%, at least 98%, or at least 99% identity) to positions 203-742 of SEQ ID NO: 982.
59. The method of claim 58, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 982, the amino acid sequence of positions 138-742 of SEQ ID NO: 982, and / or the amino acid sequence of positions 203-742 of SEQ ID NO: 982.
60. The method of any one of claims 53-59, further comprising, prior to step (i), introducing a first nucleic acid molecule comprising the viral genome into the cell.61 . The method of any one of claims 53-60, wherein the cell comprises a second nucleic acid molecule encoding the AAV capsid variant, optionally wherein the method further comprises, prior to step (i), introducing the second nucleic acid molecule into the cell.
62. The method of any one of claims 53-61, wherein the cell comprises a mammalian cell (e.g., anI-IEK293 cell), an insect cell (e.g., an Sf9 cell), or a bacterial cell.
63. A pharmaceutical composition comprising the AAV particle of any one of claims 1-51, and a pharmaceutically acceptable excipient.
64. A pharmaceutical composition comprising the AAV particle of any one of claims 5-22, and a pharmaceutically acceptable excipient.
65. A pharmaceutical composition comprising the AAV particle of any one of claims 9-15 and 50. and a pharmaceutically acceptable excipient.
66. A pharmaceutical composition comprising the A AV particle of any one of claims 16-22. and 51, and a pharmaceutically acceptable excipient.
67. A method of delivering an AAV particle encoding a modulatory polynucleotide for reducing or eliminating expression of mutated DMPK mRNA to a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 63-66 or the AAV particle of any one of claims 1-51.
68. The method of claim 67, wherein the subject has, has been diagnosed with having, or is at risk of having a DMPK -related disorder.
69. The method of claim 67 or claim 68, wherein the disorder is myotonic dystrophy type 1 (DM1 ), optionally congenital DM1 .
70. A method of treating a subject having or diagnosed with having a DMPK-related disorder, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 63-66 or the AAV particle of any one of claims 1-51.
71. A method of treating a subject having or diagnosed with having a DMPK-related disorder, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 64 or the AAV particle of any one of claims 5-22.
72. A method of treating a subject having or diagnosed with having a DMPK-related disorder, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 65 or the AAV particle of any one of claims 9-15 and 50.
73. A method of treating a subject having or diagnosed with having a DMPK-related disorder, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 66 or the AAV particle of any one of claims 16-22 and 51.
74. The method of any one of claims 70-73, wherein the DMPK-related disorder is a DMPK-related neurodegenerative or neuromuscular disorder.
75. The method of claim 74, wherein the DMPK-related neurodegenerative or neuromuscular disorder is myotonic dystrophy type i (DM1). optionally congenital DM1.
76. A method of treating a subject having myotonic dystrophy type 1 (DM1), comprising administering to the subject an effective amount of the plrarmaceutical composition of any one of claims 63-66 or die AAV particle of any one of claims 1-51.
77. A method of treating a subject having myotonic dystrophy type 1 (DM1), comprising administering to the subject an effective amount of pharmaceutical composition of claim 64 or the AAV particle of any one of claims 5-22.
78. A method of treating a subject having myotonic dystrophy type 1 (DM1). comprising administering to the subject an effective amount of the pharmaceutical composition of claim 65 or the AAV particle of any one of claims 9- 15 and 50.
79. A method of treating a subject having myotonic dy strophy type 1 (DM1), comprising administering to the subject an effective amount of the pharmaceutical composition of claim 66 or the AAV particle of any one of claims 16-22 and 51.
80. The method of any one of claims 67-79, wherein the subject lias one or more mutations in the DMPK gene.
81. The method of claim 80, wherein the at least one mutation in the DMPK gene comprises a trinucleotide repeat expansion.
82. The method of claim 81 , wherein the trinucleotide repeat expansion in the DMPK gene is 50 or more CTG repeats (SEQ ID NO: 6434).
83. The method of any one of claims 70-82, wherein the treating results in prevention of progression of the disorder in the subject.
84. The method of any one of claims 70-83, wherein the treating results in amelioration of at least one symptom of the DMPK-related disorder and / or a change in one or more biomarkers of the disorder.
85. The method of claim 84, wherein the at least one symptom comprises cataracts, myotonia, muscle weakness and wasting, cardiac conduction abnormalities, a myopathic face, learning difficulties, psychosocial problems including depression and / or anxiety, slurred speech, decreased fetal movement in the uterus, polyhydramnios, clubfoot, ventriculomegalv. hypotonia, a tented appearance oftbe upper lip, dysarthria, intellectual disability, hypotonia, respiratory insufficiency, or a combination thereof.
86. The method of any one of claims 67-85, wherein the subject is a human.
87. The method of any one of claims 67-86, wherein the pharmaceutical composition or AA V particle is delivered to a cell, tissue, or region of muscle, optionally wherein the pharmaceutical composition or AAV particle is delivered via intravenous administration.
88. The method of claim 87, wherein the muscle is one or more of cardiac, smooth, and / or skeletal muscle (e.g., quadriceps, vastus lateralis, and / or gastrocnemius), optionally' wherein the pharmaceutical composition or AAV particle is delivered via intravenous administration.
89. The method of any one of claims 67-88, wherein the pharmaceutical composition or AAV particle is delivered to a cell, tissue, or region of the central nervous system, e.g., the brain.
90. The method of claim 89, wherein the pharmaceutical composition or AA V particle is delivered to the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof, and / or to neurons, e.g., GABAergic neurons, glutamatergic neurons, or a combination thereof.
91. The method of any one of claims 67-90, further comprising evaluating, e.g., measuring, the level of modulatory polynucleotide expression, the level of mutated DMPK mRNA expression, and / or the level of normal DMPK splicing in the subject, optionally DMPK mRNA splicing, in the subject, e.g., in a ceil, tissue, or fluid of the subject.
92. The method of claim 91 , wherein evaluating the level of modulatoty- polynucleotide expression is performed prior to and subsequent to administration of the pharmaceutical composition or A AV particle, optionally wherein the level of modulatoty polynucleotide expression prior to treatment is compared to the level of modulatory polynucleotide expression subsequent to administration.
93. The method of claim 91 or claim 92, comprising evaluating the level of modulatory’ polynucleotide expression in a muscle cell or tissue.
94. The method of claim 91 or claim 92, comprising evaluating the level of modulatory polynucleotide expression in a cell or tissue of the central nervous system (e.g., parenchyma).
95. The method of any one of claims 91-94, wherein the subject’s level of mutated DMPK mRNA expression subsequent to administration is decreased relative to the subject’s level of mutated DMPK mRNA expression prior to administration.
96. The method of any one of claims 67-88 or 91-93 wherein the administration results in an increase in:(i) an increase in the number and / or level of viral genomes ( VG) per ceil in a muscle cell or tissue of the subjec t relative to the number and / or level of VG per cell in a non-muscle ceil or tissue of the subject;(ii) a decrease in mutated DMPK mRNA expression in a muscle cell or tissue of the subject relative to baseline and / or relative to mutated DMPK mRNA expression in a muscle cell or tissue of an individual with a DMPK-related disorder who has not been administered the pharmaceutical composition or AA V particle; and / or(iii) an increase in normal mRNA splicing, optionally DMPK mRNA splicing, in a muscle cell or tissue of the subject relative to baseline and / or relative to normal mRNA splicing, optionally DMPK mRNA splicing, in a muscle cell or tissue of an individual with a DMPK-related disorder who has not been administered the pharmaceutical composition or AAV particle.
97. The method of any one of claims 67-87, any one of claims 89-92, or 94, wherein administering the pharmaceutical composition or AAV particle results in:(i) an increase in the number and / or level of viral genomes (VG) per cell in a CNS tissue (e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof of the subject relative to the number and / or level of VG per cell in a peripheral tissue of the subject;(ii) a decrease in mutated DMPK mRNA expression in a cell or a tissue of the CNS (e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen. thalamus, superior colliculus, the spinal cord, or a combination thereof) of the subject relative to baseline and / or relative to mutated DMPK mRNA expression in a CNS cell or tissue of an individual with a DMPK-related disorder who has not been administered tire pharmaceutical composition or AAV particle; and / or(iii) an increase in normal mRNA splicing, optionally DMPK mRNA splicing, in a cell or tissue of the CNS (e.g., the parenchyma, the cortex, substantia nigra, caudate cerebellum, striatum, corpus callosum, cerebellum, brainstem, caudate, putamen, thalamus, superior colliculus, the spinal cord, or a combination thereof) of the subject relative to baseline and / or relative to normal mRNA splicing, optionally DMPK mRNA splicing, in a CNS cell or tissue of an individual with a DMPK- related disorder who has not been administered the pharmaceutical composition or AAV’ particle.
98. The method of any one of claims 67-97, further comprising administering to the subject at least one additional therapeutic agent and / or therapy.
99. The method of claim 98, wherein the at least one additional therapeutic agent and / or therapy comprises an agent and / or therapy for treating the DMPK-related disorder, optionally wherein the at least one additional therapeutic agent and / or therapy comprises an anti-diabetic drug, an anti- myotonic drug (e.g., mexiletine), a non-steroidal anti-inflammatory drug, or a combination thereof.
100. The method of any one of claims 67-99, further comprising administering an immunosuppressant to the subject.101 . The method of claim 100, wherein the immunosuppressant comprises a corticosteroid (for example, and without limitation, prednisone, prednisolone, methylprednisolone, and / or dexamethasone), adrenocorticotropic hormone, rapamycin, mycophenolate mofetil. tacrolimus, rituximab, eculizumab hydroxycldoroquine, alemtuzumab, hydroxyurea, fludarabine. and / or busulfan.
102. The pharmaceutical composition of any one of claims 63-66 or the AAV particle of any one of clanns 1-51, for use in the treatment of a DMPK-related disorder, optionally wherein the DMPK- related disorder is myotonic dystrophy type 1 (DM1).
103. The pharmaceutical composition or AAV particle for use of claim 102, wherein the DMPK- related disorder is congenital DM1 .
104. Use of the pharmaceutical composition of any one of claims 63-66 or the AAV particle of anyone of claims 1-51 in the manufacture of a medicament for the treatment of a DMPK-related disorder, optionally wherein the DMPK-related disorder is myotonic dystrophy type 1 (DM1).
105. The pharmaceutical composition or AAV particle for use of claim 104, wherein the DMPK- related disorder is congenital DM1.
Citation Information
Patent Citations
Compositions and methods for reducing spliceopathy and treating RNA dominance disorders
US20210269825A1
Combination therapy for treating muscular dystrophy
US20220031865A1
Engineered central nervous system compositions
WO2023039480A2
